Systems and methods for multiplex measurement of single cells and aggregate cells
By treating immune cells in the compartment and using transposases and adaptors to label chromatin, the problem of difficulty in detecting nucleosome localization, chromatin accessibility and transcription factor binding in the prior art is solved, and the individual cells are realized Multiple measurements and simplification of sample preparation.
Patent Information
- Application Number
- CN202410933332.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-02-05
- Filing Date
- 2018-12-19
- Publication Date
- 2024-11-26
AI Technical Summary
Existing methods are difficult to simultaneously detect the mutual influence of nucleosome localization, chromatin accessibility and transcription factor binding, and require millions of cells as starting materials, making sample preparation complex and time-consuming.
A method for treating immune cells is provided, including capturing immune cells, producing labeled gDNA fragments and cDNA molecules, determining the correlation of genomic DNA with the V(D)J region through sequencing, and performing partitioning and labeling reactions in the compartment , chromatin is labeled with transposase and adaptors, and the reaction is terminated to release adaptors.
Multiple measurements of individual immune cells are achieved, the sample preparation process is simplified, the cell number requirement is reduced, and the effects of nucleosome localization, chromatin accessibility and transcription factor binding are simultaneously detected.
Smart Images

Figure CN119020348A_ABST
Abstract
Description
[0001] This application is a divisional application. The application number of the parent application is 201880092114.X, the application date is December 19, 2018, and the name of the invention is “Systems and methods for multiplexed measurements of single cells and collective cells”.
[0002] Cross-references
[0003] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 626,603, filed on February 5, 2018, the entire contents of which are incorporated herein by reference.
[0004] Statement Regarding Federally Funded Research
[0005] This invention was made with government support under Contract HG007735 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art
[0006] Samples can be processed for a variety of purposes, such as identifying species within a sample. Samples can be biological samples. Biological samples can be processed, for example, for detecting a disease (e.g., cancer) or identifying a particular species. There are a variety of methods for processing samples, such as polymerase chain reaction (PCR) and sequencing.
[0007] Biological samples can be processed in various reaction environments (e.g., compartments). Compartments can be wells or droplets or other compartments within a microfluidic device. Compartments can be used to process biological samples in a manner that enables biological samples to be partitioned and processed individually. For example, such droplets can be fluidically isolated from other droplets, thereby enabling precise control of the respective environments in the droplets.
[0008] The biological sample in the compartment can be subjected to various processes, for example, chemical processes or physical processes. The sample in the compartment can be subjected to heating or cooling or chemical reactions, for example to produce substances that can be processed qualitatively or quantitatively. Summary of the invention
[0009] Eukaryotic genomes are hierarchically packaged into chromatin, and the nature of such packaging plays a central role in gene regulation. The main insights into the epigenetic information encoded in the nucleoprotein structure of chromatin come from high-throughput, genome-wide methods for measuring chromatin accessibility ("open chromatin"), nucleosome positioning, and transcription factor (TF) occupancy separately. Although there are disclosed schemes, these methods require millions of cells as starting materials, involve complex and time-consuming sample preparation, and cannot simultaneously detect the mutual influence of nucleosome positioning, chromatin accessibility, and TF binding. Therefore, it is recognized herein that at least the problems described above need to be addressed.
[0010] In one aspect, a method for processing immune cells is provided, comprising: (a) capturing immune cells, wherein the immune cells contain genomic deoxyribonucleic acid (gDNA) and messenger ribonucleic acid (mRNA) molecules; (b) contacting the gDNA from the immune cells with a transposase to produce labeled gDNA fragments in a labeling reaction; (c) generating complementary DNA (cDNA) molecules from the mRNA molecules, wherein the cDNA molecules contain sequences corresponding to the V(D)J regions of the immune cell genome.
[0011] In some embodiments, the immune cell is a T cell.
[0012] In some embodiments, the immune cell is a B cell.
[0013] In some embodiments, capturing comprises partitioning in compartments. In some embodiments, the compartments are chambers. In some embodiments, the compartments are wells. In some embodiments, the compartments are droplets.
[0014] In some embodiments, the method further comprises, prior to (b), lysing the immune cells.
[0015] In some embodiments, capturing comprises separating the immune cell from a plurality of immune cells. In some embodiments, separating comprises flow cytometry sorting or magnetic cell sorting.
[0016] In some embodiments, the labeled gDNA fragments each comprise one or more adaptors. In some embodiments, the one or more adaptors comprise an adaptor sequence.
[0017] In some embodiments, (c) comprises contacting an mRNA molecule from an immune cell with a primer and a reverse transcriptase. In some embodiments, the primer comprises a sequence that is specific to an mRNA molecule or a sequence that targets an mRNA molecule.
[0018] In some embodiments, the mRNA molecule comprises a T cell receptor alpha (TRA) or a T cell receptor beta (TRB) RNA molecule. In some embodiments, the mRNA molecule comprises a T cell receptor alpha (TRA) and a T cell receptor beta (TRB) RNA molecule. In some embodiments, (c) comprises contacting the mRNA molecule with a primer, wherein the primer comprises the following sequence: a sequence specific to a constant region encoding a TRA and TRB RNA molecule or a sequence targeting a constant region encoding a TRA and TRB RNA molecule.
[0019] In some embodiments, the method further comprises contacting the labeled gDNA fragments and cDNA molecules with a plurality of primers and a polymerase to produce labeled gDNA fragment amplicons or cDNA molecule amplicons. In some embodiments, the method further comprises contacting the labeled gDNA fragments and cDNA molecules with a plurality of primers and a polymerase to produce labeled gDNA fragment amplicons and cDNA molecule amplicons. In some embodiments, at least one subset of the plurality of primers each comprises the following sequence: a sequence specific to a constant region or a variable region encoding a T cell receptor (TCR) or a sequence targeting a constant region or a variable region encoding a T cell receptor (TCR). In some embodiments, at least one subset of the plurality of primers each comprises the following sequence: a sequence specific to a constant region and a variable region encoding a T cell receptor (TCR) or a sequence targeting a constant region and a variable region encoding a T cell receptor (TCR).
[0020] In some embodiments, the method further comprises generating amplicons from the genomic DNA fragments and cDNA molecules of the label, wherein each amplicon comprises a barcode sequence for identifying an immune cell. In some embodiments, each amplicon comprising a barcode sequence for identifying an immune cell is generated from other amplicons of the gDNA fragments or cDNA molecules of the label. In some embodiments, the method further comprises sequencing the amplicon. In some embodiments, the method further comprises determining in the immune cell the correlation between the accessible genomic DNA of the genomic DNA and the sequence corresponding to the V(D)J region of the genome from the immune cell.
[0021] In some embodiments, the method further comprises sequencing the labeled gDNA fragments and cDNA molecules or their derivatives.
[0022] The method according to claim 1, further comprising, after (b), terminating the labeling reaction. In some embodiments, terminating comprises using a chelating agent. In some embodiments, the labeling reaction comprises chelating divalent metal ions required for the transposase complex from the transposase and releasing the transposase complex from the labeled gDNA fragments. In some embodiments, the chelating agent is selected from ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA) and diethylenetriaminepentaacetic acid (DTPA).
[0023] In some embodiments, the labeling reaction includes the use of a detergent. In some embodiments, the detergent is a nonionic surfactant. In some embodiments, the detergent is ethoxylated nonylphenol.
[0024] On the other hand, a method for processing an immune cell is provided, comprising: (a) capturing an immune cell, wherein the immune cell comprises a genomic deoxyribonucleic acid (gDNA) and a messenger ribonucleic acid (mRNA) molecule; (b) generating a labeled gDNA fragment from accessible gDNA and complementary DNA (cDNA) of the mRNA molecule of the immune cell, wherein the cDNA molecule comprises a sequence corresponding to the V(D)J region of the immune cell genome; and (c) mapping the correlation between the accessible genomic DNA and the sequence corresponding to the V(D)J region from one or more sequencing reads of the labeled gDNA fragment or its derivative and the cDNA molecule or its derivative.
[0025] In another aspect, a method of treating a cell is provided, comprising: (a) capturing a cell, wherein the cell comprises a genomic deoxyribonucleic acid (gDNA) and a guide RNA (gRNA) molecule, or a gRNA identification barcode thereof. (b) contacting accessible gDNA from the cell with a transposase to produce labeled gDNA fragments in a labeling reaction; and (c) generating complementary DNA (cDNA) molecules from the gRNA molecule or its gRNA identification barcode.
[0026] In some embodiments, the cell is an immune cell. In some embodiments, the immune cell is a T cell. In some embodiments, the immune cell is a B cell.
[0027] In some embodiments, capturing comprises partitioning in compartments. In some embodiments, the compartments are chambers. In some embodiments, the compartments are wells. In some embodiments, the compartments are droplets.
[0028] In some embodiments, the method further comprises lysing the cells prior to (b).
[0029] In some embodiments, capturing comprises separating the cell from a plurality of cells.
[0030] In some embodiments, the labeled gDNA fragments each comprise one or more adaptors. In some embodiments, the one or more adaptors comprise an adaptor sequence.
[0031] In some embodiments, the barcode in its barcode identifies the identity of the gRNA molecule in the gRNA molecule. In some embodiments, the barcode is attached to the gRNA molecule.
[0032] In some embodiments, the gRNA molecule comprises a target sequence configured to target a sequence associated with a transcription factor, a chromatin modifier, or a non-coding RNA. In some embodiments, the gRNA molecule comprises a plurality of different target sequences. In some embodiments, a first gRNA molecule in the gRNA molecule comprises a first target sequence in a plurality of different target sequences, and a second gRNA molecule in the gRNA molecule comprises a second target sequence in a plurality of different target sequences, wherein the first target sequence and the second target sequence are different.
[0033] In some embodiments, the method further comprises, prior to (a), introducing a gRNA molecule into the cell.
[0034] In some embodiments, (c) includes contacting a gRNA molecule or its barcode from a cell with a primer and a reverse transcriptase. In some embodiments, the primer includes a reverse primer, which includes a sequence specific to the 3' end of the gRNA molecule or the 3' end of the targeting gRNA molecule. In some embodiments, the method also includes contacting the gRNA molecule with another set of primers, wherein the other set of primers includes a forward primer, and the forward primer includes a sequence specific to the 5' variable end of the gRNA molecule or the 5' variable end of the targeting gRNA molecule.
[0035] In some embodiments, the method further comprises contacting the labeled gDNA fragments and cDNA molecules with a plurality of primers and a polymerase to produce labeled gDNA fragment amplicons or cDNA molecule amplicons. In some embodiments, the method further comprises contacting the labeled gDNA fragments and cDNA molecules with a plurality of primers and a polymerase to produce labeled gDNA fragment amplicons and cDNA molecule amplicons.
[0036] In some embodiments, the method further comprises generating amplicons from the labeled genomic DNA fragments and cDNA molecules, wherein each amplicon comprises a barcode sequence that identifies the cell. In some embodiments, each amplicon comprising a barcode sequence that identifies the cell is generated from other amplicons of the labeled gDNA fragments or cDNA molecules. In some embodiments, the method further comprises sequencing the amplicons.
[0037] In some embodiments, the method further comprises determining a correlation between the accessibility of genomic DNA in the cell in response to perturbation of the gRNA molecule by the gRNA molecule.
[0038] In some embodiments, the method further comprises sequencing the labeled gDNA fragments and cDNA molecules or their derivatives.
[0039] In some embodiments, the method further comprises, after (b), terminating the labeling reaction. In some embodiments, terminating comprises using a chelating agent. In some embodiments, the labeling reaction comprises chelating divalent metal ions required for the transposase complex from the transposase and releasing the transposase complex from the labeled gDNA fragments. In some embodiments, the chelating agent is selected from ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA) and diethylenetriaminepentaacetic acid (DTPA).
[0040] In some embodiments, the labeling reaction includes the use of a detergent. In some embodiments, the detergent is a nonionic surfactant. In some embodiments, the detergent is ethoxylated nonylphenol.
[0041] Another aspect of the present disclosure provides systems, methods, and compositions for barcoding, processing, and analyzing nucleic acid molecules from cells.
[0042] Another aspect of the present disclosure provides a non-transitory computer-readable medium containing machine-executable code, which, when executed by one or more computer processors, implements any of the methods described above or elsewhere herein.
[0043] Another aspect of the present disclosure provides a system comprising one or more computer processors and a computer memory coupled thereto. The computer memory comprises machine executable code that, when executed by one or more computer processors, implements any method described above or elsewhere herein.
[0044] Other aspects and advantages of the present disclosure will become apparent to those skilled in the art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. It will be appreciated that the present disclosure is capable of other and different embodiments, and that its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Therefore, the drawings and description are to be regarded as illustrative in nature, and not restrictive.
[0045] Incorporated by Reference
[0046] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that publications and patents or patent applications incorporated by reference conflict with the disclosure contained in this specification, this specification is intended to supersede and / or take precedence over any such conflicting material. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and accompanying drawings (also referred to as "FIG..." and "FIG...") showing illustrative embodiments utilizing the principles of the present invention, wherein:
[0049] Figure 1 An exemplary protocol and / or workflow for the Transcript Indexing Assay for Transposase Accessible Chromatin using Sequencing (T-ATAC-seq) is shown.
[0050] Figure 2 Pie charts are shown indicating the overlap of T cell receptor sequencing (TCR-seq) and ATAC-seq data from T cells.
[0051] Figure 3 Plots following quality control filters are shown.
[0052] Figure 4 Comparison of aggregate (Panel A) and single-cell T-ATAC-seq (Panel B) profiles are shown.
[0053] Figure 5 Heat maps of T cell receptor alpha (TRA) or T cell receptor beta (TRB) rearrangements in cells are shown.
[0054] Figure 6 Demonstrated use of TCR-Seq clones to identify mouse or human genomes.
[0055] Fig. 7A Shown is a graph of identified epigenomic features generated from T-ATAC-seq. Figure 7B Shows Fig. 7A A zoomed-in view of the genomic locus of .
[0056] Figure 8 Shown is a heat map of transcription factor (TF) deviation z-scores for Jurkat cells compared to other cell types.
[0057] Fig. 9 A heat map of ATAC-seq fragment counts is shown.
[0058] Fig.10 A diagram showing the epigenomic profiles of pooled T cell subtypes.
[0059] Fig.11 A diagram showing the epigenomic profiles of pooled T cell subtypes.
[0060] Fig.12 is a heatmap showing the clusters of the most highly altered ATAC-seq peaks.
[0061] Fig.13 Immunological signatures obtained from ATAC-seq are shown.
[0062] Fig.14 Pearson correlation plots of PC scores for pooled ATAC-seq profiles are shown.
[0063] Fig.15 The workflow for T-ATAC-seq analysis in primary human T cells is shown.
[0064] Fig.16 t-SNE projections of various T cells are shown.
[0065] Fig.17 A plot showing bias-corrected enrichment of TFs in aggregated single-cell populations.
[0066] Fig.18 Plots showing t-SNE projections of individual T cells highlighting motif accessibility.
[0067] Fig.19 T for aggregation is shown H 17 The difference in the ranking of memory cells relative to clustered naive cells and the average bias-corrected deviation for ranking of clustered memory cells relative to clustered naive cells.
[0068] Fig. 20 Shown is a heat map showing ATAC-seq fragment counts in peaks containing the indicated motifs from aggregated single cells.
[0069] Fig.21 Shown is the biased enrichment of TFs in clonal versus non-clonal memory T cells for two memory T cell clones (top and bottom).
[0070] Fig. 22 The workflow of T-ATAC-seq analysis in T cell samples from leukemia patients is shown.
[0071] Fig.23 Shown is a heat map of TRB rearrangements in peripheral blood samples from patients with the disease condition.
[0072] Fig.24 Shown are t-SNE projections of naive and memory T cells from healthy and diseased patient samples.
[0073] Fig.25 A heat map of ATAC-seq fragment counts in the peaks is shown.
[0074] Fig.26 MSigDB perturbation signatures of TRB7-9 specific ATAC-seq peaks obtained from GREAT analysis are shown.
[0075] Fig. 27 Shown is the TF bias-corrected enrichment in aggregated CD26- cells relative to CD26+ cells.
[0076] Fig.28 A T-ATAC-seq protocol outlining the biochemical reactions occurring in each microfluidic chamber in an IFC is shown.
[0077] Fig.29 FACS analysis of Jurkat cells is shown.
[0078] Fig.30 ATAC-seq quality measurements of a single Jurkat cell in a single experiment are shown.
[0079] Fig.31 Shown is a comparison of ATAC-seq fragment 3102 and TCR-seq paired-end reads in single Jurkat cells.
[0080] Fig.32 Overlap of single-cell TCR-seq and ATAC-seq data is shown.
[0081] Fig.33 Panel A shows the t-SNE projection of T-ATAC-seq data from a single Jurkat cell.
[0082] Fig.34 Shown is the Spearman correlation plot of TF z-scores in pooled ATAC-seq data in Jurkat cells compared to aggregated single cells.
[0083] Fig.35 Histograms of pre-gated live cells are shown.
[0084] Fig.36 Graph showing the post-sort purity of CD4+ T cell subsets.
[0085] Fig.37 T-ATAC-seq data quality control filters are shown.
[0086] Fig.38 Quality measurement plots of TCR-seq profiles from T-ATAC-seq in single cells are shown.
[0087] Fig.39 Pearson correlations of PC scores for single cells and collections of cells are shown.
[0088] Fig.40t-SNE projections of PCA scores for all cells (Panel A) or primary human T cells (Panel B) are shown.
[0089] Fig.41 Shown is a heatmap of TF bias z-scores for pooled T cell ATAC-seq profiles.
[0090] Fig.42 Comparison of TF bias z-score enrichment (mean difference) among cell subtypes is shown.
[0091] Fig.43 t-SNE projections of sorted single-cell subtypes are shown.
[0092] Fig.44 Cell-to-cell variations in TF motif accessibility in cell subtypes are shown.
[0093] Fig.45 Shown are t-SNE projections of individual T cells.
[0094] Fig.46 Pearson correlations of TF bias z scores for individual naive, memory, and TH17 cells are shown.
[0095] Fig.47 Shown is the confirmation of TCRβ sequences obtained in clonal CTCL cells using T-ATAC-seq and immunoSEQ analysis.
[0096] Fig.48 Representative FACS strategies and post-sorting purity of CD26+ and CD26- CTCL cells are shown.
[0097] Fig.49 Shown are the presence of expanded TCR clones in CD26+ and CD26-CD4+ T cell populations in CTCL patients #2 and #3.
[0098] Fig.50 Shown is the TF bias-corrected deviated enrichment in clustered clonal T cells compared to all other T cells.
[0099] Fig.51 A browser screenshot from the tcr.buenrostrolab.com software is shown showing the drop-down menu options to navigate the single-cell TF bias scores and TCR sequences. Fig.52 A schematic depicting a traditional clustered regularly interspaced short palindromic repeats (CRISPR) screen is shown.
[0100] Fig.53 A schematic diagram of the workflow of perturbation-ATAC is shown.
[0101] Fig.54An overview of the categories of biological questions that can be asked from perturbation-ATAC data is shown.
[0102] Fig.55 Schematic diagram of the perturbation-ATAC protocol, lentiviral constructs, and generation of sequencing libraries for guide RNA detection is shown.
[0103] Fig.56 Shown are scatter plots of guide barcode reads from pools of cells transduced with one of the two guide constructs.
[0104] Fig.57 Scatter plots of ATAC fragments and the fraction of ATAC fragments in the peak area per cell are shown.
[0105] Fig.58 Density histograms of ATAC fragment size distribution are shown, indicating the expected nucleosome phasing and relative frequency of ATAC insertions around transcription start sites in pooled single cells and bulk cells.
[0106] Fig.59 A diagram of the genomic locus of the SPI1 gene is shown.
[0107] Fig.60 Box plots showing accessibility of merged single cells for individual genomic regions identified as altered in bulk ATAC-seq.
[0108] Fig.61 A plot showing the relative accessibility of regions containing the SPI1 motif.
[0109] Fig.62 Histograms of total guide barcode sequencing reads per cell are shown.
[0110] Fig.63 A histogram of the second most common guide barcode identified in each cell is shown.
[0111] Fig.64 Scatter plots of ATAC fragments and the fraction of fragments in the peak area are shown.
[0112] Fig.65 Heatmaps of cells (rows) versus guide barcodes (columns) are shown, indicating the proportion of total reads associated with each barcode.
[0113] Fig.66 Volcano plots are shown to identify significantly altered genomic features between cells carrying non-targeting guides and guides targeting various genes.
[0114] Fig.67 A heat map of the perturbed factors relative to the genomic annotation is shown.
[0115] Fig.68 Panel A shows a heat map indicating quantification of the number of features, genomic regions, or ratio of flanking to central nucleosome occupancy at the peak of alteration that are significantly altered upon a single perturbation.
[0116] Fig.69 An exemplary workflow diagram for identifying genomic features that exhibit correlated activities across cells is shown.
[0117] Fig.70 Heatmap showing Pearson correlations between features in non-targeted cells.
[0118] Fig.71 A heat map is shown demonstrating the difference in correlation between non-targeted cells and IRF8 knockdown cells.
[0119] Fig.72 Heatmaps demonstrating module 5 feature correlations in non-targeted cells (lower half) and IRF8 (upper half) knockdown cells are shown.
[0120] Fig.73 Heatmaps demonstrating module 2 feature correlations in non-targeted cells (lower half) and DNMT3A (upper half) knockdown cells are shown.
[0121] Fig.74 Scatter plots of cell accessibility with linear best-fit curves are shown, indicating correlations under specific conditions.
[0122] Fig.75 A hypothetical model for IRF8 cofactor activity with AP1 and IKZF1 is shown.
[0123] Fig.76 Heatmap showing the fraction of feature-feature correlations that are changed within a module by a perturbation, showing the specific impact on a particular module under different perturbations.
[0124] Fig.77 A schematic diagram of the calculation of expected accessibility in a double knockdown setting based on an additive model integrating the accessibility in each single knockdown condition is shown.
[0125] Fig.78 Shown are box plots representing the distribution of SPI1 binding site (left) and IKZF1 binding site (right) accessibility for 1221 individual cells under corresponding single or double knockdown conditions.
[0126] Fig.79 A scatter plot of observed7902 relative to expected7904 accessibility for epistatic interactions is shown. Each dot represents a single annotation in the pair of two perturbed factors.
[0127] Fig.80 Histograms of the background-corrected interaction extent for each feature are shown.
[0128] Fig.81 Scatter plots of observed interactions relative to expected interactions are shown.
[0129] Fig.82 Shown is a scatter plot of observed 8202 versus expected 8204 accessibility changes in H3K27me3-marked regions in cells depleted of EZH2 and one other factor.
[0130] Fig.83 Shown are scatter plots of the relative accessibility of EZH2 knockdown cells compared to control cells for various subsets of H3K27me3 peaks.
[0131] Fig.84 Shown are heat maps indicating changes in accessibility due to EZH2 depletion at regions marked by H3K27me3 in GM12878 and demonstrating H3K27ac marks in each of the other specific cell types.
[0132] Fig.85 A schematic diagram indicating the workflow for clustering SNPs associated with autoimmune diseases with 3D chromatin contact regions is shown.
[0133] Fig.86 Heatmaps showing the absolute change in accessibility for each autoimmune disease and perturbed SNP contact signature set.
[0134] Fig.87 Schematic diagram of the cell culture model system of human epidermis and epidermal differentiation is shown.
[0135] Fig.88 tSNE projections of TF signature activities of epidermal cells are shown.
[0136] Fig.89 Heatmaps of cells sorted by pseudo-time relative TF feature activity are shown.
[0137] Fig.90 Density histograms of pseudo-time values for cells from each day of differentiation are shown.
[0138] Fig.91 tSNE projections of TF activities are shown.
[0139] Fig.92 Schematic diagram of sgRNA expression vector and library amplification for direct sequencing readout of guide RNA identity is shown.
[0140] Fig.93 A heatmap of sgRNA identities (columns) versus individual cells (rows) is shown, indicating the proportion of all reads associated with each sgRNA.
[0141] Fig.94 Heat maps of genetic perturbations versus TF signatures are shown, indicating the activity of the TF signature in perturbed cells versus non-targeted (NT) cells.
[0142] Fig.95 A diagram of the genomic locus of the SPRR2E gene is shown.
[0143] Fig.96 Displayed are the representation of positive and negative regulation between targeted genes (factors) and sets of genomic regions (signatures).
[0144] Fig.97 A heat map showing the frequency of cells in each of eight bins representing progression along the differentiation trajectory is shown.
[0145] Fig.98 A heatmap of perturbations relative to feature modules is shown.
[0146] Fig.99 Representative peak signals for each interaction category are shown.
[0147] Fig.100 Scatter plots of observed versus expected accessibility in double knockout cells are shown.
[0148] Fig.101 Heatmaps showing altered activities of features (rows) and their expected activities in the case of various gene knockdowns in the same cells.
[0149] Fig.102 Bar graphs showing the proportion of interaction features belonging to each category are shown.
[0150] Fig.103 Heat maps are shown indicating the significance of genomic overlap or gene expression correlation corresponding to pairwise TF pairs.
[0151] Fig.104 Heat maps indicating the relative accessibility of genomic regions that exhibit cooperative behavior in double knockout cells are shown.
[0152] Fig.105 A hypothetical model for KLF4 and ZNF750 redundancy in maintaining accessibility at co-occupied loci is shown.
[0153] Fig.106 An example of a microfluidic channel structure for partitioning individual bioparticles is shown.
[0154] Fig.107 An example of a microfluidic channel structure for delivering barcode-carrying beads to droplets is shown.
[0155] Fig.108 An example of a microfluidic channel structure for co-partitioning bioparticles and reagents is shown.
[0156] Fig.109 An example of a microfluidic channel structure for controlled partitioning of beads into discrete droplets is shown.
[0157] Fig.110 An example of a microfluidic channel structure used to increase the throughput of droplet generation is shown.
[0158] Fig.111 Another example of a microfluidic channel structure for increasing droplet generation throughput is shown.
[0159] Fig.112A A cross-sectional view of another example of a microfluidic channel structure having geometric features for controlled partitioning is shown. Fig.112B Shows Fig.112A A perspective view of the channel structure.
[0160] Fig.113 Examples of beads carrying barcodes are shown.
[0161] Fig.114 A computer system is shown that is programmed or otherwise configured to implement the methods provided herein.
[0162] Fig.115 A schematic diagram of the lentiviral plasmid encoding the sgRNA for CRISPRi as well as a selectable marker containing the guide barcode is shown.
[0163] Fig.116 An overview of the computational pipeline that takes sequencing reads of GBCs and produces a final table of guide identifications for each cell is shown.
[0164] Fig.117 Details on the derivation of filtering parameters for sequencing depth and background reads per cell are shown.
[0165] Fig.118 Bar graphs indicating counts of sgRNA sequence mismatches for random guides or for perturbation-ATAC selected guides are shown.
[0166] Fig.119 A workflow for computationally predicting off-target CRISPRi activity based on the contribution of mismatches is shown.
[0167] Fig.120Shown is qPCR validation of CRISPRi gene expression knockdown following transduction with sgRNA targeting a specific gene.
[0168] Fig.121 Shown are bar graphs indicating the categories of sgRNA mismatched loci based on ATAC peak proximity and accessibility observed compared to non-targeted cells.
[0169] Fig.122 Shown are tSNE plots of all cells assayed in the GM12878 experiment based on the chromVAR feature deviation z-score.
[0170] Fig.123 Violin plots of single cell accessibility relative to the average accessibility in non-targeted cells are shown for features that were significantly altered in cells targeted with EBER1, EBF1, EZH2, or SPI1.
[0171] Fig.124 Shown are scatter plots of accessibility under knockdown conditions, NFKB1 versus RELA (left) or EBER1 versus EBER1 (right).
[0172] Fig.125 Volcano plots are shown for each individual perturbation condition, comparing perturbed cells to nontargeted control cells.
[0173] Fig.126 Shown is a schematic depicting the generation of short (<100 bp) ATAC fragments from subnucleosomal regions and large fragments (180-247 bp) spanning nucleosome protected regions.
[0174] Fig.127 Metacurves of subnucleosomal and nucleosomal fragment signals for CTCF motif regions overlapping with CTCF ChIP-seq peaks in GM12878 are shown.
[0175] Fig.128 Metacurves of subnucleosomal and nucleosomal signals at differentially accessible regions are shown.
[0176] Fig.129 Heatmaps of the correlation matrices for genomic features are shown.
[0177] Fig.130 A list of key features in each module is shown.
[0178] Fig.131 A heat map of the correlation matrix of genomic signatures in IRF8 knockdown cells is shown.
[0179] Fig.132Box plots of single-cell accessibility of CTCF and SMAD5 signatures in non-targeted and DNMT3A knockdown cells are shown.
[0180] Fig.133 Heatmap showing the differences in feature correlations between NFKB1 knockdown cells (bottom) and RELA knockdown cells (top).
[0181] Fig.134 Heatmap showing the feature correlation of module 1 relative to module 5 in non-targeted or EBER2 knockdown cells.
[0182] Fig.135 Histograms of changes in feature correlations for SPI1 knockdown versus non-targeted 1 cells are shown to give information about the threshold used to designate altered correlations.
[0183] Fig.136 A table showing counts based on a 5% FDR threshold and correlation features with the highest changes highlighted is shown.
[0184] Fig.137 Schematic diagram of lentiviral plasmids used for sgRNA and Cas9 expression is shown.
[0185] Fig.138 Sanger sequencing traces of 100 bp around the 3' end of the sgRNA are shown for each target gene.
[0186] Fig.139 A schematic diagram of the lentiviral plasmid encoding sgRNA for CRISPR knockout is shown.
[0187] Fig.140 The distribution of reads per cell mapped to sgRNA variable sequences is shown. For each plate, a clear pattern of high reads was identified and used to determine the depth cutoff.
[0188] Fig.141 The distribution of the proportion of all reads per cell that mapped to known sgRNA sequences is shown.
[0189] Fig.142 The distribution of the proportion of reads per cell associated with the background (third most common) guide sequence is shown.
[0190] Fig.143 The distribution of the proportion of reads associated with the second most common guidance is shown.
[0191] Fig.144 Shown is a scatter plot of the proportion of reads associated with the two guide sequences for all cells that passed the final filter.
[0192] Fig.145 Signal traces indicating ZNF750 binding sites that gain accessibility in targeted cells are shown, indicating the repressive activity of ZNF750.
[0193] Fig.146 A scatter plot of principal component (PC) values for unperturbed keratinocytes is shown.
[0194] Fig.147 Shown are scatter plots of the 1397 PC values for all perturbed and non-targeted cells embedded in PC space.
[0195] Fig.148 Shown are scatter plots of observed relative to expected (based on additive model) accessibility in double knockout cells.
[0196] Fig.149 Shown are scatter plots of the absolute log2 fold changes of features in single knockout cells versus double knockouts (r~0.18). DETAILED DESCRIPTION OF THE INVENTION
[0198] Although various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art may conceive of many changes, variations and substitutions. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed.
[0199] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are still described.
[0200] Where a value is described as a range, it will be understood that the disclosure includes disclosure of all possible subranges within the range, as well as specific numerical values falling within the range, regardless of whether a specific numerical value or a specific subrange is explicitly stated. As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value, as determined by one skilled in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, in accordance with the conventions of the relevant art, "about" can mean 1 standard deviation or more than 1 standard deviation. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value.
[0201] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
[0202] The headings provided herein are not limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined below as a whole are more fully defined by reference to the specification as a whole.
[0203] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994) and Hale & Markham, THE HARPER COLLINSDICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide those skilled in the art with the general meaning of many of the terms used herein. Nevertheless, for clarity and ease of reference, certain terms are defined below.
[0204] The term "sample" as used herein generally refers to a biological sample of a subject. A biological sample can include any number of macromolecules, such as cellular macromolecules. In one embodiment, the term used in a broad sense refers to any plant, animal or viral material containing DNA or RNA, such as, for example, tissue or liquid (including but not limited to plasma, serum, cerebrospinal fluid, lymph, tears, saliva and tissue sections) separated from an individual or tissue or liquid separated from an in vitro cell culture component and a sample from the environment. The sample can be a cell sample. The sample can be a cell line or a cell culture sample. The sample can include one or more cells. The sample can include one or more microorganisms. The biological sample can be a nucleic acid sample or a protein sample. The biological sample can also be a carbohydrate sample or a lipid sample. The biological sample can be derived from another sample. The sample can be a tissue sample, such as a biopsy, a core biopsy, a needle aspirate or a fine needle aspirate. The sample can be a fluid sample, such as a blood sample, a urine sample or a saliva sample. The sample can be a skin sample. The sample can be a cheek swab. The sample can be a plasma or serum sample. The sample can be a cell-free sample. The cell-free sample can include extracellular polynucleotides. The extracellular polynucleotides may be isolated from a body sample which may be selected from the group consisting of blood, plasma, serum, urine, saliva, mucosal excretions, sputum, feces and tears.
[0205] As used herein, the term "nucleic acid sample" generally refers to a sample containing nucleic acids. As used herein, nucleic acid samples may be complex because they contain multiple different molecules containing sequences. A genomic DNA sample from a mammal (e.g., mouse or human) is a type of complex sample. A complex sample may have more than about 104 , 10 5 , 10 6 or 10 7 , 10 8 , 10 9 or 10 10 Different nucleic acid molecules. The DNA target can be from any source, for example, genomic DNA or an artificial DNA construct. Any sample containing nucleic acid can be used herein, for example, genomic DNA from tissue culture cells or a tissue sample.
[0206] The term "mixture" as used herein generally refers to a combination of elements that are interspersed and not arranged in any particular order. A mixture is heterogeneous and cannot be spatially separated into its different components. Examples of mixtures of elements include many different elements dissolved in the same aqueous solution and many different elements attached to a solid support at random positions (i.e., in no particular order). Mixtures are not addressable. For illustration, as well known in the art, the array of spatially separated surface-bound polynucleotides is not a mixture of surface-bound polynucleotides, because the types of surface-bound polynucleotides are spatially clear and the array is addressable.
[0207] As used herein, the term "nucleotide" generally includes not only known purine and pyrimidine bases, but also those parts of other heterocyclic bases that have been modified. Such modifications include methylated purine or pyrimidine, acylated purine or pyrimidine, alkylated ribose or other heterocycles. In addition, the term "nucleotide" includes those parts that include haptens or fluorescent labels and may include not only conventional ribose and deoxyribose but also other sugars. Modified nucleosides or nucleotides also include modifications to sugar moieties, such as where one or more hydroxyls are replaced by halogen atoms or aliphatic groups, or are functionalized to ethers, amines, etc.
[0208] As used interchangeably herein, the terms "nucleic acid," "oligonucleotide," and "polynucleotide" are generally meant to describe polymers of any length, e.g., greater than about 2 bases, greater than about 10 bases, greater than about 100 bases, greater than about 500 bases, greater than 1000 bases, greater than 10,000 bases, greater than 100,000 bases, greater than about 1,000,000 bases, up to about 10 10One or more bases, which are composed of nucleotides (e.g., deoxyribonucleotides or ribonucleotides), and can be produced enzymatically or synthetically (e.g., PNA described in U.S. Pat. No. 5,948,902 and references cited therein), which can hybridize with naturally occurring nucleic acids in a sequence-specific manner similar to two naturally occurring nucleic acids, for example, can participate in Watson-Crick base pairing interactions. Naturally occurring nucleotides include guanine, cytosine, adenine, thymine, uracil (G, C, A, T and U, respectively). DNA and RNA have deoxyribose and ribose sugar backbones, respectively, while the backbone of PNA consists of repeated N-(2-aminoethyl)-glycine units connected by peptide bonds. In PNA, various purine and pyrimidine bases are connected to the backbone by methylene carbonyl bonds. Locked nucleic acids (LNA) (commonly referred to as inaccessible RNA) are modified RNA nucleotides. The ribose moiety of the LNA nucleotide is modified by an additional bridge connecting the 2' oxygen and the 4' carbon. The bridge "locks" the ribose in a 3'-endo (North) conformation, which is typically found in an A-type duplex. LNA nucleotides can be mixed with DNA or RNA residues in an oligonucleotide as desired. The term "non-structural nucleic acid" or "UNA" is a nucleic acid containing non-natural nucleotides that bind to each other with reduced stability. For example, a non-structural nucleic acid can include G' residues and C' residues, wherein these residues correspond to non-naturally occurring forms of G and C that base pair with each other with reduced stability but retain the ability to base pair with naturally occurring C and G residues, respectively, i.e., analogs. Non-structural nucleic acids are described in US20050233340, the disclosure of which for UNA is incorporated herein by reference.
[0209] As used herein, term " primer " generally refers to natural or synthetic oligonucleotide molecule, it can serve as the starting point of nucleic acid synthesis after forming duplex with polynucleotide template and extend along template from its 3 ' end, thereby forming extended duplex. The sequence of nucleotides added in the extension process can be determined by the sequence of template polynucleotide. Usually, primer is extended by DNA polymerase. Primer usually has a length compatible with its use in the synthesis of primer extension product, and the length is generally 8 to 100 nucleotides, for example, 10 to 75, 15 to 60, 15 to 40, 18 to 30, 20 to 40, 21 to 50, 22 to 45, 25 to 40, etc. The length of typical primers can be 10-50 nucleotides, for example, 15-45, 18-40, 20-30, 21-25, etc., and any length between the ranges. In some embodiments, a primer is typically no more than about 10, 12, 15, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, or 70 nucleotides in length.
[0210] Primers are usually single-stranded to maximize amplification efficiency, but can alternatively be double-stranded. If double-stranded, the primer is usually treated to separate its chain before being used to prepare extension products. The denaturation step is usually carried out by heating, but alternatively, alkali can also be used and then neutralized. Therefore, "primers" are complementary to the template and are compounded with the template by hydrogen bonding or hybridization to obtain a primer / template complex for initiating synthesis by a polymerase, and the primer is extended by adding a covalently bonded base complementary to the template at its 3' end during DNA synthesis. Primers are sequence-specific and can hybridize with unique sequences in messenger RNA (mRNA) or target RNA.
[0211] As used herein, the term "hybridization" or "hybridization" generally refers to such a process, wherein under normal hybridization conditions, the region of a nucleic acid chain anneals to a second complementary nucleic acid chain and forms a stable duplex (homoduplex or heteroduplex) with the second complementary nucleic acid chain, and does not form a stable duplex with an unrelated nucleic acid molecule under the same normal hybridization conditions. The formation of a duplex is completed by annealing two complementary nucleic acid chain regions in a hybridization reaction. The hybridization reaction can be made highly specific by adjusting the hybridization conditions (commonly referred to as hybridization stringency) in which the hybridization reaction occurs, so that under normal stringent conditions, the two nucleic acid chains will not form a stable duplex (e.g., a duplex retaining a certain double-stranded region), unless the two nucleic acid chains contain a certain number of nucleotides that are substantially or completely complementary in a specific sequence. For any given hybridization reaction, it is easy to determine "normal hybridization or normal stringent conditions". See, for example, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press. As used herein, the term "hybridization" or "hybridization" refers to any process by which a nucleic acid strand joins with a complementary strand through base pairing.
[0212] As used herein, "selectively hybridizable" nucleic acid generally refers to a reference nucleic acid sequence in which two sequences specifically hybridize to each other under moderate to high stringency hybridization and washing conditions. Moderate and highly stringent hybridization conditions are known (see, e.g., Ausubel, et al., Short Protocols in Molecular Biology, 3rd edition, Wiley & Sons 1995 and Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001 Cold Spring Harbor, NY). An example of high stringency conditions includes hybridization at about 42°C in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS, and 100 μg / ml denatured carrier DNA, followed by washing twice at room temperature in 2X SSC and 0.5% SDS and then twice again at 42°C in 0.1X SSC and 0.5% SDS.
[0213]
[00136] The terms "duplex" or "duplexing" as used herein generally refer to two complementary polynucleotide regions that are base paired (ie, hybridized together).
[0214] The term "amplification" or "amplified" as used herein generally refers to the process of synthesizing a nucleic acid molecule complementary to one or both strands of a template nucleic acid. Amplification of nucleic acid molecules may include denaturing the template nucleic acid, annealing the primer to the template nucleic acid at a temperature lower than the melting temperature of the primer, and enzymatic extension from the primer to produce an amplified product. Denaturation, annealing and extension steps may each be performed once or multiple times. In some cases, denaturation, annealing and extension steps are performed multiple times so that the amount of the amplified product increases, usually exponentially, although the method does not require exponential amplification. Amplification generally requires the presence of deoxyribonucleoside triphosphates, DNA polymerase and appropriate buffer and / or a cofactor for making the polymerase have optimal activity. The term "amplification product" refers to the nucleic acid produced by the amplification process defined herein.
[0215] The terms "determine," "measure," "assess," "estimate," "measure," and "analyze" are used interchangeably herein and generally refer to any form of measurement, and include determining whether an element is present or not. These terms include quantitative and / or qualitative determinations. Assessments may be relative or absolute. "Assessing the presence of" includes determining the amount of something present, as well as determining whether something is present or not.
[0216] The term "use" as used herein generally refers to its conventional meaning, and thus can mean to employ (e.g., put into use) a method or composition to achieve a purpose. For example, if a program is used to generate a file, the program is executed to generate the file, which is generally the output of the program. In another example, if a computer file is used, it is generally accessed, read, and the information stored in the file is employed to achieve a purpose. Similarly, if a unique identifier (e.g., a barcode) is used, the unique identifier is generally read to identify, for example, an object or file associated with the unique identifier.
[0217] The term "ligation" as used herein generally refers to the enzymatic joining of the terminal nucleotide at the 5' terminus of a first DNA molecule to the terminal nucleotide at the 3' terminus of a second DNA molecule.
[0218] As used herein, "plurality" generally refers to comprising at least 2 members. In some cases, a plurality can have at least 2, at least 5, at least 10, at least 100, at least 10,000, at least 10,000, at least 10,000, or more. 6 At least 10 7 At least 10 8 or at least 10 9 or more members.
[0219] If two nucleic acids are "complementary", they can typically hybridize to each other under high stringency conditions. The term "fully complementary" is often used to describe a duplex in which every base of one nucleic acid is base paired with a complementary nucleotide in the other nucleic acid. In many cases, two complementary sequences have at least 10, e.g., at least 12 or 15 complementary nucleotides.
[0220] As used herein, an "oligonucleotide binding site" generally refers to a site in a target polynucleotide to which an oligonucleotide hybridizes. If an oligonucleotide "provides" a binding site for a primer, then the primer can hybridize to the oligonucleotide or its complement.
[0221] As used herein, term "chain" generally refers to a nucleic acid composed of nucleotides covalently linked together by a covalent bond (e.g., a phosphodiester bond). In cells, DNA is usually present in a double-stranded form, therefore has two complementary nucleic acid chains, referred to herein as "upper" and "lower" chains. In some cases, the complementary strands in a chromosome region can be referred to as "positive" and "negative" strands, "first" and "second" strands, "coding" and "non-coding" strands, "Watson" and "Crick" strands or "sense" and "antisense" strands. Whether a chain is designated as an upper or lower strand is arbitrary and does not imply any specific direction, function or structure. The nucleotide sequence of the first strand of several exemplary mammalian chromosome regions (e.g., BACs, assemblies, chromosomes, etc.) is known, and for example can be found in the Genbank database of NCBI.
[0222] As used herein, the term "upper strand" generally refers to either strand of a nucleic acid, not both strands of a nucleic acid. When an oligonucleotide or primer "binds or anneals to only one upper strand," it binds to only one strand and not to the other strand. As used herein, the term "lower strand" refers to the strand that is complementary to the "upper strand." When an oligonucleotide "binds or anneals to only one strand," it binds to only one strand (e.g., the first or second strand) and not to the other strand.
[0223] The term "sequencing" as used herein generally refers to a method by which the identities of consecutive nucleotides of a polynucleotide are obtained (e.g., the identities of at least 10, at least 20, at least 50, at least 100, or at least 200 or more consecutive nucleotides).
[0224] As used herein, the term "next generation sequencing" or "high throughput sequencing" generally refers to the so-called parallel synthesis sequencing or ligation sequencing platforms currently used by Illumina, Life Technologies, and Roche, etc. Next generation sequencing methods may also include nanopore sequencing methods or electronic detection-based methods, for example, the Ion Torrent technology commercialized by Life Technologies or the single molecule fluorescence-based methods commercialized by Pacific Biosciences.
[0225] As used herein, the terms "barcode", "barcode sequence" or "molecular barcode" generally refer to a label or identifier that conveys or is capable of conveying information about an analyte. A barcode can be part of an analyte. A barcode can be independent of an analyte. A barcode can be a label or combination of labels attached to an analyte (e.g., a nucleic acid molecule) in addition to being an endogenous feature of an analyte (e.g., one or more terminal sequences or the size of an analyte). A barcode can be unique. A barcode can have a variety of different formats. For example, a barcode can include: a polynucleotide barcode; a random nucleic acid and / or amino acid sequence; and a synthetic nucleic acid and / or amino acid sequence. A barcode can be attached to an analyte in a reversible or irreversible manner. A barcode can be added to a fragment of, for example, a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before, during, and / or after sample sequencing. A barcode can allow identification and / or quantification of individual sequencing reads.
[0226] As used herein, the term "in vitro" generally refers to reactions that occur in a container with isolated components, rather than reactions that occur in cells.
[0227] In the context of cleavage sites distributed along the length of a target nucleic acid molecule, the term "distributed" as used herein generally refers to insertion sequences that are spaced apart from one another along the length of the target nucleic acid molecule. It is not necessary that all insertion sequences are spaced apart by the same amount. Rather, the spacing between insertion sequences may be random, semi-random, or non-random.
[0228] As used herein, the term "chromatin" generally refers to a molecular complex including proteins and polynucleotides (e.g., DNA, RNA) found in the nucleus of a eukaryotic cell. Chromatin is composed in part of histones that form nucleosomes, genomic DNA, and other DNA binding proteins (e.g., transcription factors) that are typically bound to the genomic DNA.
[0229] As used herein, the term "treating" generally refers to combining under conditions (eg, suitable temperature, time, and conditions) that result in a reaction (eg, cleavage).
[0230] As used herein, the term "chromatin isolated from a cell population" generally refers to the source of chromatin that makes the chromatin available. Isolated nuclei (which can be lysed to produce chromatin) and isolated chromatin (i.e., the product of lysed nuclei) are both considered types of chromatin isolated from a cell population.
[0231] As used herein, the term "transcription factor" generally refers to any polypeptide that can act by itself or in combination with at least one other polypeptide to regulate the level of gene expression. The term includes, but is not limited to, polypeptides that directly bind to DNA sequences. Transcription factors can increase or inhibit expression levels. Examples of transcription factors include, but are not limited to, Myc / Max, AP-1 (Jun, Fos, ATF), CREB, SMAD, HIF, ETS, ERG, ELK, STAT, estrogen receptor (ER) and androgen receptor (AR), glucocorticoid receptor (GR), progesterone receptor (PR), NFκB, p53, OCT, SOX and PAX. Transcription factors can be transcription factors identified by sequence analysis or naturally occurring reading frame sequences that have not been previously characterized as transcription factors. Polypeptides can also be artificially produced or chemically or enzymatically modified polypeptides.
[0232] The term "insertionase complex" as used herein generally refers to a complex comprising an insertionase and two adaptor molecules ("transposon tags") that bind to a polynucleotide to fragment and add adaptors to the polynucleotide. Such systems are described in various publications including Caruccio (Methods Mol. Biol. 2011 733: 241-55) and US20100120098, which are incorporated herein by reference.
[0233] The term "labeled fragment" as used herein generally refers to a polynucleotide fragment attached to a tag.
[0234] As used herein, the term "region" generally refers to a continuous length of nucleotides in an organism's genome. The range of a chromosome region can be from 1bp to the length of the entire chromosome. In some cases, the length of a region can be at least 200bp, at least 500bp, at least 1kb, at least 10kb or at least 100kb or more (e.g., up to 1Mb or 10Mb or more). Genomes can be from any eukaryotic organism, such as animal or plant genomes, such as humans, monkeys, rats, fish or insect genomes.
[0235] As used herein, the term "epigenetic map" generally refers to any presentation of epigenetic features (e.g., sites of nucleosomes, regions without nucleosomes, binding sites of transcription factors, etc.). The map can be physically displayed, for example, on a computer monitor. An exemplary epigenetic map is shown on Fig. 7A , 9 , 13, 20, etc.
[0236] The term "mapping information" as used herein generally refers to the assembly of experimentally obtained information about a region onto a physical map of the region.
[0237] As used herein, the term "sequence read abundance" generally refers to the number of times a particular sequence or nucleotide is observed in a collection of sequence reads.
[0238] As used herein, the term "nucleosome-free fragment" generally refers to a fragment of genomic DNA that is relatively depleted or lacks nucleosomes (ie, between nucleosomes).
[0239] As used herein, the term "chromatin accessibility" generally refers to the degree of accessibility of nucleic acid sites within a polynucleotide (e.g., in genomic DNA), i.e., the degree of "openness" of chromatin. Nucleic acid sites associated with polypeptides (e.g., associated with genomic DNA in nucleosomes) are generally inaccessible. Nucleic acid sites that are not complexed with polypeptides (e.g., complexed with genomic DNA between nucleosomes) are generally accessible (except for nucleic acid sites complexed with transcription factors and other DNA binding proteins).
[0240] As used herein, the term "DNA binding protein occupancy" generally refers to whether a DNA binding protein occupies a binding site of a sequence-specific DNA binding protein (eg, a binding site of a transcription factor). DNA binding protein occupancy can be measured quantitatively or qualitatively.
[0241] As used herein, the term "global occupancy" generally refers to whether a plurality of different binding sites (e.g., binding sites of transcription factors) of a DNA binding protein distributed throughout a genome are bound by the DNA binding protein. DNA binding protein occupancy can be measured quantitatively or qualitatively.
[0242] The term "diagnosis" as used herein generally refers to determining whether a subject has a particular disease or condition.
[0243] The term "prognosis" as used herein generally refers to the prediction of clinical outcome (eg, disease recurrence, disease recovery, death) as well as the prediction of whether a subject with a particular disease or condition will respond to a particular treatment.
[0244] As used herein, the term "cDNA copy" generally refers to a DNA molecule having the reverse complement of an RNA molecule (ie, first-strand cDNA) or a DNA molecule having the same sequence as an RNA molecule except that U is T (ie, second-strand cDNA).
[0245] As used herein, the term "real time" may generally refer to a response time of less than about 1 second, one tenth of a second, one hundredth of a second, millisecond, or less. The response time may be greater than 1 second. In some cases, real time may refer to processing, detection, or identification performed simultaneously or substantially simultaneously.
[0246] The term "subject" as used herein generally refers to an animal, e.g., a mammal (e.g., a human) or avian (e.g., a bird), or other organism, e.g., a plant. For example, a subject can be a vertebrate, a mammal, a rodent (e.g., a mouse), a primate, an ape, or a human. Animals can include, but are not limited to, farm animals, sports animals, and pets. A subject can be a healthy or asymptomatic individual, an individual suffering from or suspected of suffering from a disease (e.g., cancer) or a susceptible disease, and / or an individual in need of treatment or suspected of needing treatment. A subject can be a patient. A subject can be a micro-animal or plant or a microorganism (e.g., bacteria, fungi, archaea, viruses).
[0247] As used herein, the term "genome" generally refers to genomic information from a subject, which may be, for example, at least a portion or all of the subject's genetic information. The genome may be encoded as DNA or RNA. The genome may include coding regions (e.g., regions encoding proteins) and non-coding regions. The genome may include sequences of all chromosomes in an organism. For example, a human genome generally has 46 chromosomes in total. All of these sequences together constitute the human genome.
[0248] The terms "adaptor(s), "linker(s)" and "tag(s)" can be used synonymously. An adaptor or tag can be coupled to a polynucleotide sequence to be "labeled" by any method, including ligation, hybridization or other methods.
[0249] As used herein, the term "sequencing" generally refers to methods and techniques for determining the sequence of nucleotide bases in one or more polynucleotides. A polynucleotide can be, for example, a nucleic acid molecule, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single-stranded DNA). Sequencing can be performed by a variety of currently available systems, such as, but not limited to, Pacific Biosciences Oxford or Life Technologies Sequencing system. Alternatively or additionally, nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR or real-time PCR) or isothermal amplification can be used for sequencing. Such a system can provide a plurality of original genetic data corresponding to the genetic information of a subject (e.g., a person), as generated by the system from a sample provided by the subject. In some examples, such a system provides sequencing readings (also referred to herein as "readings"). Readings may include a string of nucleic acid bases corresponding to the sequence of sequenced nucleic acid molecules. In some cases, the systems and methods provided herein can be used together with proteome information.
[0250] The term "bead" as used herein generally refers to a particle. A bead can be a solid or semi-solid particle. A bead can be a gel bead. A gel bead can include a polymer matrix (e.g., a matrix formed by polymerization or cross-linking). A polymer matrix can include one or more polymers (e.g., polymers with different functional groups or repeating units). The polymers in the polymer matrix can be randomly arranged, such as in a random copolymer, and / or have an ordered structure, such as in a block copolymer. Crosslinking can be performed by covalent, ionic or induced, interactive or physical entanglement. A bead can be a macromolecule. A bead can be a sol-gel. A bead can be formed by nucleic acid molecules bound together. Beads can be formed by covalent or non-covalent assembly of molecules (e.g., macromolecules) such as monomers or polymers. Such polymers or monomers can be natural or synthetic. Such polymers or monomers can be or include, for example, nucleic acid molecules (e.g., DNA or RNA). Beads can be formed by polymeric materials. Beads can be magnetic or non-magnetic. Beads can be rigid. Beads can be flexible and / or compressible. Beads can be destructible or soluble. The beads may be solid particles (eg, metal-based particles, including but not limited to iron oxide, gold, or silver) covered with a coating comprising one or more polymers. Such coatings may be destructible or dissolvable.
[0251] As used herein, the term "biological particle" generally refers to a discrete biological system derived from a biological sample. Biological particles can be macromolecules. Biological particles can be small molecules. Biological particles can be viruses. Biological particles can be cells or derivatives of cells. Biological particles can be organelles. Biological particles can be rare cells from a cell population. Biological particles can be any type of cell, including but not limited to prokaryotic cells, eukaryotic cells, bacteria, fungi, plants, mammals or other animal cell types, mycoplasmas, normal tissue cells, tumor cells or any other cell type, whether derived from unicellular or multicellular organisms. Biological particles can be components of cells. Biological particles can be or can include DNA, RNA, organelles, proteins or any combination thereof. Biological particles can be or can include a matrix (e.g., a gel or polymer matrix) containing cells or one or more components from cells (e.g., cell beads), such as DNA, RNA, organelles, proteins or any combination from cells. Biological particles can be obtained from the tissue of a subject. Biological particles can be hardened cells. Such hardened cells may or may not include cell walls or cell membranes. Biological particles can include one or more components of cells, but may not include other components of cells. An example of such a component is a cell nucleus or a cell organelle. The cell may be a living cell. The living cell may be capable of being cultured, for example, when enclosed in a gel or polymer matrix, or when containing a gel or polymer matrix.
[0252] As used herein, the term "macromolecule component" generally refers to a macromolecule contained in or from a bioparticle. The macromolecule component may include a nucleic acid. In some cases, the bioparticle may be a macromolecule. The macromolecule component may include DNA. The macromolecule component may include RNA. RNA may be coded or non-coded. For example, RNA may be a messenger RNA (mRNA), a ribosomal RNA (rRNA), or a transfer RNA (tRNA). RNA may be a transcript. RNA may be a small RNA having a length of less than 200 nucleic acid bases, or a large RNA having a length of greater than 200 nucleic acid bases. Small RNA may include 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), small nucleolar RNA (snoRNA), Piwi interacting RNA (piRNA), tRNA-derived small RNA (tsRNA) and small rDNA-derived RNA (srRNA). RNA may be double-stranded RNA or single-stranded RNA. RNA may be a circular RNA. The macromolecule component may include a protein. The macromolecule component may include a peptide. The macromolecular component may comprise a polypeptide.
[0253] The term "molecular tag" as used herein generally refers to a molecule capable of binding to a macromolecular component. A molecular tag can bind to a macromolecular component with high affinity. A molecular tag can bind to a macromolecular component with high specificity or selectivity. A molecular tag can comprise a nucleotide sequence. A molecular tag can comprise a nucleic acid sequence. A nucleic acid sequence can be at least a portion or all of a molecular tag. A molecular tag can be a nucleic acid molecule or can be a portion of a nucleic acid molecule. A molecular tag can be an oligonucleotide or a polypeptide. A molecular tag can comprise a DNA aptamer. A molecular tag can be or comprise a primer. A molecular tag can be or comprise a protein. A molecular tag can comprise a polypeptide. A molecular tag can be a barcode.
[0254] As used herein, the term "compartment" generally refers to a space or volume that may be suitable for containing one or more substances or performing one or more reactions. A compartment can be a physical compartment, such as a droplet or a hole. A compartment can isolate a space or volume from another space or volume. A droplet can be a first phase (e.g., an aqueous phase) in a second phase (e.g., an oil) that is immiscible with the first phase. A droplet can be a first phase in a second phase that is not separated from the first phase, such as a capsule or a liposome in an aqueous phase. A compartment can include one or more other (internal) compartments. In some cases, a compartment can be a virtual compartment, which can be defined and identified by an index (e.g., an index library) across multiple and / or remote physical compartments. For example, a physical compartment can include multiple virtual compartments.
[0255] As used herein, the term "analyte" generally refers to a substance or one or more components thereof that can be identified, for example, by detection (e.g., by sequencing detection). Examples of analytes include, but are not limited to, DNA, RNA, synthetic oligonucleotides, markers described herein, antibodies, and proteins. An analyte can be a cell or one or more components of a cell.
[0256] The analytes may be of different types. In some examples, in a plurality of analytes, a given analyte is different in structural or functional class from other analytes in the plurality of analytes. Examples of different types of analytes include DNA and RNA; nucleic acid molecules and markers; transcripts and genomic nucleic acids; multiple nucleic acid molecules, each of which has a different function, such as a different cellular function. A sample may have multiple different types of analytes, for example, a mixture of DNA and RNA molecules, or a mixture of nucleic acid molecules and markers.
[0257] As used herein, the term "epitope binding fragment" or "antibody fragment" generally refers to a portion of an intact antibody that is capable of binding to the same epitope as an intact antibody, although not necessarily to the same extent. Although multiple types of epitope binding fragments are possible, epitope binding fragments generally include at least one pair of heavy chain variable regions and light chain variable regions (VH and VL, respectively) that are held together (e.g., by disulfide bonds) to retain an antigen binding site and do not include all or part of the Fc region. The epitope binding fragment of an antibody can be obtained from a given antibody by any suitable technique (e.g., recombinant DNA technology or enzymatic or chemical cleavage of an intact antibody), and can generally be screened for specificity in the same manner as screening intact antibodies. In some embodiments, the epitope binding fragment includes a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fd fragment, or a Fv fragment. In some embodiments, the term "antibody" includes antibody-derived polypeptides, such as single-chain variable fragments (scFv), diabodies or other multimeric scFvs, heavy chain antibodies, single domain antibodies, or other polypeptides containing sufficient portions of an antibody (e.g., one or more complementary determining regions (CDRs)) to confer specific antigen binding capabilities to the polypeptide.
[0258] Provided are systems and methods and / or various aspects thereof that can be combined with T cell receptor sequencing (TCR-seq) and assays of transposase accessible chromatin using sequencing (ATAC-seq). Such methods may be generally referred to herein as transcript index assays of transposase accessible chromatin using sequencing (T-ATAC-Seq). Also provided are systems and methods and / or various aspects thereof that can be combined with ATAC-seq and perturbation sequencing (perturbation-seq). Such methods may be generally referred to herein as perturbation index assays of transposase accessible chromatin using sequencing (perturbation-ATAC-Seq).
[0259] Methods described herein can separate (for example, partition) the analysis of individual cells or a small amount of cell colonies (including the analyte of individual cells or a small amount of cell groups), and then allow the analysis to be attributed back to the individual cells or a small amount of cell groups from which the analyte is derived. Unique identifiers such as barcodes (for example, the sequence carrying barcodes) can be delivered to the compartments of the cells that are separated or partitioned in advance, subsequently or simultaneously, so as to allow the characteristics of individual cells to be attributed to specific compartments later. In addition, unique identifiers (such as barcodes) can be coupled or attached to analytes, and can be delivered to the compartments of the cells that are separated or partitioned in advance, subsequently or simultaneously, so as to allow the characteristics of individual cells to be attributed to specific compartments later. Barcodes can be delivered (for example, on oligonucleotides) to compartments by any suitable mechanism (for example, as described elsewhere herein, attached to gel beads, in solution, etc.). In some aspects, the unique identifier is provided in the form of an oligonucleotide comprising a nucleic acid barcode sequence that can be attached to or otherwise associated with the nucleic acid content of an individual cell (or other components of a cell, or particularly fragments of such nucleic acids).
[0260] Transcript Indexing Assay for Transposase Accessible Chromatin Using Sequencing (T-ATAC-Seq)
[0261] The accessibility of chromatin can be assessed together with other protein coding genes. In some cases, the assessment may include sequencing polynucleotides and / or other nucleic acid molecules. Provided herein is a system and method for processing and analyzing immune cells (e.g., T lymphocytes) by sequencing cell receptor coding genes together with transposase accessible chromatin. The method described herein can be combined with T cell receptor sequencing (TCR-seq) and the determination of transposase accessible chromatin (ATAC-seq) using sequencing, and / or its various aspects. Such a method may be generally referred to herein as the transcript index determination (T-ATAC-Seq) of transposase accessible chromatin using sequencing. Systems and methods related to T-ATAC-Seq are described in Ansuman T. Satpathy et al., Transcript-indexed ATAC-seq for precision immune profiling, 24 Nature Medicine 580-90 (2018), which are incorporated herein by reference as a whole.
[0262] Analyte of particular interest is immune cell.Especially, conventional analysis techniques (such as some set sequencing processes) may not provide information about how the epigenomic profile in cloned T cells phenotypically causes T cell malignancy, immunity and / or immunotherapy effectiveness.Beneficially, epigenetic profiles (such as, the epigenomic state of individual T cells) and T cell specificity can be analyzed simultaneously at the single cell level.Advantageously, such analysis can promote the discovery of antigens driving certain T cell fate and / or drive the cis and trans regulators of T cell clone expansion.For example, methods described herein can make it possible to identify cancer clone-specific epigenomic features (which are not obvious according to some set measurements in other cases).
[0263] In some cases, T-ATAC-seq includes systems and methods for amplifying and sequencing TRA and TRB loci (which can encode TCR-α and TCR-β chains of individual cells, respectively).T-ATAC-seq can also include the measurement of genome-wide epigenetic changes, such as ATAC-seq or scATAC-seq, which enables the measurement of regulatory DNA elements by directly transposing sequencing adapters to accessible chromatin regions.In some cases, scATAC-seq identifies cis- and trans-regulatory elements and cell-to-cell differences in factors affecting epigenetic cell states.ATAC-seq can also provide insights into epigenetic regulation, for example, by using base pair resolution to identify enhancer and promoter sequences, identify the positioning of nucleosomes, cis-regulatory DNA elements, and the interference of transcription factors bound to each site by DNA footprints in inaccessible regions of transposase.Advantageously, the correlation between accessible genomic DNA and the sequence corresponding to the V (D) J region of the immune cell genome can be determined. Such correlation can be mapped based on sequencing reads associated with accessible genomic DNA and sequencing reads associated with sequences corresponding to the V(D)J regions of the genome.
[0264] Provided herein is a method for processing immune cells. The method may include capturing immune cells, wherein the immune cells contain genomic deoxyribonucleic acid (gDNA) and messenger ribonucleic acid (mRNA) molecules, contacting the gDNA from the immune cells with a transposase to produce labeled gDNA fragments in a labeling reaction, and generating complementary DNA (cDNA) molecules from the mRNA molecules, wherein the cDNA molecules contain sequences corresponding to the V(D)J regions of the immune cell genome.
[0265] Non-limiting examples of immune cells that can be analyzed using the methods described herein include B cells, T cells (e.g., cytotoxic T cells, natural killer T cells, regulatory T cells, and T helper cells, etc.), natural killer cells, cytokine-induced killer (CIK) cells, myeloid cells, such as granulocytes (basophils, eosinophils, neutrophils / hypersegmented neutrophils), monocytes / macrophages, mast cells, platelets / megakaryocytes, and dendritic cells.
[0266] In some cases, individual T cells are analyzed using methods disclosed herein. In some cases, individual B cells are analyzed using methods disclosed herein. Although some methods described herein describe the processing of T cells with reference to T-ATAC-Seq, it should be understood that the method can be applicable to and / or adapted to other types of immune cells, e.g., B cells. For example, since the sequence encoding the T cell receptor (TCR) can be sequenced together with the chromatin accessible to the transposase for processing T cells, the sequence encoding the B cell receptor (BCR) can be sequenced together with the chromatin accessible to the transposase for processing B cells.
[0267] In some cases, immune cells can be separated and / or captured from multiple immune cells. In some cases, immune cells can be one of the subgroups of immune cells separated and / or captured from multiple immune cells. Separation and / or capture can be in one or more stages. For example, in one stage, multiple immune cells can be sorted for the type of immune cells. For example, T cells can be sorted from immune cells. In another example, B cells can be sorted from immune cells. Subgroups comprising T cells and subgroups comprising B cells can be separated from the same immune cell colony. In some cases, in the next stage, after separation by cell type, in a further separation operation, cell subtypes can be separated. For example, a subgroup of T cells comprising one or more TCRs can be separated and / or captured from multiple T cells. Alternatively, a subgroup of T cells can be separated and / or captured from multiple immune cells.
[0268] In some cases, separation may include magnetic cell sorting. In some cases, separation may include flow cytometry sorting. In some cases, cell samples can be sorted based on molecular labels (e.g., fluorescent labels). For example, cells can be sorted, separated and / or captured from heterogeneous cell populations (e.g., blood) by magnetic activated cell sorting (MACS) or fluorescence activated cell sorting (FACS) using known methods of labeled antibodies for cell surface markers. For example, using FACS or MACS, T cells and / or B cells can be separated from cell samples. Subpopulations of these cells can be separated using antibodies for cell surface markers.
[0269] The capture of immune cells can include zoning immune cells in compartments. Compartments can be any compartments described elsewhere herein, for example, chambers, holes, micropores or droplets. Compartments can contain immune cells within a set of defined boundaries (enclosed or partially enclosed), and / or separate the space or volume within a compartment from any space or volume outside other compartments or compartments. In some cases, a compartment may prevent its contents from escaping the compartment in one or more cases. In some cases, a compartment may prevent an external object from entering the compartment in one or more cases. A compartment can be a separate compartment, for example, a separate hole or a separate chamber or a separate droplet. A compartment can be one of a plurality of compartments, for example, in an integrated device such as a fluid chip.
[0270] The method for ATAC-seq can generally be performed on partitioned immune cells, for example, according to one or more methods and systems outlined in U.S. Patent Publication No. 2016 / 0060691 and PCT Patent Publication No. WO 2018 / 218226A1 (hereinafter referred to as "Belhocine"), each of which is incorporated herein by reference in its entirety. Such a method may include fragmenting a polynucleotide (e.g., gDNA) into multiple fragments during the insertion of a molecular tag. The polynucleotide may be combined with multiple associated molecules. The associated molecule may be, for example, a protein, a nucleic acid, or a sugar. In some cases, the associated molecule may include a histone. In other cases, the associated molecule may include an adapter. In some cases, the fragments may be amplified and sequenced to produce sequencing reads. Such readings can be used to determine the accessibility of the polynucleotide at any given site. As described elsewhere herein, the fragments can be sequenced using high-throughput sequencing technology. In some cases, sequencing reads can be standardized based on the sequence insertion preference of the insertase. The length of the sequencing reads can be used to determine the chromatin state annotation. In some cases, ATAC-seq can further identify one or more proteins, such as transcription factors, that bind to the polynucleotide at the site. In some cases, the molecular tags can be used to generate an accessibility map of the polynucleotide.
[0271] In the compartment, immune cells can be subjected to lysis conditions before gDNA fragmentation. Lysis conditions can lyse immune cells and release chromatin while maintaining chromatin organization, and the released chromatin fragmentation. Alternatively, cells (or nuclei) can be permeabilized or permeable to allow transposase-nucleic acid complexes to enter the nucleus to produce nucleic acid fragments, and then lyse to release the fragments into the compartment. Permeabilization can be performed in a manner that disturbs the nucleus in the cell sample to a minimum. In some cases, permeabilization agents can be used to permeabilize cell samples. Examples of permeabilization agents include but are not limited to NP40, digitonin, tween, streptolysin and cationic lipids. In other cases, hypotonic shock and / or ultrasonic treatment can be used to permeabilize cell samples. In other cases, the insertion enzyme can be highly charged, which can allow it to penetrate the cell membrane.
[0272] In some cases, cells can be subjected to lysis conditions that maintain the nucleus intact. The nuclear precipitate can then be recollected and resuspended in a transposition buffer comprising one or more types of transposases. The chromatin used in the method can be prepared by any suitable method. In some cases, the nucleus can be separated, lysed, and the chromatin can be further purified, for example, from the nuclear envelope. In other cases, the chromatin can be separated by contacting the separated nucleus with a reaction buffer (which comprises an insertion enzyme complex and other necessary reagents). In these embodiments, the separated nucleus can be lysed when contacted with the reaction buffer, and this allows the insertion enzyme complex to approach the chromatin.
[0273] The gDNA can be fragmented and labeled in the labeling reaction. The chromatin can be treated with an insertion enzyme complex to produce labeled genomic DNA fragments. In this step, the chromatin can be labeled (i.e., cut and labeled in the same reaction) using an insertion enzyme (e.g., Tn5 or MuA), which cuts the genomic DNA in an open region (e.g., accessible region) of the chromatin and adds adapters to both ends of the fragment. Methods for labeling isolated genomic DNA are known in the art (see, e.g., Caruccio Methods Mol. Biol. 2011 733: 241-55; Kaper et al., Proc. Natl. Acad. Sci. 2013110: 5552-7; Marine et al., Appl. Environ. Microbiol. 2011 77: 8071-9 and US20100120098), and are commercially available from Illumina (San Diego, CA) and other suppliers. Such a system can be easily adapted for use herein. In some cases, conditions can be adjusted to obtain a desired level of insertion in the chromatin (e.g., an average of one insertion every 50 to 200 base pairs in an open region). Upon isolation of nuclei, they can be combined with a transposase and an adapter, wherein the combination results in lysis of the nucleus to release chromatin and generation of adapter-tagged fragments of genomic DNA.
[0274] Insertion enzyme can be any enzyme that can insert nucleic acid sequence into polynucleotide. In some cases, insertion enzyme can insert nucleic acid sequence into polynucleotide in a substantially sequence-independent manner. Insertion enzyme can be prokaryotic or eukaryotic. Examples of insertion enzyme include, but are not limited to, transposase, HERMES and HIV integrase. Transposase can be Tn transposase (e.g., Tn3, Tn5, Tn7, Tn10, Tn552, Tn903), MuA transposase, Vibhar transposase (e.g., from Vibrio harveyi), Ac-Ds, Ascot-1, Bs1, Cin4, Copia, En / Spm, F element, hobo, Hsmar1, Hsmar2, IN (HIV), IS1, IS2, IS3, IS4, IS5, IS6, IS10, IS21, IS30, IS50, IS51, IS150, IS256, IS407, IS427, IS630, IS903, IS911, IS982, IS1031, ISL2, L1, Mariner, P element, Tam3, Tc1, Tc3, Tel, THE-1, Tn / O, TnA, Tn3, Tn5, Tn7, Tn10, Tn552, Tn903, Toll, Tol2, TnlO, Ty1, and any prokaryotic transposase or any transposase related to and / or derived from those described above. In some cases, a transposase related to and / or derived from a parent transposase can comprise a peptide fragment having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% amino acid sequence homology to the corresponding peptide fragment of the parent transposase. The peptide fragment can be at least about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 400, or about 500 amino acids in length. For example, a transposase derived from Tn5 may comprise a peptide fragment that is 50 amino acids in length and is about 80% homologous to the corresponding fragment in the parent Tn5 transposase. In some cases, insertion may be facilitated and / or triggered by the addition of one or more cations. The cation may be a divalent cation, e.g., Ca 2+ Mg 2+ and Mn 2+ .
[0275] In some cases, the insertion enzyme may comprise two or more enzyme parts, which may be optionally linked together. The enzyme parts may be linked by using any suitable chemical synthesis or biological conjugation method. For example, the enzyme part may be connected by ester / amide bonds, sulfhydryl addition to maleimide, native chemical connection (NCL) technology, click chemistry (i.e., alkyne-azide pairs) or biotin-streptavidin pairs. In some cases, each enzyme part may insert a common sequence into a polynucleotide. The common sequence may comprise a common barcode. In some embodiments, the polynucleotide may be fragmented into multiple fragments during the insertion process. It can be determined that the fragments comprising the common barcode are adjacent in the three-dimensional structure of the polynucleotide.
[0276] In some cases, the insertion enzyme may further comprise an affinity tag. In some cases, the affinity tag may be an antibody. The antibody may bind, for example, a transcription factor, a modified nucleosome, or a modified nucleic acid. Examples of modified nucleic acids include, but are not limited to, methylated or hydroxymethylated DNA. In other cases, the affinity tag may be a single-stranded nucleic acid (e.g., ssDNA, ssRNA). In some instances, the single-stranded nucleic acid may bind to a target nucleic acid. In other cases, the insertion enzyme may further comprise a nuclear localization signal.
[0277] The gDNA fragments of the labeling can include one or more adapters. One or more adapters can be connected to the gDNA fragments. The adapter can be connected to both ends of each fragment. The first adapter is attached to the first end, and the second adapter is attached to the second end, wherein the first adapter and the second adapter are different. The adapter can include sequencing adapters, locked nucleic acids (LNA), zipper nucleic acids (ZNA), RNA, affinity active molecules (e.g., biotin, dig), self-complementary molecules, thiophosphate modifications, azide or alkynyl. In some cases, the adapter can further include a barcode molecule. In some cases, the barcode molecule can include a unique sequence. Such a unique sequence can be used to identify each insertion event. The adapter can further include a fluorescent label (e.g., fluorescein, rhodamine, Cy3, Cy5, thiazole orange, etc.). The adapter can include one or more adapter sequences. In a non-limiting example, for example, the adapter can each include one or more of a transposon end sequence (mosaic end sequence), a barcode sequence, a sequencing primer sequence, a primer sequence, an index sequence, a P5 sequence, a P7 sequence, or other sequences. Possible adaptor configurations and components are described in further detail in Belhocine.
[0278] After the gDNA fragments of the mark are produced, and before the reverse transcription reaction is initiated using the mRNA molecule, the mark reaction can be suppressed or quenched, for example, using magnesium chloride, or otherwise terminating the mark reaction. In some cases, the mark operation can include using a detergent, an insertion enzyme complex (for example, a transposase complex) and a divalent metal ion for the cell. In some cases, the detergent can be a nonionic surfactant, such as ethoxylated nonylphenol, such as NP-40. In some cases, termination can be completed by chelating the divalent metal ions required for the insertion enzyme complex (for example, a transposase complex), thereby terminating the reaction and releasing the insertion enzyme complex (for example, a transposase complex) from the DNA of the mark. In some cases, chelation can be completed by ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA) or diethylenetriaminepentaacetic acid (DTPA) or other chelating agents. Any other reaction terminator can promote the termination reaction. The mark reaction (and / or its termination) and the reverse transcription reaction can occur in the same compartment or in different compartments. For example, labeling (and / or its termination) can occur in the first compartment and reverse transcription can occur in different second compartments. In another example, labeling (and / or termination thereof) can occur in a first compartment and reverse transcription can occur in the same first compartment.
[0279] After the chromatin has been fragmented and labeled to produce labeled fragments of genomic DNA, at least some of the adapter-tagged fragments or derivatives thereof (e.g., amplicons) can be sequenced to produce multiple sequence reads. The fragments can be sequenced using any convenient method. For example, the fragments can be sequenced using the reversible terminator method of Illumina, the pyrophosphate sequencing method of Roche (454), the ligation sequencing (SOLiD platform) of Life Technologies, or the Ion Torrent platform of Life Technologies. Examples of such methods are described in the following references: Margulies et al. (Nature 2005 437:376-80); Ronaghi et al. (Analytical Biochemistry 1996 242:84-9); Shendure et al. (Science 2005 309:1728-32); Imelfort et al. (Brief Bioinform. 2009 10:609-18); Fox et al. (Methods Mol Biol. 2009;553:79-108); Appleby et al. (Methods Mol Biol. 2009;513:19-39) and Morozova et al. (Genomics. 2008 92:255-64), which are incorporated herein by reference as a general description of the methods and specific steps of the methods, including all starting products, library preparation methods, reagents, and final products of each step. Forward and reverse sequencing primer sites compatible with the selected next-generation sequencing platform can be added to the ends of the fragments during the amplification step.
[0280] The labeled gDNA fragments can be amplified using primers (e.g., polymerase chain reaction (PCR) primers). In some cases, the primers can hybridize to one or more adapter sequences in the labeled gDNA fragments. In some cases, the primers used for PCR can have a 5' tail that is compatible with a specific sequencing platform. In some cases, the primers used can contain cell-specific barcode sequences so that different libraries (e.g., of amplicons) can be merged together before sequencing, and the cell-specific barcode sequences can be used to trace sequence reads back to a specific sample.
[0281] ATAC-Seq and / or aspects thereof may be performed in conjunction with TCR-seq and / or aspects thereof. For example, after the labeling reaction is quenched or otherwise terminated, the mRNA molecule may be subjected to a reverse transcription reaction to produce a cDNA molecule. The method may include producing a cDNA molecule using a primer and a reverse transcriptase.
[0282] In T cells, the mRNA molecules from which cDNA molecules are produced can include T cell receptor alpha (TRA) and / or T cell receptor beta (TRB) RNA molecules. In some cases, at least one subset of primers may include the following sequence: a sequence specific to the constant region encoding TRA and TRB RNA molecules or a sequence targeting the constant region encoding TRA and TRB RNA molecules. Therefore, at least one subset of the cDNA produced can correspond to the V (D) J region of the immune cell genome. In some cases, such cDNA can be barcoded. PCT Patent Publication No. WO / 2018 / 075693 and U.S. Patent Publication U.S. Patent Application No. 2018 / 0105808 (each of which is incorporated herein by reference in its entirety) describe methods and compositions suitable for barcoding cDNA produced by mRNA transcripts (including mRNA transcripts encoding V (D) J regions of immune cell receptors) and / or barcoding methods and compositions including template switching oligonucleotides.
[0283] Provided herein are beads suitable for processing nucleic acid sequences (e.g., mRNA, complementary DNA derived from reverse transcription of mRNA) encoding at least a portion of a V(D)J sequence of an immune cell receptor (e.g., TCR or BCR). The beads can be gel beads. The barcoded primers can be coupled or otherwise attached to the gel beads. In some cases, the barcoded primers can be releasably attached to the gel beads. Therefore, the first barcode molecule may include a priming sequence that can trigger a nucleic acid sequence of at least a portion of such a V(D)J sequence encoding an immune cell receptor. In some cases, the nucleic acid molecule with such a nucleic acid sequence is a cDNA, which is produced by reverse transcription of the corresponding mRNA, such as using a primer containing poly-T. The cDNA produced can then be barcoded using a primer that includes a barcode sequence (and optionally, a unique molecular identifier (UMI) sequence) hybridized with at least a portion of the cDNA produced. In some cases, a template switching oligonucleotide in combination with a terminal transferase or reverse transcriptase having terminal transferase activity can be used to generate a priming region on the cDNA, to which the barcoded primer can hybridize during cDNA generation. For example, the terminal transferase activity can add a poly-C tail to the 3' end of the cDNA, thereby allowing the template switching oligonucleotide to bind through the poly-G priming sequence and further extend the 3' end of the cDNA. The original mRNA template and template switching oligonucleotide can then be denatured from the cDNA, and a barcoded primer comprising a sequence complementary to at least a portion of the priming region generated on the cDNA can then be hybridized to the cDNA and generate a barcoded construct comprising a barcode sequence (and any optional UMI sequence) and a complementary sequence to the cDNA.
[0284] The cDNA and / or labeled gDNA fragments can be amplified in a PCR reaction, for example, by contacting them with a plurality of primers and a polymerase to produce a cDNA molecule amplicon and / or a labeled gDNA fragment amplicon. In some cases, at least one subset of a plurality of primers may include the following sequence: a sequence specific to a constant region and / or a variable region encoding TCR or a sequence targeting a constant region and / or a variable region encoding TCR. In some cases, the amplicon of the cDNA and the amplicon of the labeled gDNA fragment may include a cell-specific barcode sequence for identifying immune cells. In some cases, such an amplicon containing a cell-specific barcode sequence can be produced from other amplicons of the labeled gDNA fragments and cDNA molecules. Sequencing readings may be associated with immune cells based at least in part on a cell-specific barcode sequence. The barcode molecule may be delivered before, simultaneously, or after the cell partition. In some cases, the barcode molecule may be delivered via beads (e.g., gel beads), as described elsewhere herein.
[0285] The cDNA, the gDNA of labeling and / or its amplicon can be sequenced to produce sequencing readings. Such sequencing readings can be used to determine the correlation between the accessible gDNA and the sequence corresponding to the V (D) J region in the immune cell. The correlation can be mapped. In some cases, the cDNA, the gDNA of labeling and / or its amplicon can be removed from the compartment before sequencing and merged for sequencing. The sequencing readings generated from the product or derivative of the compartment that partitions the immune cell can be associated with the immune cell.
[0286] In some embodiments, the chromatin and T cell receptors of T cells can be analyzed (e.g., ATAC-seq and / or T-ATAC-seq). T cells can be collected, partitioned, lysed and transposed. After transposase treatment and reaction quenching, the sample can be reverse transcribed and PCR can be performed using a primer mixture including multiple V-α and V-β region primers and C-α and C-β primers. These processes can be performed in a microfluidic chip. For example, the automated microfluidic platform Fluidigm can be used for single cell capture, lysis, and downstream processing.
[0287] The library of harvest can be further amplified. For example, when checking T cells, T cell receptor (TCR) primers can be used. After this, an aliquot of the sample can be used as a template for subsequent PCR reactions. Subsequent PCR reactions can be nested PCR reactions, such as using primers for TCRV-α, TCRV-β, TCRC-α and TCRC-β primers. The products of these reactions can be used as templates for PCR reactions subsequently, which incorporate barcodes to enable sequencing.
[0288] Purification of the library can be obtained by selecting selected nucleotide fragments. Nucleotide fragments can be selected by their size, isoelectric point or other biochemical or biophysical properties. For example, nucleotide fragments can be purified by size by using polyacrylamide gel electrophoresis and selecting fragments of the desired size.
[0289] After barcoding, the amplicons from the PCR can be purified and sequenced to form a library. Prior to sequencing, the library can be additionally amplified and / or quantified.
[0290] Various applications of T-ATAC-seq data can be envisioned. In a non-limiting example, the epigenomic features in immortalized leukemia T cells can be compared with the epigenomic features of primary human T cells from healthy patients and primary human T cells from leukemia patients. Data from T-ATAC-seq can be used, for example, to identify leukemia and non-leukemia regulatory pathways in T cells. In some cases, T-ATAC-seq can identify cancer clone-specific epigenomic features that are not easily found from collections or batch measurements. In another application, the heterogeneity of T cells in a population can be characterized, for example, by identifying cis and trans regulators of naive relative memory T cell states. Intercellular variability and intermediate epigenomic phenotypes can also be characterized in single cells, which are usually obscured by batch measurements. Identifying TCR-α-β coding sequences may also help understand the identity of single T cells and help discover clonal gene regulatory pathways. Similarly, T-ATAC-seq can be used to separate clonal and non-clonal regulatory pathways in cells from the same individual. It is therefore apparent to one skilled in the art that T-ATAC-seq can enable analysis of epigenomic profiles in clonal T cells and may be valuable in studies related to T cell malignancies, immunity, and immunotherapy.
[0291] Figure 1An example scheme and / or workflow 100 for T-ATAC-seq is shown. Single T cells 102 are isolated in a microfluidic chip using a microfluidic single-cell capture mechanism 104, such as those found in an integrated fluid circuit or partition mechanism described elsewhere herein. The chip may include multiple chambers. T cells are sequentially subjected to operations 108 related to ATAC-seq, including lysis 108a (or separation of nuclei), release 108b transposase, initiation of a labeling reaction to generate labeled gDNA fragments, and quenching 108c labeling reactions. After quenching, TRA and TRB transcripts are reverse transcribed 110. The labeled gDNA fragments and cDNAs, and / or their amplicons (e.g., ATAC-seq and TCR-seq amplicons) are then amplified 112. Then, optionally, single-cell libraries are amplified with cell identification barcodes 114a, b, and merged 116a, b. The amplicons are analyzed by high-throughput sequencing.
[0292] Some embodiments of the method may involve making an epigenetic map of a cellular genomic region. This can be done by mapping the information obtained from the sequence reads to the region. In these cases, the sequence reads can be subjected to computer analysis to generate a number of digital outputs that are mapped to a presentation (e.g., a graphical presentation) of the region of interest. As will be explained in more detail below, many types of information can be mapped, including but not limited to: (i) the cleavage site of the transposase; (ii) the size of the fragments produced in step a); (iii) the length of the fragment; (iv) the position of the sequence reads whose length is within a defined range; (v) the abundance of the sequence reads; and (vi) the deviation of transcription factors.
[0293] In some cases, data obtained from T-ATAC-seq can be used to distinguish cell subtypes. For example, Fig.10 A diagram showing the epigenomic profiles of pooled T cell subtypes. Fig.10 A principal component analysis (PCA) is shown, which shows different chromatin states of T cell subsets (e.g., naive and memory T cell subtypes). The percentage of variation explained by each PC is listed (1002, 1004). The principal components can then be trained on the pooled ATAC-seq data to remove contaminating non-T cells that may remain after sorting. PCA of the pooled ATAC-seq profiles from CD4+T cell subtypes is shown.
[0294] Sequence readings can be subjected to computer analysis to identify the ends of the fragments (from which the transposon cleavage site can be inferred). In these embodiments, one end of the fragment can be defined by the sequence at the beginning of the sequencing reading, and the other end of the fragment can be defined by the sequence at the beginning of the second sequencing reading, wherein the first and second sequencing readings are obtained by paired end sequencing (e.g., using the sequencing platform of Illumina). The same information can be obtained by checking the beginning and end of the longer sequence reading (theoretically, it should have the sequence of two adapters; one at one end and the other at the other end). In these embodiments, a single sequence reading can include two adapter sequences, in which case the two ends of the fragment (which correspond to two cleavage sites of two separate transposases) can be inferred from a single sequence reading. The length of the fragment can be calculated by, for example, mapping the fragment ends to the nucleotide sequence of the region of interest, and counting the number of base pairs between those positions. The information used can be obtained using the nucleotide sequence at the beginning and / or end of the sequence reading.
[0295] In some cases, sequence reads can be grouped by length. In some embodiments, some sequences can be annotated as nucleosome-free sequences (i.e., sequences from fragments predicted to be between nucleosomes) based on their size. Reads associated with mononucleosomes, dinucleosomes, and trinucleosomes can also be identified. Figure 4 The data shown in determine these cutoffs. Fragment length (providing the same information as sequence read length) can also be processed in the same way. In some cases, sequence read abundance can be calculated, i.e., the number of times a particular sequence in a genomic region is present in sequence reads.
[0296] The resulting epigenetic map can provide an analysis of chromatin in the region of interest. For example, based on the mapped information, the map can display one or more of the following: a spectrum of chromatin accessibility along the region; DNA binding protein (e.g., transcription factor) occupancy at a site in the region; nucleosome-free DNA in the region; nucleosome positioning along the region; and a spectrum of chromatin states along the region. In some embodiments, the method may also include measuring the overall occupancy of binding sites by DNA binding proteins, for example, by aggregating data on multiple sites bound by a DNA binding protein. In some cases, the map can also be annotated with sequence information and information about sequences (e.g., the location of promoters, introns, exons, known enhancers, transcription start sites, untranslated regions, terminators, etc.) so that epigenetic information can be viewed in the context of annotations.
[0297] In some cases, the epigenetic map may include one or more presentations of one or more calculations of transcription factor (TF) deviations. TF deviation can be performed by calculating the original accessibility deviation, that is, the number of ATAC-seq readings in the peak of each single cell observed minus the number of ATAC-seq readings in the peak of the expected given motif. The expected readings can then be calculated from the population average of all cells in the experiment. The deviation value can be bias-corrected (for example, minus the average deviation calculated using similar accessibility and GC content). In some cases, the deviation value can be divided by the standard deviation of the background to obtain a Z score. Other methods of data analysis, peak processing, peak classification and data processing are contemplated.
[0298] In some embodiments, epigenetic maps can provide information about active regulatory regions and / or transcription factors bound to regulatory regions. For example, the position of nucleosomes can be inferred from the length of the sequencing reads generated. Alternatively, transcription factor binding sites can be inferred from the size, distribution and / or position of the sequencing reads generated. In some cases, new transcription factor binding sites can be inferred from the sequencing reads generated. In other cases, new transcription factors can be inferred from the sequencing reads generated.
[0299] Provided herein are some embodiments of methods for treating cells. In one aspect, a method is provided, comprising: (a) labeling accessible genomic DNA in one or more cell nuclei to produce labeled genomic DNA, (b) terminating the labeling reaction, and (c) after operation (b), adding primers, reverse transcriptase and dNTPs to one or more cells to reverse transcribe RNA in one or more cells to produce cDNA.
[0300] In some embodiments, the method is performed in a single container or compartment. In some embodiments, operation (b) is performed by mixing a reaction terminator with the reactants of operation (a), and operation (c) is performed by adding primers, reverse transcriptase, and dNTPs to the reactants of operation (b), without transferring any reactants to a second container or compartment.
[0301] In some embodiments, the labeling operation (a) is completed by combining one or more cells with a detergent, an insertion enzyme complex (e.g., a transposase complex) and a divalent metal ion. In some embodiments, the detergent is a nonionic surfactant, such as ethoxylated nonylphenol, such as NP-40. In some embodiments, the termination operation (b) is completed by chelating the divalent metal ions required for the insertion enzyme complex (e.g., a transposase complex), thereby terminating the reaction and releasing the insertion enzyme complex (e.g., a transposase complex) from the labeled DNA. In some embodiments, chelation is performed by ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA) or diethylenetriaminepentaacetic acid (DTPA). In some embodiments, the reverse transcription operation (c) includes adding an excess of divalent metal ions to the reactants. Any other reaction terminator can promote the termination reaction. The labeling reaction (and / or its termination) and the reverse transcription reaction can occur in the same compartment or in different compartments.
[0302] In some embodiments, one or more cells are mammalian cells. In some embodiments, one or more cells are single cells. In some embodiments, one or more cells are multiple cells.
[0303] In some embodiments, the primer of (c) is an oligo(d)T primer, a random primer, or a gene-specific primer.
[0304] In some embodiments, the method includes after operation (c), amplifying the genomic DNA and cDNA of the cell mark. In some embodiments, amplification is completed by PCR. In some embodiments, the genomic DNA and cDNA of the mark are amplified separately. In some embodiments, the method also includes sequencing the genomic DNA and the cDNA of the amplification of the mark from the cell. In some embodiments, the method also includes identifying the correlation between chromatin structure and gene expression.
[0305] Figure 2 Pie charts are shown indicating the overlap of TCR-seq and ATAC-seq data from single Jurkat cells that passed quality control filters (n=231 single cells). The pie charts show the proportion of cells that generated ATAC-seq profiles for which TRA or TRB sequences were also obtained. 204 shows the fraction of cells for which ATAC-seq data were obtained but not TRA or TRB data.
[0306] Figure 3Figures following quality control filters are shown. In panel A, the number of unique ATAC-seq nuclear fragments per cell is plotted compared to the percentage of fragments in ATAC-seq peaks derived from the pooled ATAC-seq profile. Panel B shows the read counts from TRA or TRB paired-end sequencing compared to the TCR dominance of the top clones per cell.
[0307] Figure 4 Comparison of aggregated (panel A) and single cell T-ATAC-seq (panel B) profile features is shown. Enrichment 402 of ATAC-seq Tn5 insertion sequences around TSS and nucleosome periodicity 404 of ATAC-seq fragment length are shown. In panel B, a graph of the distance from the TSS 406 of a single cell is shown, as well as the frequency (count) of fragment length 408. Fragment length 408 indicates the genomic distance between two Tn5 insertion sites, as determined by paired-end sequencing of ATAC fragments.
[0308] Figure 5 A heat map of TRA or TRB rearrangements in cells is shown. Each axis represents all possible genes within the TRA or TRB locus shown. The labeled genes 502 indicate sequences identified using T-ATAC-seq.
[0309] Figure 6 Demonstrated use of TCR-Seq clones to identify mouse or human genomes.
[0310] Fig. 7A A graph showing the identification of epigenomic features generated from T-ATAC-seq is shown. Genomic tracks comparing clustered T-ATAC-seq profiles 706 with pooled ATAC-Seq 704 and DHS-seq 702 profiles. Figure 7B Shows Fig. 7A A zoomed-in view of the genomic locus of .
[0311] Figure 8 A heat map of transcription factor (TF) deviation z-scores obtained using T-ATAC-seq for Jurkat cells 802 compared to other previously published cell types 804 is shown. Exemplary single letter amino acid sequences 806 are presented for the identified CDR3 regions.
[0312] Fig. 9 A heat map 902 is shown showing ATAC_seq fragment counts in peaks (rows) containing the indicated motif from aggregated single cells. 904 shows genomic tracks of aggregated T-ATAC-seq data.
[0313] Fig.10A graph showing the epigenomic profiles of pooled T cell subtypes is shown. A PCA of pooled ATAC-seq profiles from CD4+ T cell subtypes is shown. The percentage of variation explained by each PC is listed (1002, 1004).
[0314] Fig.11 A graph showing the epigenomic profiles of pooled T cell subtypes. The graph shows distinct ATAC-seq peaks for different T cell subtypes.
[0315] Fig.12 is a heat map of clusters displaying the most highly altered ATAC-seq peaks.
[0316] Fig.13 The immunological signatures obtained from ATAC-seq are shown. In panel A, the MsigDB immunological signature of regulatory T cell-specific ATAC-seq obtained from GREAT analysis is shown. In panel B, the T H MsigDB pathway features of 1-specific ATAC-seq peaks. Figure C , collective ATAC-seq genomic loci data are shown.
[0317] Fig.14 Shown are plots of the Pearson correlation of the pooled ATAC-seq profiles 1402 and the PC scores of the pooled ATAC-seq profiles after downsampling to 10,000 1404 or 1,000 1406 fragments. The heatmaps demonstrate that CD4+ T cell subtype profiles can be distinguished from each other.
[0318] Fig.15 The workflow of T-ATAC-seq analysis in primary human T cells is shown. Single cells are sequentially classified 1502 as the main blood lineage and subsequently classified as T cell subsets by similarity to the set reference ATAC-seq spectrum. T-ATAC-seq data 1504 from classified single T cells are analyzed for accessibility and TF activity at regulatory DNA elements, and TCR (TRA and TRB) sequence identity 1506. Integration analysis is then performed to identify genomic features 1508 in T cell clones.
[0319] Fig.16 t-SNE projections of various T cells are shown.
[0320] Fig.17A plot of TF bias-corrected deviated enrichment in aggregated single cell populations is shown. TF enrichment was calculated as the difference in average TF motif accessibility between two single cell populations. Enrichment of all T cells 1704 compared to monocytes 1702, memory T cells 1708 compared to naive T cells 1706, and T cells 1709 compared to memory T cells 1708 are shown. H 17 1710 Enrichment of cells. The axis represents the difference 1710 between -log(P value) and mean TF accessibility.
[0321] Fig.18 Shown are plots of t-SNE projections of individual T cells highlighting the motif accessibility TF z-scores for ZBTB7B, STAT1, RORA, and FOSL2.
[0322] Fig.19 T for aggregation is shown H Figure 17 shows the difference between naive cells and aggregated memory cells and the average bias-corrected deviation for the ranking of aggregated memory cells versus aggregated naive cells. The TF motifs of the selected factors are shown in each quadrant. As can be seen from these figures, the BATF motif 1902 shows a strong affinity for both memory T cells and T cells. H In contrast, RORA motif 1904 showed increased accessibility in T H 17 increased accessibility in T cells but not in memory T cells.
[0323] Fig. 20 Shown is a heat map showing ATAC-seq fragment counts in peaks containing the indicated motifs from aggregated single cells.
[0324] Fig.21 Shown is the biased enrichment of TFs in clonal versus non-clonal memory T cells for two memory T cell clones (top and bottom).
[0325] Fig. 22 The workflow of T-ATAC-seq analysis in T cell samples from leukemia patients is shown. Single cells are first classified as leukemic cells or non-leukemic cells based on TCR sequence identity. ATAC-seq data from classified single T cells are then analyzed for accessibility and TF activity at regulatory DNA elements.
[0326] Fig.23In panel A, a heat map of TRB rearrangements in peripheral blood samples from patients with Sézary syndrome is shown. Panel B shows the bias enrichment of TF bias correction in aggregated clonal T cells compared to all other T cells. Shown are TCR (TRA and TRB) sequences identified in putative leukemic T cell clones (top). TF enrichment (bottom) is calculated as the difference in average TF motif accessibility between aggregated leukemic T cell clone spectrum and non-clonal T cell spectrum in the same patient. Selected TF motifs enriched or depleted in T cell clones are indicated. P values were calculated using a two-tailed t-test (n=139 cells, n=3 independent experiments).
[0327] Fig.24 t-SNE projections of naive and memory T cells from healthy individuals (n=320 cells, n=6 independent experiments) and patient cells (n=139 cells, n=3 independent experiments) are shown, colored by cell ID, clonal versus non-clonal cells, BATF TF score, and GATA3 TF score. The scale bar indicates the range of TF z scores.
[0328] Fig.25 A heat map of ATAC-seq fragment counts in peaks containing the indicated motif 2502 is shown. Labels indicate genes associated with differential peaks, including genes 2504 previously shown to be mutated in individuals with CTCL.
[0329] Fig.26 MSigDB perturbation signatures of TRB7-9 specific ATAC-seq peaks obtained from GREAT analysis are shown. Cells were sorted for CD26+ and CD26-CD4+ T cells 2602 and clonal TCR repertoires within each population 2604. Lack of CD26 expression has previously been used to distinguish leukemic from non-leukemic cells. TF bias-corrected bias enrichment in aggregated CD26- cells (n=56 single cells) relative to CD26+ cells (n=49 single cells). P values were calculated using a two-tailed t-test. Fig.23 The TF identified above the dashed line in B is labeled 2606.
[0330] Fig. 27 The bias-corrected enrichment of TFs in aggregated CD26- cells (n=56 single cells) relative to CD26+ cells (n=49 single cells) is shown. P values were calculated using a two-tailed t-test.
[0331] Fig.28 A T-ATAC-seq protocol outlining the biochemical reactions occurring in each microfluidic chamber in an IFC is shown. Microfluidic chambers are represented as boxes.
[0332] Fig.29 FACS analysis of Jurkat cells before sorting 2902 and after sorting 2904 is shown. Cells were sorted for single live cells and then loaded into IFC. Numbers represent the percentage of cells within the indicated gates.
[0333] Fig.30 ATAC-seq quality measurements for individual Jurkat cells in a single experiment (96 cells) are shown. The graph shows unique nuclear ATAC-seq fragments 3002 and read alignment rate 3004 for each individual cell. ATAC-seq fragment number 3006 and TSS enrichment rate 3008 for individual cells from three independent T-ATAC-seq experiments on Jurkat cells are compared. Dashed line 3010 represents a quality filter of 500 unique nuclear fragments per cell.
[0334] Fig.31 Panel A shows a comparison of ATAC-seq fragments 3102 and TCR-seq paired-end reads 3104 in a single Jurkat cell from three separate T-ATAC-seq experiments. The dashed lines represent quality filters for 500 unique nuclear fragments for ATAC-seq data and 100 reads for TCR-seq data. Panel B shows TCR-seq quality control measurements in Jurkat cells. Shown are TCRα reads 3106 or TCRβ reads 3108 in a single cell and the associated strengths of the major TCR clones. The bottom panels 3110, 3112 show the CDR3 sequences and gene usage of the Jurkat TCR.
[0335] Fig.32 Overlap of single cell TCR-seq and ATAC-seq data is shown for all cells in which TCRα 3202, TCRβ 3204, or ATAC 3206 sequences were obtained.
[0336] Fig.33 Panel A shows t-SNE projections of T-ATAC-seq data 3302 from single Jurkat cells, scATAC-seq data 3304 from single Jurkat cells, and scATAC-seq data from previously published single GM12878 3306, H1 ESC 3308, and K562 cells 3310. Panel B shows the Pearson correlation of TF bias z-scores in the single cells described in Panel A. Figure CTF bias-corrected bias enrichment in the aggregated single cell populations described in panel A is shown. TF bias-corrected bias enrichment in K562 cells compared to H1 ESCs, and in panel D, Jurkat cells compared to GM12878 cells. TF enrichment was calculated as the difference in mean TF motif accessibility between the two single cell populations. P values were calculated using a two-tailed t-test.
[0337] Fig.34 Panel A shows a plot of Spearman correlation 3402 of TF z-scores in pooled ATAC-seq data for Jurkat cells compared to pooled single cells. The number of pooled single cells 3404 in each comparison is recorded on the x-axis. Cells were obtained from 3 independent experiments. The dark black boxes in the violin plots extend from 25% to 75%, and the boundaries of the violins are the maximum and minimum values. Panel B shows the Pearson correlation of fragment counts in ATAC-seq peaks in pooled ATAC-seq data for Jurkat cells compared to fragment counts in pooled single cells. The number of pooled single cells in each comparison is recorded on the x-axis. Cells were obtained from 3 independent experiments. The dark black boxes in the violin plots extend from 25% to 75%, and the boundaries of the violins are the maximum and minimum values.
[0338] Fig.35 Histograms of pre-gated live cells are shown. Numbers represent the percentage of cells within the indicated gates.
[0339] Fig.36 A graph showing the post-sort purity of CD4+ T cell subsets is shown. Numbers represent the percentage of cells within the indicated gates.
[0340] Fig.37 T-ATAC-seq data quality control filters are shown. The number of unique ATAC-seq nuclear fragments 3702 in each single primary T cell is shown compared to the percentage of fragments in ATAC-seq peak 3704 derived from the collection T cell ATAC-seq data (panel A). Panel B shows the individual single cell spectra of four cells. Single cells show enrichment on the transcription start site (TSS) and the nucleosome periodicity of ATAC-seq fragment length. Fragment length represents the genomic distance between two Tn5 insertion sites, as determined by paired end sequencing of ATAC fragments.
[0341] Fig.38Panel A shows a quality measurement plot of a TCR-seq profile from T-ATAC-seq in a single cell. The TCR alpha reads 3802 and TCR beta reads 3804 in each single cell are shown compared to the TCR read preponderance 3806 in each cell. Panel B shows an example sequence used to generate the TCR data.
[0342] Fig.39 Pearson correlations of PC scores for individual cells (x-axis; 879 individual cells) and aggregated cells (y-axis; 93 aggregated cell types) are shown. The aggregated cell types are derived from data generated in this study (T cell subtypes, 3 independent experiments) and from Corces et al. (2016)9.
[0343] Fig.40 t-SNE projections of PCA scores for all cells (Panel A) or primary human T cells (Panel B) are shown.
[0344] Fig.41 Panel A shows a heatmap of TF bias z-scores for pooled T cell ATAC-seq profiles. Panel B shows the ranked TF motif z-scores for each T cell subtype compared to the mean TF z-score calculated across all other subtypes.
[0345] Fig.42 Shown is a comparison of TF bias z-score enrichment (mean difference) in TH17 cells relative to all other T cell subtypes 4202 and in TH1 cells relative to all other T cell subtypes 4204. The enrichment of TFs in each subtype is compared to their enrichment in all T cell memory subtypes compared to naive cells 4206.
[0346] Fig.43 t-SNE projections of sorted individual naive, memory, and TH17 T cells are shown. Cells are colored by LEF1, IRF7, PRDM1, and RUNX1 motif accessibility TF scores. Scale bar indicates the range of TF z-scores.
[0347] Fig.44 A single naive 4402, memory 4404 and TH are shown 17 Cell-to-cell variation in TF motif accessibility in 4406 cells. Shown are TF variability and error estimates (grey shading) observed in sorted T cell populations. Variability measured from permuted background is shown as grey dots for comparison (see Methods for details on background calculation). Selected highly variable TFs are indicated by arrows.
[0348] Fig.45Shown is a t-SNE projection of a single T cell. Naive T cells (left) or TH17 cells (right) are shaded by the number of unique nuclear ATAC-seq fragments obtained in the cell. Light gray cells are other populations of T cells (including memory T cells and CTCL cells). These figures show that the different clusters of naive T cells are not a byproduct of the differences in the ATAC-seq fragments obtained for each cell. For each subtype, the highlighted cells were obtained from 2 independent experiments.
[0349] Fig.46 Pearson correlations of TF deviation z-scores for individual naive, memory, and TH17 cells are shown. TF modules associated with typical T helper cell phenotypes are shown on the right.
[0350] Fig.47 Shown is confirmation of TCRβ sequences obtained in cloned CTCL cells using T-ATAC-seq and ImmunoSEQ analysis (Adaptive Biotechnologies) from the same sample.
[0351] Fig.48 Representative FACS strategies and post-sort purity of CD26+ and CD26- CTCL cells are shown. Peripheral CD4+ blood cells were stained for expression of the markers shown. Numbers represent the percentage of cells within the gates shown. Cells were double sorted to ensure high purity of the desired populations. Data represent 3 independent experiments. (c) Expansion of TCR clones in CD26+ and CD26-CD4+ T cell populations in CTCL patients #2 and #3.
[0352] Fig.49 Showing the presence of expanded TCR clones in CD26+ and CD26-CD4+ T cell populations in CTCL patients #2 and #3.
[0353] Fig.50 TF bias-corrected biased enrichment of aggregated clonal T cells from patient #2 compared to all other T cells is shown (left). TF biased enrichment in aggregated clonal cells was not enriched in CD26- cells compared to CD26+ cells (right).
[0354] Fig.51 Panel A shows a browser screenshot from tcr.buenrostrolab.com showing drop-down menu options to navigate single-cell TF bias scores and TCR sequences. Panel B shows an example screenshot showing single cells with TRBV12-3 identity (left) and colored by TCF4 TF bias z-score (right).
[0355] Fig.52A schematic depicting a traditional CRISPR screen is shown.
[0356] Perturbation-indexed single-cell ATAC-Seq (Perturbation-ATAC-Seq)
[0357] Another aspect of the present disclosure provides systems, methods and compositions for high-throughput simultaneous measurement of CRISPR perturbations and chromatin states in single cells. The methods and systems described herein can combine ATAC-seq and perturbation sequencing (perturbation-seq) and / or various aspects thereof. Such methods may be generally referred to herein as perturbation index determination (perturbation-ATAC-seq or perturbation-ATAC) of transposase accessible chromatin using sequencing. In some cases, perturbation-ATAC is used, wherein a cell sample comprising one or more cells is perturbed by introducing CRISPR guide RNA, and then the CRISPR guide RNA and open chromatin sites detected simultaneously by ATAC-seq are analyzed. Beneficially, perturbation-ATAC may reveal regulatory factors that control epigenomic states. In some cases, perturbation-ATAC may reveal regulatory factors that control cis-element accessibility and / or trans-acting factor occupancy. In some cases, perturbation-ATAC may reveal the positioning of nucleosomes. In some cases, perturbation-ATAC may reveal regulatory modules with coordinated activities in cell types (e.g., coordinated trans-acting factor activities, cooperative activities of co-bound TFs on cis-elements, etc.) In some cases, perturbation-ATAC is performed in a high-throughput manner, and single-cell data including epigenomic variability can be obtained.
[0358] In some embodiments, a selected perturbation (i.e., CRISPR inhibition) is applied to a cell or cell population. In other embodiments, unbiased perturbations can be performed to reveal different trans-acting factor activities occurring in biological processes, e.g., cell differentiation, metastasis, migration, etc. Global analysis of perturbed factors and their corresponding target regions can reveal interconnected regulatory networks that generate information that would otherwise not be obtained from a single target perturbation.
[0359] Perturbation-ATAC can be used to infer various genotype-phenotype relationships. In some cases, perturbation-ATAC is applied to transcription factors. In a non-limiting example, perturbation-ATAC can also be applied to chromatin modifiers and non-coding RNAs. Combinations of perturbation-ATAC assay factors can be used.
[0360] In some cases, perturbation-ATAC can be used to reveal the hierarchical organization of TF that controls cell behavior. For example, cell state, cell variation, cell fate, cytopathology (e.g., disease-related cis-regulatory elements), epistatic relationships of TF, genome co-localization of TF and / or synergistic and / or inhibitory interactions of TF can be inferred from perturbation-ATAC. Perturbation-ATAC can also be used to analyze gene regulatory networks in development and disease. In some cases, perturbation-ATAC can be found to establish epigenetic interactions of gene expression patterns that are the basis of development, differentiation, cell-cell and / or cell-matrix interactions and cell-environment reactions. In some cases, perturbation-ATAC can be used to identify gene targets, gene signatures, transcription factors, regulatory factors and / or cell states that are affected by the perturbation of a given cell and / or drive different cell states.
[0361] Methods for treating cells are provided. The methods may include capturing cells, wherein the cells contain genomic deoxyribonucleic acid (gDNA) and guide RNA (gRNA) molecules or their gRNA identification barcodes, contacting accessible gDNA from the cells with a transposase to produce labeled gDNA fragments in a labeling reaction, and generating complementary DNA (cDNA) molecules from the gRNA molecules or their gRNA identification barcodes.
[0362] The cell can be any type of cell described herein. For example, the cell can be an immune cell, as described elsewhere herein. The cell may not be an immune cell. Although some of the methods described herein describe the treatment of B cells with reference to perturbation-ATAC, it should be understood that the method can be applied and / or adapted to other types of cells, including other immune cells and non-immune cells. The cell can be from any source, as described elsewhere herein.
[0363] In some cases, cells can be separated and / or captured from multiple cells. In some cases, cells can be one of the subpopulations of cells separated and / or captured from multiple cells. Separation and / or capture can be in one or more stages. For example, in one stage, multiple cells can be classified for the type of cells. In the next stage, the subtype of the cell type can be separated. In some cases, separation can include magnetic cell sorting. In some cases, separation can include flow cytometry sorting. For example, such a method can be used for sorting between at least two or more of the following types of cells: stem cells, cancer stem cells, blood cells, T cells, dendritic cells, NK cells, precursor cells, granulocytes, platelets, erythrocytes, endothelial cells, epithelial cells or their subpopulations. Antibodies for cell surface markers can be used to further separate cell subpopulations.
[0364] In some embodiments, cells are pre-sorted based on transduced markers before analysis by FACS or MACS (e.g., t-ATAC-seq, perturbation-ATAC). For example, cells can be transduced with fluorescent proteins (e.g., GFP, YFP, CFP, mCherry, mRuby, etc.). In some cases, fluorescent proteins can be transduced with sgRNA boxes. The selection of cells expressing sgRNA boxes can be performed by a pre-sorting mechanism. In some cases, one or more selection markers can be used. For example, cells can be transduced with drug resistance (e.g., puromycin, blasticidin resistance) genes to select sgRNA vectors.
[0365] The plurality of cells may include any number of cells, for example, about 500 to about 10 6In some cases, the plurality of cells may consist of less than about 1000, about 2000, about 3000, about 4000, about 5000, about 6000, about 7000, about 8000, about 9000, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about about 100,000, about 120,000, about 140,000, about 160,000, about 180,000, about 200,000, about 250,000, about 300,000, about 350,000, about 400,000, about 450,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, or about 1,000,000 cells. In other cases, the plurality of cells can comprise more than about 1000, about 2000, about 3000, about 4000, about 5000, about 6000, about 7000, about 8000, about 9000, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or more. About 100,000, about 120,000, about 140,000, about 160,000, about 180,000, about 200,000, about 250,000, about 300,000, about 350,000, about 400,000, about 450,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, or about 1,000,000 cells.
[0366] The capture of cells can include partitioning cells into compartments. Compartments can be any compartments described elsewhere herein, for example, chambers, holes, micropores or droplets. Compartments can contain cells within a set of defined boundaries (enclosed or partially enclosed), and / or separate the space or volume within a compartment from any space or volume outside other compartments or compartments. In some cases, a compartment may prevent its contents from escaping the compartment in one or more cases. In some cases, a compartment may prevent an external object from entering a compartment in one or more cases. A compartment can be a separate compartment, such as a separate hole or a separate chamber or a separate droplet. A compartment can be one of a plurality of compartments, for example, in an integrated device such as a fluid chip.
[0367] Methods for ATAC-seq can generally be performed on partitioned cells, for example, according to one or more of the methods described elsewhere herein, to generate labeled gDNA fragments.
[0368] After the gDNA fragments of the label are produced, and before the reverse transcription reaction is started using the gRNA molecules, the labeling reaction can be suppressed or quenched, such as using magnesium chloride, or the labeling reaction can be terminated in other ways. In some cases, the labeling operation can include the use of detergents, insertion enzyme complexes (e.g., transposase complexes) and divalent metal ions of cells. In some cases, the detergent can be a nonionic surfactant, such as ethoxylated nonylphenol, such as NP-40. In some cases, termination can be completed by chelating the divalent metal ions required for the insertion enzyme complex (e.g., transposase complex), thereby terminating the reaction and releasing the insertion enzyme complex (e.g., transposase complex) from the DNA of the label. In some cases, chelation can be completed by ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA) or diethylenetriaminepentaacetic acid (DTPA) or other chelating agents. Any other reaction terminator can promote the termination reaction. Labeling reaction (and / or its termination) and reverse transcription reaction can occur in the same compartment or in different compartments.
[0369] After the chromatin has been fragmented and labeled to produce labeled genomic DNA fragments, at least some of the adapter-labeled fragments or derivatives thereof (e.g., amplicons) can be sequenced to produce multiple sequence reads. The fragments can be sequenced using any convenient method. For example, the fragments can be sequenced using the reversible terminator method of Illumina, the pyrophosphate sequencing method of Roche (454), the ligation sequencing (SOLiD platform) of Life Technologies, or the Ion Torrent platform of Life Technologies. Examples of such methods are described in the following references: Margulies et al. (Nature 2005 437:376-80); Ronaghi et al. (Analytical Biochemistry 1996 242:84-9); Shendure et al. (Science 2005 309:1728-32); Imelfort et al. (Brief Bioinform. 2009 10:609-18); Fox et al. (Methods Mol Biol. 2009;553:79-108); Appleby et al. (Methods Mol Biol. 2009;513:19-39) and Morozova et al. (Genomics. 2008 92:255-64), which are incorporated herein by reference as a general description of the methods and specific steps of the methods, including all starting products, library preparation methods, reagents, and final products of each step. Forward and reverse sequencing primer sites compatible with the selected next-generation sequencing platform can be added to the ends of the fragments during the amplification step.
[0370] The labeled gDNA fragments can be amplified using primers (e.g., polymerase chain reaction (PCR) primers). In some cases, the primers can hybridize to one or more adapter sequences in the labeled gDNA fragments. In some cases, the primers used for PCR can have a 5' tail that is compatible with a specific sequencing platform. In some cases, the primers used can contain a cell-specific barcode sequence so that different libraries (e.g., of amplicons) can be merged together before sequencing, and the cell-specific barcode sequence can be used to trace the sequence reads back to a specific sample.
[0371] ATAC-Seq and / or aspects thereof may be performed in conjunction with perturbation-seq and / or aspects thereof. For example, after the labeling reaction is quenched or otherwise terminated, the gRNA molecule may be subjected to a reverse transcription reaction to produce a cDNA molecule. The method may include producing a cDNA molecule using a primer and a reverse transcriptase.
[0372] Perturbation of cells can be achieved by transducing cells with a perturbation-ATAC vector (i.e., clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA (gRNA, as used herein, also referred to as single gRNA (sgRNA))). gRNA can be designed for each target gene, and different regions between the transcription start side and the gene body can be targeted. The vector can be cloned, amplified, and assembled into a lentiviral vector. The gRNA sequence can be sequenced to confirm the identity. The generation of gRNA is known and described in, for example, Adamson, B. et al., A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. 167 Cell 1867-82. e21 (2016); and SW Cho et al. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element, 173 Cell 1398-1412. e22 (2018), each of which is incorporated herein by reference in its entirety.
[0373] Barcodes can be added to gRNA vectors.Barcodes can be gRNA identification barcodes including barcode sequences.Such barcode sequences can correspond to the identity of gRNA encoded by a vector, for example, for identifying gRNA in individual cells after a population of cells targeted by mixed gRNA is used for high-throughput analysis.Barcode sequences can be any length.For example, the length of the barcode sequence can be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more base pairs (bp).Alternately or in addition, the barcode sequence can have a length of up to about 60, 50, 40, 30, 20, 10 or less bp.In some cases, non-human genome targeting gRNA can be transduced in a subpopulation of cells. In some cases, cells can be transduced with one or more gRNAs to stably express dCas9-KRAB. Cells can then be pooled after transduction for perturbation-ATAC analysis. In some cases, the fidelity of paired barcode detection with epigenetic phenotype measurement can be assessed.
[0374] The gRNA molecule can be attached to a barcode. The barcode can include a barcode sequence that can identify the identity of the gRNA molecule to which it is attached. Each gRNA with different target sequences can have a unique barcode sequence between other gRNAs with different target sequences. In some cases, the gRNA molecule can include a target sequence that is configured to target a sequence associated with a transcription factor, a chromatin modifier, a non-coding RNA or other complexes. In some cases, the gRNA molecule introduced into the cell can include the same target sequence. In other cases, the gRNA molecule introduced into the cell can include different target sequences. For example, the first gRNA molecule can include a first target sequence, and the second gRNA molecule can include a second target sequence.
[0375] After gRNA is introduced into cells, transposase (e.g., Tn5) can be used to lyse cells and transpose DNA. After transposition, Tn5 can be released from open chromatin fragments, and CRISPR guide RNA (gRNA) or its gRNA identification barcode can be reverse transcribed. Reverse transcription can be performed on gRNA (e.g., directly) and / or its gRNA identification barcode to produce cDNA molecules. Reverse transcription can be performed on gRNA and / or its gRNA identification barcode to produce cDNA molecules. The sequencing reading generated from the cDNA generated from the gRNA identification barcode can be processed according to the known list or table of gRNA identification barcode. The sequencing reading generated directly from the cDNA generated from the gRNA can be processed for the known list or table of gRNA (e.g., its sequence). For example, in the case where the vector construct used does not include a gRNA identification barcode, such a method can be used. Reverse transcription can be performed using primer sequences that target the sequences of the gRNA or gRNA identification barcode flanks (or otherwise adjacent) respectively.
[0376] For example, in the case of reverse transcription of the gRNA directly, a reverse primer that matches the common 3' end of the gRNA can be used for reverse transcription. Afterwards, the ATAC-seq fragments can be extended. The contents of the chamber can then be amplified by PCR. In some cases, the PCR amplification can include a forward primer that matches the variable 5' end of the gRNA used in the experiment. The single-cell library can then be collected and the gRNA and / or ATAC amplicons can be further amplified with cell-identifiable barcoded primers, combined, and sequenced. For example, Fig.92 Schematic diagram of sgRNA expression vector and library amplification for direct sequencing readout of guide RNA identity is shown. Fig.92As shown, cDNA can be generated from mRNA molecules containing the variable region and common region of the gRNA, wherein the reverse transcription reaction uses a reverse primer corresponding to the common 3' end of the gRNA. Then, during PCR amplification (e.g., "PCR 1"), a forward primer corresponding to the variable 5' end of the gRNA can be used. Further extension reactions (e.g., by polymerase chain reaction (PCR)) (e.g., "PCR 2"; "PCR 3") can be performed to generate derivatives containing cell identification barcode sequences.
[0377] In another example, where the gRNA identification barcode is reverse transcribed, the primers used in the reverse transcription reaction can correspond to (and / or target) sequences flanking the gRNA identification barcode. For example, Fig.55 A schematic diagram for generating sequencing reads corresponding to gRNA identification barcodes is shown. Fig.55 As shown, cDNA can be generated from an mRNA molecule containing a gRNA identification barcode, wherein the reverse transcription reaction uses a primer targeting a sequence flanking the 3' end of the barcode. Then, during PCR amplification (e.g., "PCR 1"), a forward primer corresponding to a sequence flanking the 5' end of the barcode can be used. A further extension reaction (e.g., by PCR) (e.g., "PCR 2"; "PCR 3") can be performed to generate a derivative product containing a cell identification barcode sequence.
[0378] CDNA (e.g., from gRNA and / or its gRNA identification barcode) and / or labeled gDNA fragments can be amplified in a PCR reaction, for example, by contacting them with multiple primers and a polymerase to produce cDNA molecule amplicons and / or labeled gDNA fragment amplicons. In some cases, the amplicons of cDNA and the amplicons of labeled gDNA fragments can contain cell-specific barcode sequences that identify cells. In some cases, such amplicons containing cell-specific barcode sequences can be produced from other amplicons of labeled gDNA fragments and cDNA molecules. Sequencing reads can be associated with cells based at least in part on cell-specific barcode sequences. Barcode molecules can be delivered before, simultaneously, or after cell partitioning. In some cases, barcode molecules can be delivered via beads (e.g., gel beads), as described elsewhere herein.
[0379] cDNA (e.g., from gRNA and / or its gRNA identification barcode), labeled gDNA and / or its amplicon can be sequenced to generate sequencing reads. Such sequencing reads can be used to determine the correlation between the accessible gDNA in the cell and the sequence corresponding to the V(D)J region. The correlation can be mapped. In some cases, cDNA, labeled gDNA and / or its amplicon can be removed from the compartment before sequencing, merged and sequenced. The cell-specific barcode sequence can associate the sequencing reads generated from the product or derivative of the compartment that partitions the cell with the cell.
[0380] Fig.53 A schematic diagram showing the workflow of perturbation-ATAC, and Fig.55 Schematic diagram of the perturbation-ATAC protocol, lentiviral constructs, and generation of sequencing libraries for guide RNA detection is shown. Fig.55 As shown, sgRNA molecules are introduced into multiple cells, cells containing sgRNA molecules are sorted (e.g., using FACS), single cells are captured in a chamber, chromatin ATAC-seq transposition is performed to generate labeled gDNA fragments, the sgRNA molecules are reverse transcribed to generate corresponding cDNA molecules, and then the cDNA molecules and the labeled gDNA fragments are amplified and sequenced.
[0381] In some embodiments, the chromatin accessibility of the cell can be analyzed after perturbation (i.e., perturbation-ATAC). For example, cells (e.g., B cells) can be collected, partitioned, lysed and subjected to a transposition reaction. After transposase treatment and reaction quenching, the sample can be reverse transcribed and PCR can be performed optionally using a primer mixture. These processes can be performed in a microfluidic chip. For example, the automated microfluidic platform Fluidigm can be used for single cell capture, lysis, and downstream processing.
[0382] The harvested library can be further amplified. For example, PCR can be used to incorporate barcodes and enable sequencing. After barcoding, the amplicons from PCR can be purified and sequenced to form a library of barcoded gDNA and (sgRNA or identifying sgRNA) cDNA sequences. Prior to sequencing, the library can be further amplified and / or quantified.
[0383] Purification of the library can be obtained by selecting selected nucleotide fragments. Nucleotide fragments can be selected by their size, isoelectric point or other biochemical or biophysical properties. For example, nucleotide fragments can be purified by size by using polyacrylamide gel electrophoresis and selecting fragments of the desired size.
[0384] In some embodiments, the presence or absence of a barcode in a given cell can be assessed. In some cases, a cutoff value can be specified to specify the presence or absence of a barcode in a given cell. In a non-limiting example, the number of reads of each possible barcode in each cell can be counted, and then adjusted for sequencing depth, such as to take into account changes during library preparation or sequencing. In another example, a minimum read cutoff of 1000 barcode reads per cell can be applied to remove cells with low coverage. Cells with high background readings can also be removed. In addition, a cutoff value based on the percentage of barcode reads matched to the second most common barcode can also be used as a cutoff value.
[0385] It is obvious to those skilled in the art that perturbation-ATAC can be used for a variety of applications in biological discovery. For example, perturbation-ATAC can identify the epigenomic functions of chromatin regulators, transcription factors, and non-coding RNAs. Performing perturbation-ATAC screening can be used to compare how widely expressed and lineage-specific trans-acting factors shape the chromatin profile of cell types. Perturbation-ATAC can also identify epigenomic phenotypes associated with genetic perturbations of different classes of trans-acting factors. For example, as a control experiment, analysis of the collection ATAC-seq spectrum of cells receiving non-human genome targeted barcodes may be expected to result in little to no changes in chromatin accessibility; however, selective perturbations using gRNAs targeting, for example, DNMT3a may result in changes in accessibility.
[0386] In some cases, more than one disturbance (i.e., more than one gRNA is applied) can be applied to the cell. The combination of disturbances can then reveal how, for example, transcription factors work together to establish chromatin profiles in cells by ATAC-seq. In a non-limiting example, disturbance-ATAC can also be used to identify the covariation regulatory network between individual cells, measure the impact of disturbances on one or more regulatory networks and / or infer the regulatory relationship between the disturbed factor and the constituent factors in the regulatory network. In one example, the double disturbance for a subset of factors in a single cell can then be determined by disturbance-ATAC The degree of genetic interaction between all genomic features. The disturbance-ATAC on the cell with more than one disturbance can be used to characterize the trans-acting factor relationship as "expected" (i.e., based on the combination of the separate effects of each disturbance) or "unexpected" (i.e., non-cumulative, prompting the interaction between disturbances). "Unexpected" relationships may be synergistic, have a counteracting effect or interact in a non-cumulative manner Trans-acting factors. Epistatic interactions analyzed from more than one perturbation can also be used to screen for disease-associated transcription factors and map the interactions of epigenomic networks.
[0387] In some cases, genome-wide nucleosome occupancy and positioning can be inferred from fragment sizes obtained from ATAC-seq. Assessment of trans-acting factors, which can control locus accessibility by modulating TF binding in pre-established nucleosome-free regions and / or by altering the position or occupancy of local nucleosomes, may yield additional information. In some cases, ATAC-seq data can determine whether changes in ATAC-seq signal for a genomic region are associated with changes in nucleosome structure rather than exchanges of TF binding within a stable nucleosome scaffold.
[0388] In some cases, perturbation-ATAC analysis can provide information about pathological processes. For example, perturbation-ATAC can provide information about regulators of noncoding regions containing genetic variants associated with human diseases. Selective perturbation of candidate factors may reveal disease-specific activities of several TFs.
[0389] In some cases, the method can be used to compare two samples. The first epigenetic map can be generated by analyzing the first cell or the first cell colony. The second epigenetic map can be generated by analyzing the second cell or the second cell colony. The two epigenetic maps can be compared, merged or otherwise processed for each other or mutually. For example, the first epigenetic map can be mapped to the second epigenetic map to determine or characterize the accessibility (e.g., chromatin openness) or transcription factor occupancy of chromatin, optionally for quality control, optionally in response to the disturbance of the target gene, and / or its variation. In some cases, the first input (the first cell or the first cell colony) can be a clone of the second input (the second cell or the second cell colony), and vice versa. In some cases, the first input and the second input can be obtained from the same source at different times. In some cases, the first input and the second input can be obtained from different sources. In some cases, the first input and the second input can be obtained from different locations or regions of the same source (e.g., individual). In some cases, the first input can be an input before treatment, and the second input can be an input after treatment, such as by treatment with a reagent (e.g., a test agent), a drug, a perturbant, etc. In this case, the first input and the second input can be clones or the same population, and the second input can be incubated in the case of treatment before performing the assays and / or methods described herein. In some cases, for example, these methods can be used to determine the mode of action of the test agent to identify changes in chromatin structure or transcription factor occupancy in response to the drug. In some cases, one of the two samples can be a control sample.
[0390] The methods described above can also be used to provide a diagnosis and / or prognosis, for example, for a patient, for example, based on one or more epigenetic profiles.
[0391] The method described herein can be used to provide reliable diagnosis for any medical condition related to the occupancy of the chromatin or DNA binding proteins that are changed. The method can be applied to the characterization, classification, differentiation, grading, staging, diagnosis or prognosis of the medical condition characterized by an epigenetic pattern (e.g., a pattern occupied by chromatin accessibility or DNA binding proteins). For example, the method can be used to determine whether the epigenetic map of the sample of an individual suspected of having a disease or medical condition is the same or different compared to the sample considered to be "normal" for the disease or medical condition. In a specific embodiment, the method can be related to diagnosing an individual with a medical condition characterized by an epigenetic pattern of a specific locus in a test sample, wherein the pattern is related to the medical condition. The method can also be used to predict the susceptibility of an individual to a disease.
[0392] Exemplary conditions suitable for analysis using the methods described herein can be, for example, a cell proliferative disease or susceptibility to a cell proliferative disease; a metabolic disorder or disease; an immune disorder, injury or disorder; a central nervous system disorder, injury or disease; symptoms of aggression or behavioral disorders; clinical, psychological and social consequences of brain injury; mental disorders and personality disorders; dementia or related syndromes; cardiovascular disease, disorder and injury; gastrointestinal disorder, injury or disease; respiratory disorder, injury or disease; pathology, inflammation, infection, immunity and / or recovery; a body disorder, injury or disease that is an abnormality in the developmental process; a disorder, injury or disease of the skin, muscle, connective tissue or bone; endocrine and metabolic disorders, injury or disease; headache or sexual dysfunction, and combinations thereof.
[0393] In some cases, the method can provide a prognosis to, for example, determine whether a patient is at risk of recurrence. Cancer recurrence is a concern associated with various types of cancer. Prognostic methods can be used to identify surgically treated patients who may experience cancer recurrence so that other treatment options can be provided to them, including preoperative or postoperative adjuvants, such as chemotherapy, radiotherapy, biological modifiers and other suitable therapies. The method is particularly effective for determining the risk of metastasis in patients who do not show measurable metastatic cancer at the time of examination or surgery.
[0394] The method can also be used to determine the appropriate course of treatment for a patient with a disease or condition (e.g., a patient with cancer). The course of treatment refers to the treatment measures taken on a patient after diagnosis or treatment. For example, determining the likelihood of recurrence, spread, or patient survival can help determine whether a more conservative or more radical treatment approach should be adopted, or whether a combination of treatments should be used. For example, when cancer may recur, it may be advantageous to perform chemotherapy, radiotherapy, immunotherapy, biological modifier therapy, gene therapy, vaccines, etc. before or after surgical treatment, or to adjust the time span of the treatment patient.
[0395] Fig.54 An overview of the categories of biological questions that can be asked from perturbation-ATAC data is shown. These include, but are not limited to, nucleosome positioning 5402, enhancer accessibility 5404, promoter accessibility 5406, and transcription factor accessibility 5408.
[0396] Fig.56 Shown are scatter plots of guide barcode reads from pools of cells transduced with one of the two guide constructs.
[0397] Fig.57 A scatter plot of the fraction of ATAC fragments and ATAC fragments in the peak region of each cell is shown. A label indicating the guide barcode detection in each cell is shown.
[0398] Fig.58 Density 5802 histograms of ATAC fragment size 5804 distributions are shown, indicating expected nucleosome phasing and relative frequency 5806 of ATAC insertions around transcription start sites 5808 in merged single cells (upper panel) and bulk cells (lower panel).
[0399] Fig.59 A diagram of the genomic locus of the SPI1 gene is shown, indicating DNase I ultrasensitive 5902 sequencing, bulk ATAC-seq 5904, and perturbation-ATAC-seq 5906. The SPI1 promoter region exhibits a selective loss of accessibility in cells expressing SPI1 sgRNA 5908.
[0400] Fig.60 Box plots showing accessibility of pooled single cells for individual genomic regions identified as altered in bulk ATAC-seq. *Indicates p-value < 1e-3 by KS1173 test.
[0401] Fig.61 A plot of the relative accessibility 6102 of regions containing the SPI1 motif is shown (z-score of relative activity of the SPI1 motif relative to all other genomic features). * indicates a false discovery rate of <1e-3 by permutation testing.
[0402] Fig.62 Histograms of total guide barcode sequencing reads per cell are shown.
[0403] Fig.63 A histogram of the second most common guide barcode identified in each cell is shown. Cells at the low end of the distribution express a single guide RNA 6302, while cells at the high end of the distribution express two guide RNAs 6304.
[0404] Fig.64Scatter plots of ATAC fragments and the fraction of fragments in the peak region are shown. Cells are shaded by total guide barcode reads.
[0405] Fig.65 Heatmaps of cells (rows) versus guide barcodes (columns) are shown, indicating the proportion of total reads associated with each barcode.
[0406] Fig.66 Volcano plots are shown to identify genomic features that are significantly altered (FDR <= 0.025) between cells carrying non-targeting guides and guides targeting EZH2 6602, SPI1 6604, and EBER2 6606. Right: Scatter plots of the fold change in mean accessibility versus accessibility of individual genomic peaks.
[0407] Fig.67 A heat map of perturbed factors (rows) versus genomic annotations (columns) is shown, indicating differences in accessibility between perturbed cells and non-targeted control cells. Only annotations that were significantly altered in at least one perturbation are shown.
[0408] Fig.68 Panel A shows a heatmap indicating the number of significantly altered features (absolute log2FC >= 1.5, mean reads / cell >= 0.4), and panel B shows the number of altered genomic regions (median, absolute chromVAR deviation Z >= 0.75, FDR <= .05), or quantification of the ratio of flanking to central nucleosome occupancy at the altered peak for each individual perturbation ( Figure C ).
[0409] Fig.69 An example workflow for identifying genomic features that exhibit correlated activity across cells is shown. Panel A shows a heat map indicating the correlation of motif activity across cells for a set of motifs. Panel B shows a comparison of non-targeted control cells to perturbed cells, identifying motif pairs whose correlation changes due to perturbation. Figure C The regulatory network hypothesized to constrain functional relationships is shown.
[0410] Fig.70 Heatmap showing Pearson correlations between features in non-targeted cells.
[0411] Fig.71 A heat map is shown demonstrating the difference in correlation between non-targeted cells and IRF8 knockdown cells.
[0412] Fig.72 Heatmaps demonstrating module 5 feature correlations in non-targeted cells (lower half) and IRF8 (upper half) knockdown cells are shown.
[0413] Fig.73Heatmaps demonstrating module 2 feature correlations in non-targeted cells (lower half) and DNMT3A (upper half) knockdown cells are shown.
[0414] Fig.74 Scatter plots of cell accessibility with linear best-fit curves are shown, indicating correlations under specific conditions.
[0415] Fig.75 A hypothetical model for IRF8 cofactor activity with AP1 and IKZF1 is shown.
[0416] Fig.76 Heatmap showing the fraction of feature-feature correlations that are changed within a module by a perturbation, showing the specific impact on a particular module under different perturbations.
[0417] Fig.77 Schematic showing the calculation of expected accessibility in a double knockdown background based on an additive model integrating the accessibility in each single knockdown condition
[0418] Fig.78 Shown are box plots representing the distribution of SPI1 binding site (left) and IKZF1 binding site (right) accessibility for 1221 individual cells under corresponding single or double knockdown conditions.
[0419] Fig.79 Scatter plots of observed 7902 versus expected 7904 accessibility for epistatic interactions are shown. Each dot represents a single annotation in the pair of two perturbed factors. Darker dots indicate significant changes in activity in either a single perturbation or both perturbations.
[0420] Fig.80 Histograms of the background-corrected interaction extent for each feature are shown. Background distributions calculated by permuting single and double knockdown associations.
[0421] Fig.81 A scatter plot of observed 8102 versus expected 8104 interactions is shown, highlighting TFAP2A (relatively low degree of interaction) and JUND (relatively high degree of interaction).
[0422] Fig.82 Shown is a scatter plot of observed 8202 relative to expected 8204 accessibility changes at H3K27me3 marked regions in cells depleted of EZH2 and one other factor.
[0423] Fig.83A scatter plot of the relative accessibility of EZH2 knockdown cells compared to control cells for various subsets of H3K27me3 peaks is shown. Common peak 8302 refers to a region that exhibits H3K27me3 status in most cell types.
[0424] Fig.84 Left: Heatmap indicating accessibility changes caused by EZH2 depletion in regions marked by H3K27me3 in GM12878 and showing H3K27ac marks in each other specific cell type. Right: Heatmap indicating accessibility changes in the same set of regions included in the left heatmap for cells depleted of both EZH2 and TF.
[0425] Fig.85 A schematic diagram indicating the workflow for clustering SNPs associated with autoimmune diseases with 3D chromatin contact regions is shown.
[0426] Fig.86 Heatmaps showing the absolute change in accessibility for each autoimmune disease and perturbed SNP contact signature set.
[0427] Fig.87 Schematic diagram of the cell culture model system of human epidermis and epidermal differentiation is shown.
[0428] Fig.88 Shown are tSNE projections of TF signature activities of epidermal cells labeled with differentiation day (left) or pseudo-time (right).
[0429] Fig.89 Heatmaps of cells sorted by pseudotime (columns) relative TF signature activity (filtered for motifs with dynamic activity) are shown. Modules represent collections of TF signatures with similar temporal profiles. Genes listed next to the heatmaps are found to be proximal (<50 kb) to genomic regions that exhibit accessibility dynamics associated with that module.
[0430] Fig.90 Panel A shows a density histogram of pseudo-time values for cells from each day of differentiation. Panel B shows Fig.89 The average accessibility spectrum of each module identified in .
[0431] Fig.91 tSNE projections of TF activity are shown, and for each plot, cells are labeled by the relative activity of individual motifs.
[0432] Fig.92 Schematic diagram of sgRNA expression vector and library amplification for direct sequencing readout of guide RNA identity is shown.
[0433] Fig.93A heatmap of sgRNA identities (columns) versus individual cells (rows) is shown, indicating the proportion of all reads associated with each sgRNA.
[0434] Fig.94 Heatmaps of genetic perturbations (represented by target genes) versus TF signatures are shown, indicating the activity of TF signatures in perturbed cells versus non-targeted (NT) cells. Similar motif signatures from the AP1, FOX, and ETS families were merged.
[0435] Fig.95 A diagram of the genomic locus of the SPRR2E gene is shown. Perturbation-ATAC track 9502 represents the signal from merged single cells identified for each sgRNA. H3K27ac 9504 and ZNF750 9506 ChIP-seq tracks (from day 3 differentiated keratinocytes, normalized to 10m reads, from Rubin et al., 2017) are also shown.
[0436] Fig.96 The presentation of positive and negative regulation between target genes (factors) and genomic region sets (features) is shown. Regulation for FDR < 0.25 is shown with arrows, and reduced transparency is associated with lower FDR. The map was generated using Cytoscape 1271 v3.1.0.
[0437] Fig.97 Top: Heatmap showing the frequency of cells in each of eight bins representing progression along the differentiation trajectory. Bottom: Heatmap indicating enrichment or depletion of cells in each differentiation bin compared to non-targeted control cells. For each perturbation, a custom dimensionality reduction space was generated to highlight the altered features.
[0438] Fig.98 Heatmaps of perturbations (targeted genes, rows) versus feature modules (columns) are shown. For each module, the mean change in feature activity is shown.
[0439] Fig.99 Exemplary representative peak signals for each interaction category are shown.
[0440] Fig.100 A scatter plot of observed versus expected (based on an additive model) accessibility in double knockout cells is shown. Only features that were significantly altered under single or double knockout conditions are plotted, and feature color indicates the class of interaction.
[0441] Fig.101Heatmaps showing altered activities of features (rows) and their expected activities in the same cells with EHF knockout, JUNB knockout or simultaneous knockout of EHF and JUNB (left panel). Right panel: Heatmaps of altered activities of EHF and ZNF750 knockouts.
[0442] Fig.102 Bar graphs showing the proportion of interacting features that belong to each category are shown. Each column represents a specific pair of targeted genes. Only features that were altered under single or double perturbation conditions were considered.
[0443] Fig.103 Heatmaps are shown indicating the significance of genomic overlap or gene expression correlation corresponding to paired TF pairs (upper panel). Lower panel: Heatmaps showing relative RNA expression of KLF4 and JUNB in tissues from the Roadmap Epigenomics Project.
[0444] Fig.104 Panel A shows a heat map indicating the relative accessibility of genomic regions (rows) that exhibit cooperative behavior in KLF4 and ZNF750 double knockout cells. Panel B shows a heat map where the rows correspond to the regions shown on the left, showing ChIP seq profiles of KLF4 and ZNF750.
[0445] Fig.105 A hypothetical model for KLF4 and ZNF750 redundancy in maintaining accessibility at co-occupied loci is shown.
[0446] Fig.115 A schematic diagram of the lentiviral plasmid encoding the sgRNA for CRISPRi and a selectable marker containing a guide barcode is shown. The reverse transcription and PCR steps of stepwise targeting are shown from top to bottom.
[0447] Fig.116 An overview of the computational pipeline that takes sequencing reads of GBCs and produces a final table of guide identifications for each cell is shown.
[0448] Fig.117 Details on the derivation of filtering parameters for per-cell sequencing depth and background reads are shown. Left: The distribution of reads matching any guide barcode is shown for each of three representative plates. Middle: The distribution of reads after adjusting for plate-specific depth for high mode, resulting in a uniform median depth for high mode across plates and a uniform filter threshold of 1,000 normalized reads per cell. Right: The distribution of reads per cell not assigned to the two most abundant guides for cells annotated as single cell or bimodal capture. Bimodal wells are separated into two modes, allowing determination of a threshold to separate unanticipated high background in single capture wells.
[0449] Fig.118 Shown are bar graphs indicating the counts of sgRNA sequence mismatches for random guides or guides selected for perturbation-ATAC.
[0450] Fig.119 The workflow for calculating predicted off-target CRISPRi activity based on the contribution of mismatches is shown. Right: Histogram of predicted relative off-target activities (including up to 4 mismatches) for all sgRNAs used in this study.
[0451] Fig.120 Shown is qPCR validation of CRISPRi gene expression knockdown following transduction with sgRNA targeting a specific gene.
[0452] Fig.121 Shown are bar graphs indicating the categories of sgRNA mismatched loci based on ATAC peak proximity and accessibility observed compared to non-targeted cells.
[0453] Fig.122 tSNE plots of all cells assayed in the GM12878 experiment based on chromVAR feature deviation Z-scores are shown. For each plot, cells assayed on a specific plate are highlighted.
[0454] Fig.123 Violin plots of single-cell accessibility relative to average accessibility in non-targeted cells are shown for significantly altered features in cells targeted for EBER1, EBF1, EZH2, or SPI1. Each point represents an individual genomic feature (a collection of genomic regions that share an annotation (e.g., TF motif or ChIP-seq peak)) in an individual cell. A maximum of 50 features are shown per genotype.
[0455] Fig.124 Shown are scatter plots of accessibility under knockdown conditions, NFKB1 versus RELA (left) or EBER1 versus EBER1 (right).
[0456] Fig.125 Volcano plots are shown for each individual perturbation condition, comparing perturbed cells to non-targeted control cells. Each dot represents a genomic feature. The significance threshold was FDR <= 0.025.
[0457] Fig.126 Shown is a schematic depicting the generation of short (<100 bp) ATAC fragments from subnucleosomal regions and large fragments (180-247 bp) spanning nucleosome protected regions.
[0458] Fig.127Metacurves of subnucleosomal and nucleosomal fragment signals for CTCF motif regions overlapping with CTCF ChIP-seq peaks in GM12878 are shown. Signals represent the average of two non-targeted cell populations and the grey range represents the standard deviation between samples.
[0459] Fig.128 Metacurves of subnucleosomal and nucleosomal signals at differentially accessible regions are shown.
[0460] Fig.129 Heatmaps of the correlation matrix for genomic features are shown. Values indicate the Pearson correlation of accessibility of two genomic features across non-targeted cells. Ward hierarchical clustering was used to identify five modules with substantial intra-cluster correlations.
[0461] Fig.130 A list of key features in each module is shown.
[0462] Fig.131 A heat map of the correlation matrix of genomic signatures in IRF8 knockdown cells is shown.
[0463] Fig.132 Box plots of single-cell accessibility of CTCF and SMAD5 signatures in non-targeted and DNMT3A knockdown cells are shown. Right: z-score histogram of the number of altered associations for each signature in DNMT3A knockdown cells.
[0464] Fig.133 Heatmap showing the differences in feature correlations between NFKB1 knockdown cells (bottom) and RELA knockdown cells (top).
[0465] Fig.134 Heatmap showing the feature correlation of module 1 relative to module 5 in non-targeted or EBER2 knockdown cells.
[0466] Fig.135 Histograms of changes in feature correlations for SPI1 knockdown versus non-targeted 1 cells are shown to give information about the threshold used to designate altered correlations.
[0467] Fig.136 A table showing counts based on a 5% FDR threshold and correlation features with the highest changes highlighted is shown.
[0468] Fig.137 Schematic diagram of lentiviral plasmids used for sgRNA and Cas9 expression is shown.
[0469] Fig.138Sanger sequencing traces of 100 bp around the 3' end of the sgRNA for each target gene are shown. Sequencing proceeds in the forward direction (left to right), resulting in a sudden drop in post-sgRNA sequencing alignment due to a mix of indels.
[0470] Fig.139 A schematic diagram showing the lentiviral plasmid encoding the sgRNA for CRISPR knockout. From top to bottom, the reverse transcription and PCR steps of the stepwise targeting are shown.
[0471] Fig.140 The distribution of reads per cell mapped to sgRNA variable sequences is shown. For each plate, a clear pattern of high reads was identified and used to determine the depth cutoff.
[0472] Fig.141 The distribution of the proportion of all reads per cell that mapped to known sgRNA sequences is shown.
[0473] Fig.142 The distribution of the proportion of reads per cell associated with the background (third most common) guide sequence is shown. Cells in low mode passed the filter.
[0474] Fig.143 The distribution of the proportion of reads associated with the second most common guide is shown. Cells are those that passed quality control, and cells in the low mode of this distribution are considered to express a single guide, while cells in the high mode are considered to express two guides.
[0475] Fig.144 Shown is a scatter plot of the proportion of reads associated with the two guide sequences for all cells that passed the final filter.
[0476] Fig.145 Signal traces indicating ZNF750 binding sites that gain accessibility in targeted cells are shown, indicating the repressive activity of ZNF750.
[0477] Fig.146 Scatter plots of principal component (PC) values for unperturbed keratinocytes are shown. PC space was generated using altered features of specific single TF knockout cells. Yellow lines represent pseudo-time trajectories connecting the centroids of cells from each differentiation day.
[0478] Fig.147 A scatter plot of 1397 PC values for all perturbed and non-targeted cells embedded in the PC space generated in (a) is shown. Cells are scored and colored by their progression along the pseudo-time trajectory. These pseudo-time values are used to assess enrichment or depletion of knockout relative to non-targeted cells.
[0479] Fig.148Shown are scatter plots of observed relative to expected (based on additive model) accessibility in double knockout cells.
[0480] Fig.149 Shown are scatter plots of the absolute log2 fold changes of features in single knockout cells versus double knockouts (r~0.18).
[0481] Systems and methods for sample separation
[0482] In one aspect, the systems and methods described herein provide for separating, depositing or partitioning one or more particles (e.g., biological particles, macromolecular components of biological particles, beads, reagents, etc.) into discrete compartments or compartments (interchangeably referred to herein as compartments), wherein each compartment keeps its own contents separate from the contents of other compartments. The compartment can be a droplet in an emulsion. A compartment can include one or more other compartments.
[0483] The compartment may contain one or more particles. The compartment may include one or more types of particles. For example, the compartment of the present disclosure may contain one or more biological particles and / or their macromolecular components. The compartment may contain one or more gel beads. The compartment may contain one or more cell beads. The compartment may include a single gel bead, a single cell bead, or both a single cell bead and a single gel bead. The compartment may include one or more reagents. Alternatively, the compartment may not be occupied. For example, the compartment may not contain beads. The cell beads may be biological particles and / or one or more macromolecular components thereof encapsulated in a gel or polymer matrix, for example, by polymerization of droplets containing biological particles and precursors capable of polymerization or gelation. As described elsewhere herein, unique identifiers such as bar codes may be injected into droplets before, after, or simultaneously with the generation of droplets, for example, by microcapsules (e.g., beads). A microfluidic channel network (e.g., on a chip) may be used to generate compartments as described herein. Other mechanisms may also be used in the compartment of a single biological particle, including a porous membrane, through which the aqueous mixture of cells is discharged into a non-aqueous fluid.
[0484] The compartment can flow in the fluid flow. The compartment may include, for example, a microcapsule bubble having an external barrier around the center or core of the internal fluid. In some cases, the compartment may include a porous matrix capable of entraining and / or maintaining the material in its matrix. The compartment may be a droplet of the first phase in the second phase, wherein the first phase and the second phase are immiscible. For example, the compartment may be a droplet of an aqueous fluid in a non-aqueous continuous phase (e.g., an oil phase). In another example, the compartment may be a droplet of a non-aqueous fluid in an aqueous phase. In some examples, the compartment may be provided in the form of an oil-in-water emulsion or an oil-in-water emulsion. Various containers are described in, for example, U.S. Patent Application Publication No. 2014 / 0155295, which are incorporated herein by reference as a whole for all purposes. An emulsion system for producing stable droplets in a non-aqueous or oil continuous phase is described in, for example, U.S. Patent Application Publication No. 2010 / 0105112, which are incorporated herein by reference as a whole for all purposes.
[0485] In the case of droplets in an emulsion, in a non-limiting example, the distribution of individual particles to discrete compartments can be achieved by introducing the flow stream of particles in an aqueous fluid into the flow stream of a non-aqueous fluid, so that droplets are generated at the junction of the two streams. Fluid properties (e.g., fluid flow rate, fluid viscosity, etc.), particle properties (e.g., volume fraction, particle size, particle concentration, etc.), microfluidic architecture (e.g., channel geometry, etc.), and other parameters can be adjusted to control the occupancy of the resulting compartments (e.g., the number of biological particles per compartment, the number of beads per compartment, etc.). For example, compartment occupancy can be controlled by providing a water flow with a certain concentration and / or flow rate of particles. In order to produce a single biological particle compartment, the relative flow rate of the immiscible fluid can be selected so that each compartment can contain less than one biological particle on average to ensure that those compartments occupied are mainly occupied alone. In some cases, a compartment in a plurality of compartments can contain at most one biological particle (e.g., bead, DNA, cell, or cell material). In some embodiments, various parameters (e.g., fluid properties, particle properties, microfluidic architecture, etc.) can be selected or adjusted so that a majority of compartments are occupied, e.g., allowing only a small percentage of unoccupied compartments. The flow and channel architecture can be controlled to ensure a given number of individually occupied compartments, less than a certain level of unoccupied compartments, and / or less than a certain level of multiply occupied compartments.
[0486] The single-cell T-ATAC-seq and perturbation-ATAC protocols described above can be performed using droplets (and / or aspects thereof). For example, cells (e.g., T cells, B cells, immune cells, other cells) treated with T-ATAC-seq or perturbation-ATAC can be co-partitioned with barcoded beads, as described elsewhere herein, to promote one or more reactions described herein. For example, they can be co-partitioned with one or more reagents described herein (e.g., lysis reagents) to promote one or more reactions of these protocols. In some cases, beads can be used as a solid support for one or more reactions.
[0487] Fig.106 An example of a microfluidic channel structure 10600 for partitioning a single biological particle is shown. The channel structure 10600 can include channel segments 10602, 10604, 10606, and 10608 connected at a channel junction 10610. In operation, a first aqueous fluid 10612 including suspended biological particles (or cells) 10614 can be delivered along the channel segment 10602 into the junction 10610, while a second fluid 10616 that is immiscible with the aqueous fluid 10612 is delivered from each of the channel segments 10604 and 10606 to the junction 10610 to produce discrete droplets 10618, 10620 of the first aqueous fluid 10612, which flow into the channel segment 10608 and flow out of the junction 10610. The channel segment 10608 can be fluidly coupled to an outlet reservoir, in which the discrete droplets can be stored and / or harvested. The generated discrete droplets may include a single biological particle 10614 (e.g., droplet 10618). The generated discrete droplets may include more than one single biological particle 10614 (e.g., droplet 10618). Fig.106 10614). A discrete droplet may not contain a biological particle 10614 (e.g., droplet 10620). Each discrete compartment may keep its own contents (e.g., a single biological particle 10614) separate from the contents of other compartments.
[0488] The second fluid 10616 can include an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, e.g., inhibiting subsequent coalescence of the resulting droplets 10618, 10620. Examples of particularly useful partitioning fluids and fluorosurfactants are described, for example, in U.S. Patent Application Publication No. 2010 / 0105112, which is incorporated herein by reference in its entirety for all purposes.
[0489] It should be understood that the channel segments described herein can be coupled to any of a variety of fluid sources or receiving components, including fluid components of a reservoir, pipeline, manifold or other system. It should be understood that microfluidic channel structure 10600 can have other geometric shapes. For example, a microfluidic channel structure can have more than one channel junction. For example, a microfluidic channel structure can have 2, 3, 4 or 5 channel segments, each of which carries particles (e.g., biological particles, cell beads and / or gel beads) that meet at a channel junction. Fluid can be guided to flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit may include a compressor (e.g., providing positive pressure), a pump (e.g., providing negative pressure), an actuator, etc. to control the flow of fluid. Fluid can also be controlled or otherwise controlled by applied pressure differential, centrifugal force, an electric pump, a vacuum, a capillary or a gravity flow, etc.
[0490] The generated droplets may include two subsets of droplets: (1) occupied droplets 10618 that include one or more biological particles 10614, and (2) unoccupied droplets 10620 that do not include any biological particles 10614. The occupied droplets 10618 may include single occupied droplets (having one biological particle) and multiply occupied droplets (having more than one biological particle). As described elsewhere herein, in some cases, a majority of the occupied compartments may include no more than one biological particle per occupied compartment, and some of the generated compartments may not be occupied (by any biological particle). However, in some cases, some of the occupied compartments may include more than one biological particle. In some cases, the partitioning process may be controlled so that less than about 25% of the occupied compartments include more than one biological particle, and in many cases, less than about 20% of the occupied compartments have more than one biological particle, and in some cases, less than about 10% or even less than about 5% of the occupied compartments include more than one biological particle per compartment.
[0491] In some cases, it may be desirable to minimize the generation of an excessive number of empty compartments to reduce costs and / or increase efficiency. Although such minimization may be achieved by providing a sufficient number of bioparticles (e.g., bioparticles 10614) at compartment junctions 10610 to ensure that at least one bioparticle is encapsulated in one compartment, a Poisson distribution may be expected to increase the number of compartments containing multiple bioparticles. Thus, in the case of obtaining a single occupied compartment, a maximum of about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or less of the compartments may be occupied.
[0492] In some cases, the flow of one or more bioparticles (e.g., in channel segment 10602) or other fluids of the directional partitioning junction (e.g., in channel segments 10604, 10606) can be controlled so that in many cases, no more than about 50% of the generated compartments, no more than about 25% of the generated compartments, or no more than about 10% of the generated compartments are occupied. These flows can be controlled to present a non-Poisson distribution of singly occupied compartments while providing a lower level of unoccupied compartments. The above-described ranges of unoccupied compartments can be achieved while still providing any of the above-described singly occupied compartments. For example, in many cases, use of the systems and methods described herein can generate resulting compartments having multiple occupancies of less than about 25%, less than about 20%, less than about 15%, less than about 10%, and in many cases less than about 5%, while having unoccupied compartments of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less.
[0493] It should be understood that the occupancy ratios described above also apply to compartments containing biological particles and additional reagents, including but not limited to microcapsules or beads (e.g., gel beads) carrying barcoded nucleic acid molecules (e.g., oligonucleotides) (relative to Fig.107 The occupied compartments (e.g., at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the occupied compartments) can include microcapsules (e.g., beads) and bioparticles containing barcoded nucleic acid molecules.
[0494] On the other hand, in addition to or as a substitute for the partition based on droplets, the bioparticles can be encapsulated in microcapsules, which include shells, coatings or porous substrates, wherein one or more single bioparticles or a small group of bioparticles are entrained. Microcapsules can include other reagents. The encapsulation of bioparticles can be carried out by a variety of methods. Such methods can combine the aqueous fluid containing bioparticles with a polymer precursor material, which can form a gel or other solid or semi-solid matrix when a specific stimulus is applied to the polymer precursor. Such stimulation can include, for example, thermal stimulation (for example, heating or cooling), light stimulation (for example, by photocuring), chemical stimulation (for example, by crosslinking, polymerization initiation of precursors (for example, by added initiators)), mechanical stimulation or its combination.
[0495] The preparation of microcapsules containing bioparticles can be performed by a variety of methods. For example, an air knife droplet or an aerosol generator can be used to dispense droplets of a precursor fluid into a gelling solution to form microcapsules containing a single bioparticle or a small group of bioparticles. Similarly, a membrane-based encapsulation system can be used to produce microcapsules containing encapsulated bioparticles as described herein. The microfluidic systems of the present disclosure (e.g., Fig.106 The system shown in ) can be readily used to encapsulate cells as described herein. In particular, and with reference to Fig.106 , an aqueous fluid 10612 containing (i) biological particles 10614 and (ii) polymer precursor material (not shown) flows into a channel junction 10610, where it is partitioned into droplets 10618, 10620 by the flow of a non-aqueous fluid 10616. In the case of an encapsulation method, the non-aqueous fluid 10616 may also contain an initiator (not shown) to cause polymerization and / or cross-linking of the polymer precursor to form microcapsules containing the entrained biological particles. Examples of polymer precursor / initiator pairs include those described in U.S. Patent Application Publication No. 2014 / 0378345, which is incorporated herein by reference in its entirety for all purposes.
[0496] For example, in the case where the polymer precursor material comprises a linear polymer material (e.g., linear polyacrylamide, PEG or other linear polymer material), the activator may include a crosslinker or a chemical that activates the crosslinker within the formed droplet. Similarly, for a polymer precursor comprising a polymerizable monomer, the activator may include a polymerization initiator. For example, in some cases, in the case where the polymer precursor comprises a mixture of acrylamide monomer and N, N'-bis-(acryloyl) cystamine (BAC) comonomer, reagents such as ammonium persulfate (APS) and tetraethylmethylenediamine (TEMED) may be provided in the second fluid stream 10616 in channel segments 10604 and 10606, which may initiate and catalyze the copolymerization of acrylamide and BAC into a crosslinked polymer network or hydrogel. Other non-limiting examples of initiators include azide-based reagents (e.g., VA-086) and lithium phenyltrimethylbenzoylphosphite.
[0497] When the second fluid stream 10616 contacts the first fluid stream 10612 at the junction 10610, during droplet formation, TEMED can diffuse from the second fluid 10616 into the aqueous fluid 10612 containing linear polyacrylamide, which will activate the crosslinking of the polyacrylamide in the droplets 10618, 10620, resulting in the formation of gel (e.g., hydrogel) microcapsules as solid or semi-solid beads or particles entraining cells 10614. Although described in terms of polyacrylamide encapsulation, other "activatable" encapsulation compositions can also be used in the context of the methods and compositions described herein. For example, the formation of alginate droplets is then exposed to divalent metal ions (e.g., Ca 2+ ions) can be used as an encapsulation method using the method. Similarly, agarose droplets can also be converted into capsules by temperature-based gelation (e.g., after cooling, etc.). In another example, the addition of complementary nucleic acids (e.g., DNA) can be used to crosslink or non-crosslink nucleic acid molecules conjugated to the polymer network.
[0498] In some cases, the encapsulated bioparticles can be selectively released from the microcapsule, such as by the passage of time or upon application of a specific stimulus, which is sufficient to degrade the microcapsule to allow the bioparticles (e.g., cells) or other contents thereof to be released from the microcapsule, such as into a compartment (e.g., droplet). For example, in the case of the polyacrylamide polymer described above, degradation of the microcapsule can be achieved by introducing a suitable reducing agent (e.g., DTT, etc.) to cleave the disulfide bonds that cross-link the polymer matrix. See, e.g., U.S. Patent Application Publication No. 2014 / 0378345, which is incorporated herein by reference in its entirety for all purposes.
[0499] The bioparticles may be subjected to other conditions sufficient to polymerize or gel the precursor. The conditions sufficient to polymerize or gel the precursor may include exposure to heating, cooling, electromagnetic radiation and / or light. The conditions sufficient to polymerize or gel the precursor may include any conditions sufficient to polymerize or gel the precursor. After polymerization or gelation, a polymer or gel may be formed around the bioparticle. The polymer or gel may be diffusely permeable to chemical or biochemical reagents. The polymer or gel may be diffusely impermeable to the macromolecular components of the bioparticles. In this way, the polymer or gel may play a role in allowing the bioparticles to be subjected to chemical or biochemical operations while spatially confining the macromolecular components in the region of the droplets defined by the polymer or gel. The polymer or gel may include one or more of disulfide cross-linked polyacrylamide, agarose, alginate, polyvinyl alcohol, polyethylene glycol (PEG)-diacrylate, PEG-acrylate, PEG-thiol, PEG-azide, PEG-alkyne, other acrylates, chitosan, hyaluronic acid, collagen, fibrin, gelatin or elastin. The polymer or gel may include any other polymer or gel.
[0500] The polymer or gel can be functionalized to bind target analytes, such as nucleic acids, proteins, carbohydrates, lipids or other analytes. The polymer or gel can be polymerized or gelled by a passive mechanism. The polymer or gel can be stable under alkaline or acidic conditions or at high temperatures. The polymer or gel can have mechanical properties similar to the mechanical properties of beads. For example, the polymer or gel can have a size similar to that of beads. The polymer or gel can have a mechanical strength similar to that of beads (e.g., tensile strength, compressive strength, rigidity, toughness, etc.). The density of the polymer or gel can be lower than that of oil. The density of the polymer or gel can be roughly similar to that of the buffer. The polymer or gel can have an adjustable pore size. The pore size can be selected to, for example, retain denatured nucleic acids. The pore size can be selected to maintain diffusion permeability for exogenous chemicals (e.g., sodium hydroxide (NaOH)) and / or endogenous chemicals (e.g., inhibitors). The polymer or gel can be biocompatible. The polymer or gel can maintain or enhance cell viability. The polymer or gel can be biochemically compatible. The polymer or gel can be polymerized and / or depolymerized by thermal, chemical, enzymatic and / or optical means.
[0501] The polymer may comprise poly(acrylamide-co-acrylic acid) cross-linked using disulfide bonds. The preparation of the polymer may comprise a two-step reaction. In the first activation step, the poly(acrylamide-co-acrylic acid) may be exposed to an acylating agent to convert the carboxylic acid into an ester. For example, the poly(acrylamide-co-acrylic acid) may be exposed to 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM). The polyacrylamide-co-acrylic acid may be exposed to other salts of 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholine. In the second cross-linking step, the ester formed in the first step may be exposed to a disulfide cross-linking agent. For example, the ester may be exposed to cystamine (2,2'-disulfide bis(ethylamine)). After these two steps, the bioparticles may be surrounded by polyacrylamide chains linked together by disulfide bonds. In this manner, the bioparticles can be encapsulated within or contain a gel or matrix (e.g., a polymer matrix) to form a "cell bead". The cell bead can contain the bioparticle (e.g., cell) or the macromolecular components of the bioparticle (e.g., RNA, DNA, protein, etc.), as described elsewhere herein.
[0502] Encapsulated bioparticles can provide some potential advantages, namely, they are easier to store and carry than bioparticles based on droplet partitioning. In addition, in some cases, it may be desirable to allow the bioparticles to be incubated for a selected period of time before analysis, for example, in order to characterize the changes of such bioparticles over time in the presence or absence of different stimuli. In this case, encapsulation can allow longer incubation than partitioning in emulsion droplets, although in some cases, the bioparticles of droplet partitions can also be incubated for different time periods, for example, at least 10 seconds, at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours or at least 10 hours or longer. The encapsulation of bioparticles can constitute the partitioning of bioparticles, in which other reagents are co-partitioned. Alternatively or additionally, the encapsulated bioparticles can be easily deposited into other compartments (e.g., droplets) as described above.
[0503] bead
[0504] The compartment can include one or more unique identifiers, such as barcodes. The barcode can be delivered in advance, subsequently or simultaneously to the compartment containing the bioparticles of the separation or partition. For example, the barcode can be injected into the droplet before, after or simultaneously with the droplet generation. The delivery of the barcode to a specific compartment allows the characteristics of a single bioparticle to be attributed to a specific compartment later. The barcode can be delivered to the compartment by any suitable mechanism (for example, on a nucleic acid molecule (for example, an oligonucleotide)). The barcoded nucleic acid molecule can be delivered to the compartment by a microcapsule. In some cases, the microcapsule may include beads. The beads are described in further detail below.
[0505] In some cases, the barcoded nucleic acid molecules can be initially associated with the microcapsule, and then released from the microcapsule. The release of the barcoded nucleic acid molecules can be passive (e.g., diffuse out of the microcapsule). Additionally or alternatively, release from the microcapsule can be performed after applying a stimulus that allows the barcoded nucleic acid molecules to dissociate or release from the microcapsule. Such a stimulus can destroy the microcapsule, couple the barcoded nucleic acid molecules to the microcapsule, or couple the interaction of the barcoded nucleic acid molecules in the microcapsule, or both. Such a stimulus can include, for example, thermal stimulation, light stimulation, chemical stimulation (e.g., pH changes or use of one or more reducing agents), mechanical stimulation, radiation stimulation; biological stimulation (e.g., enzymes) or any combination thereof.
[0506] Fig.107An example of a microfluidic channel structure 10700 for delivering beads carrying barcodes to a droplet is shown. The channel structure 10700 may include channel segments 10701, 10702, 10704, 10706, and 10708 connected at a channel junction 10710. In operation, the channel segment 201 may transport an aqueous fluid 10712 containing a plurality of beads 10714 (e.g., having nucleic acid molecules, oligonucleotides, molecular tags) along the channel segment 10701 into the junction 10710. The plurality of beads 10714 may be derived from a suspension of beads. For example, the channel segment 10701 may be connected to a reservoir containing an aqueous suspension of beads 10714. The channel segment 10702 may transport an aqueous fluid 10712 containing a plurality of biological particles 10716 along the channel segment 10702 into the junction 10710. The plurality of biological particles 10716 may be derived from a suspension of biological particles. For example, channel segment 10702 can be connected to a reservoir containing an aqueous suspension of biological particles 10716. In some cases, the aqueous fluid 10712 in the first channel segment 10701 or the second channel segment 10702 or both segments can include one or more reagents, as further described below. A second fluid 10718 that is immiscible with the aqueous fluid 10712 (e.g., oil) can be delivered to the junction 10710 from each of the channel segments 10704 and 10706. Upon encountering the aqueous fluid 10712 from each of the channel segments 10701 and 10702 and the second fluid 10718 from each of the channel segments 10704 and 10706 at the channel junction 10710, the aqueous fluid 10712 can be partitioned into discrete droplets 10720 in the second fluid 10718 and flow out of the junction 10710 along the channel segment 10708. Channel segment 10708 can transport discrete droplets to an outlet reservoir fluidly coupled to channel segment 10708, where the discrete droplets can be collected.
[0507] Alternatively, channel segments 10701 and 10702 may meet at another junction upstream of junction 10710. At such a junction, beads and bioparticles may form a mixture that is directed along another channel to junction 10710 to produce droplets 10720. The mixture may provide beads and bioparticles in an alternating manner such that, for example, a droplet contains a single bead and a single bioparticle.
[0508] Beads, bioparticles and droplets can flow along the channel with a substantially regular flow spectrum (e.g., with a regular flow rate). Such a regular flow spectrum can allow the droplet to include a single bead and a single bioparticle. Such a regular flow spectrum can allow the droplet to have an occupancy rate greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% (e.g., droplets with beads and bioparticles). Such a regular flow spectrum and a device that can be used to provide such a regular flow spectrum are provided in, for example, U.S. Patent Publication No. 2015 / 0292988, which is incorporated herein by reference in its entirety.
[0509] The second fluid 10718 may include an oil, such as a fluorinated oil, which includes a fluorinated surfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 10720. Other surfactants, such as Span 80, Triton X-100, SDS, perfluorooctanol (PFO), perfluoropolyethers, etc., may also be used to prevent droplet coalescence.
[0510] The generated discrete droplets may contain a single biological particle 10716. The generated discrete droplets may contain beads carrying barcodes or other reagents 10714. The generated discrete droplets may contain both a single biological particle and a bead carrying a barcode, such as droplet 10720. In some cases, the discrete droplets may contain more than one single biological particle or no biological particles. In some cases, the discrete droplets may contain more than one bead or no beads. The discrete droplets may be unoccupied (e.g., no beads, no biological particles).
[0511] Beneficially, discrete droplets of partitioned bioparticles and barcode-carrying beads can effectively allow attribution of barcodes to macromolecular components of the bioparticle within a compartment.The contents of a compartment can be kept discrete from the contents of other compartments.
[0512] It should be understood that the channel segments described herein can be coupled to any of a variety of fluid sources or receiving components, including fluid components of a reservoir, pipeline, manifold or other system. It should be understood that microfluidic channel structure 10700 can have other geometric shapes. For example, the microfluidic channel structure can have more than one channel junction. For example, the microfluidic channel structure can have 2,3,4 or 5 channel segments, each of which carries beads that meet at the channel junction. Fluid can be guided to flow along one or more channels or reservoirs via one or more fluid flow units. The fluid flow unit may include a compressor (for example, providing positive pressure), a pump (for example, providing negative pressure), an actuator, etc. to control the flow of fluid. Fluid can also be controlled by applied pressure differential, centrifugal force, an electric pump, a vacuum, a capillary or a gravity flow, etc.
[0513] The beads can be porous, non-porous, solid, semi-solid, semi-fluid, fluid and / or combinations thereof. In some cases, the beads can be soluble, destructible and / or degradable. In some cases, the beads can be non-degradable. In some cases, the beads can be gel beads. The gel beads can be hydrogel beads. The gel beads can be formed by molecular precursors (e.g., polymers or monomeric substances). Semi-solid beads can be liposome beads. Solid beads can contain metals, including iron oxide, gold and silver. In some cases, beads can be silica beads. In some cases, beads can be rigid. In other cases, beads can be flexible and / or compressible.
[0514] The beads can be of any suitable shape. Examples of bead shapes include, but are not limited to, spherical, non-spherical, elliptical, rectangular, amorphous, circular, cylindrical, and variations thereof.
[0515] The beads can have a uniform size or a heterogeneous size. In some cases, the diameter of the beads can be at least about 10 nanometers (nm), 100nm, 500nm, 1 micrometer (μm), 5μm, 10μm, 20μm, 30μm, 40μm, 50μm, 60μm, 70μm, 80μm, 90μm, 100μm, 250μm, 500μm, 1mm or more. In some cases, the diameter of the beads can be less than about 10nm, 100nm, 500nm, 1μm, 5μm, 10μm, 20μm, 30μm, 40μm, 50μm, 60μm, 70μm, 80μm, 90μm, 100μm, 250μm, 500μm, 1mm or less. In some cases, the beads may have a diameter of about 40-75 μm, 30-75 μm, 20-75 μm, 40-85 μm, 40-95 μm, 20-100 μm, 10-100 μm, 1-100 μm, 20-250 μm, or 20-500 μm.
[0516] In some aspects, beads can be provided as a population of beads having a relatively monodisperse size distribution or a plurality of beads having a relatively monodisperse size distribution. Where it may be desirable to provide a relatively consistent amount of reagent within a compartment, maintaining relatively consistent bead characteristics (e.g., size) can contribute to overall consistency. In particular, beads described herein can have a size distribution having a coefficient of variation of less than 50%, less than 40%, less than 30%, less than 20%, and in some cases less than 15%, less than 10%, less than 5%, or less in its cross-sectional dimension.
[0517] The beads may comprise natural and / or synthetic materials. For example, the beads may comprise natural polymers, synthetic polymers, or both natural and synthetic polymers. Examples of natural polymers include proteins and sugars, for example, deoxyribonucleic acid, rubber, cellulose, starch (e.g., amylose, amylopectin), proteins, enzymes, polysaccharides, silk, polyhydroxyalkanoates, chitosan, dextran, collagen, carrageenan, psyllium ovata, gum arabic, agar, gelatin, shellac, karaya gum, xanthan gum, corn gum, guar gum, karaya gum, agarose, alginic acid, alginate, or its natural polymers. Examples of synthetic polymers include acrylic, nylon, silicone, spandex, viscose rayon, polycarboxylic acids, polyvinyl acetate, polyacrylamide, polyacrylate, polyethylene glycol, polyurethane, polylactic acid, silica, polystyrene, polyacrylonitrile, polybutadiene, polycarbonate, polyethylene, polyethylene terephthalate, poly(chlorotrifluoroethylene), poly(ethylene oxide), poly(ethylene terephthalate), polyethylene, polyisobutylene, poly(methyl methacrylate), poly(methylene oxide), polyoxymethylene, polypropylene, polystyrene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), poly(vinyl chloride), poly(vinylidene chloride), poly(vinylidene fluoride), poly(vinyl fluoride), and / or combinations (e.g., copolymers) thereof. Beads may also be formed from materials other than polymers, including lipids, micelles, liposomes, ceramics, glass ceramics, material composites, metals, other inorganic materials, and the like.
[0518] In some cases, beads may include molecular precursors (e.g., monomers or polymers), which can form polymer networks by polymerization of molecular precursors. In some cases, precursors can be polymerized substances that can be further polymerized by, for example, chemical crosslinking. In some cases, precursors can include one or more of acrylamide or methacrylamide monomers, oligomers or polymers. In some cases, beads may include prepolymers, which are oligomers that can be further polymerized. For example, polyurethane beads can be prepared using prepolymers. In some cases, beads may include a single polymer that can be further polymerized together. In some cases, beads can be produced by polymerization of different precursors so that they include mixed polymers, copolymers and / or block copolymers. In some cases, beads can include covalent bonds or ionic bonds between polymer precursors (e.g., monomers, oligomers, linear polymers), nucleic acid molecules (e.g., oligonucleotides), primers and other entities. In some cases, covalent bonds can be carbon-carbon bonds, thioether bonds or carbon-heteroatom bonds.
[0519] Depending on the specific cross-linking agent used, the cross-linking may be permanent or reversible. Reversible cross-linking may allow the polymer to linearize or dissociate under appropriate conditions. In some cases, reversible cross-linking may also allow reversible attachment of materials bound to the bead surface. In some cases, the cross-linking agent may form disulfide bonds. In some cases, the chemical cross-linking agent that forms disulfide bonds may be cystamine or modified cystamine.
[0520] In some cases, disulfide bonds can be formed between molecular precursor units (e.g., monomers, oligomers, or linear polymers) or precursors incorporated into beads and nucleic acid molecules (e.g., oligonucleotides). For example, cystamine (including modified cystamine) is an organic reagent containing disulfide bonds that can be used as a cross-linking agent between individual monomers or polymeric precursors of beads. Polyacrylamide can be polymerized in the presence of cystamine or a substance containing cystamine (e.g., modified cystamine) to produce polyacrylamide gel beads containing disulfide bonds (e.g., chemically degradable beads containing a chemically reducible cross-linking agent). When the beads are exposed to a reducing agent, the disulfide bonds can allow the beads to be degraded (or dissolved).
[0521] In some cases, the linear polysaccharide polymer chitosan can be cross-linked with glutaraldehyde via hydrophilic chains to form beads. Cross-linking of the chitosan polymer can be achieved by chemical reactions initiated by heat, pressure, pH changes, and / or radiation.
[0522] In some cases, beads may include acrylate moieties that can be used in some aspects to attach one or more nucleic acid molecules (e.g., barcode sequences, barcoded nucleic acid molecules, barcoded oligonucleotides, primers, or other oligonucleotides) to beads. In some cases, acrylate moieties may refer to acrylate analogs produced by the reaction of acrylates with one or more substances, such as the reaction of acrylates with other monomers and crosslinkers during a polymerization reaction. The acrylate moiety can be modified to form a chemical bond with a substance to be attached, such as a nucleic acid molecule (e.g., a barcode sequence, a barcoded nucleic acid molecule, a barcoded oligonucleotide, a primer, or other oligonucleotide). The acrylate moiety can be modified by a thiol group that is capable of forming a disulfide bond, or the acrylate moiety can be modified with a group that already contains a disulfide bond. A thiol or disulfide (by disulfide exchange) can be used as an anchor point for the substance to be attached, or another portion of the acrylate moiety can be used for attachment. In some cases, the attachment may be reversible, such that when the disulfide bond is broken (eg, in the presence of a reducing agent), the attached substance is released from the bead. In other cases, the acrylate moiety may contain reactive hydroxyl groups that can be used for attachment.
[0523] Functionalization of beads for attachment of nucleic acid molecules (e.g., oligonucleotides) can be achieved by a variety of different methods, including activation of chemical groups in the polymer, incorporation of reactive or activatable functional groups into the polymer structure, or attachment at the prepolymer or monomer stage during bead production.
[0524] For example, the precursor (e.g., monomer, cross-linking agent) that is polymerized to form beads can include an acrylate moiety so that when beads are produced, the beads also include an acrylate moiety. The acrylate moiety can be attached to a nucleic acid molecule (e.g., an oligonucleotide), which can include a primer sequence (e.g., a primer for amplifying a target nucleic acid, a random primer, a primer sequence for mRNA) and / or one or more barcode sequences. One or more barcode sequences can include sequences that are identical to all nucleic acid molecules coupled to a given bead and / or sequences that are different between all nucleic acid molecules coupled to a given bead. Nucleic acid molecules can be incorporated into beads.
[0525] In some cases, the nucleic acid molecule may comprise a functional sequence, e.g., a sequence for attachment to a sequencing flow cell, e.g., for In some cases, the nucleic acid molecule or its derivative (e.g., an oligonucleotide or polynucleotide produced by the nucleic acid molecule) may include another functional sequence, for example, a P7 sequence, which is used to attach to a sequencing flow cell for Illumina sequencing. In some cases, the nucleic acid molecule may include a barcode sequence. In some cases, the primer may further include a unique molecular identifier (UMI). In some cases, the primer may include an R1 primer sequence for Illumina sequencing. In some cases, the primer may include an R2 primer sequence for Illumina sequencing. Examples of such nucleic acid molecules (e.g., oligonucleotides, polynucleotides, etc.) and uses thereof that can be used with the compositions, devices, methods and systems of the present disclosure are provided in U.S. Patent Publications 2014 / 0378345 and 2015 / 0376609 (each of which is incorporated herein by reference in its entirety).
[0526] In various aspects, provided herein is a bead (e.g., barcoded bead) suitable for processing a nucleic acid sequence (e.g., mRNA, complementary DNA derived from the reverse transcription of mRNA) of at least a portion of a V (D) J sequence encoding, for example, an immune cell receptor (e.g., TCR or BCR), at least a portion of a guide RNA, and / or at least a portion of a guide RNA identifying a barcode. The bead can be a gel bead. The barcoded primer can be coupled or otherwise attached to the gel bead. In some cases, the barcoded primer can be releasably attached to the gel bead, as described herein. Therefore, the first barcode molecule can include a priming sequence that can induce a nucleic acid sequence of at least a portion of a V (D) J sequence encoding, for example, an immune cell receptor (e.g., TCR or BCR), at least a portion of a guide RNA, and / or at least a portion of a guide RNA identifying a barcode. In some cases, the nucleic acid molecule with such a nucleic acid sequence is a cDNA, which is produced by reverse transcription of the corresponding mRNA, such as using a primer (or other primer) containing poly-T. The generated cDNA can then be barcoded using a primer comprising a barcode sequence (and optionally, a unique molecular identifier (UMI) sequence) that hybridizes to at least a portion of the generated cDNA. In some cases, a template switching oligonucleotide and a terminal transferase or reverse transcriptase having terminal transferase activity can be combined to generate a priming region on the cDNA to which the barcoded primer can hybridize during cDNA generation. For example, the terminal transferase activity can add a poly-C tail to the 3' end of the cDNA, thereby allowing the template switching oligonucleotide to bind through the poly-G priming sequence and further extend the 3' end of the cDNA. The original mRNA template and template switching oligonucleotide can then be denatured from the cDNA, and a barcoded primer comprising a sequence complementary to at least a portion of the priming region generated on the cDNA can then be hybridized to the cDNA and generate a barcoded construct comprising the barcode sequence (and any optional UMI sequence) and the complementary sequence of the cDNA.
[0527] In various aspects, beads (e.g., beads) suitable for processing gDNA or its derivatives are provided herein. Beads can be gel beads. Beads can be suitable for processing at least a portion of the V (D) J sequence encoding, for example, an immune cell receptor (e.g., TCR or BCR), at least a portion of a guide RNA, and / or the same beads of at least a portion of a nucleic acid sequence (e.g., mRNA, cDNA, etc.) for guiding RNA identification barcodes. For example, beads can include a variety of different types of primers. Barcoded primers can be coupled or otherwise attached to gel beads. In some cases, barcoded primers can include partially double-stranded adapters. In some cases, adapters can be forked with single-stranded regions (e.g., with a "Y" shape). In some cases, adapters may not have forks. In some cases, barcoded primers can be releasably attached to gel beads, as described elsewhere herein. Barcoded primers can interact (e.g., to form a complex) with an enzyme (e.g., a transposase). In some cases, beads may be coupled or otherwise attached to the transposase-primer complex.
[0528] Fig.113 An example of a bead carrying a barcode is shown. A nucleic acid molecule 11302 (e.g., an oligonucleotide) can be coupled to a bead 11304 via a releasable bond 11306 (e.g., a disulfide bond). The same bead 11304 can be coupled (e.g., via a releasable connection) to one or more other nucleic acid molecules 11318, 11320. The nucleic acid molecule 11302 can be or include a barcode. As described elsewhere herein, the structure of a barcode can include multiple sequence elements. The nucleic acid molecule 11302 can include a functional sequence 11308 that can be used in subsequent processing. For example, the functional sequence 11308 can include one or more sequencer-specific flow cell attachment sequences (e.g., for P5 sequence for sequencing system) and sequencing primer sequence (e.g., for R1 primer of sequencing system). Nucleic acid molecule 11302 can include barcode sequence 11310 for barcoding samples (e.g., DNA, RNA, protein, etc.). In some cases, barcode sequence 11310 can be bead-specific, such that barcode sequence 11310 is common to all nucleic acid molecules (e.g., including nucleic acid molecule 11302) coupled to the same bead 11304. Alternatively or additionally, barcode sequence 11310 can be compartment-specific, such that barcode sequence 11310 is common to all nucleic acid molecules coupled to one or more beads partitioned into the same compartment. Nucleic acid molecule 11302 can include specific priming sequence 11312, for example, mRNA (e.g., gRNA, TRA, TRB, etc.) specific priming sequence (e.g., poly-T sequence), targeted priming sequence and / or random priming sequence. Nucleic acid molecule 11302 may include an anchor sequence 11314 to ensure that the specific priming sequence 11312 hybridizes at the end of the sequence (e.g., of mRNA). For example, anchor sequence 11314 may include a random short sequence of nucleotides, such as a 1-mer, 2-mer, 3-mer, or longer sequence, which can ensure that the poly-T segment is more likely to hybridize at the end of the sequence of the poly-A tail of the mRNA.
[0529] Nucleic acid molecule 11302 may include a unique molecule identification sequence 11316 (e.g., a unique molecule identifier (UMI)). In some cases, the unique molecule identification sequence 11316 may include about 5 to about 113 nucleotides. Alternatively, the unique molecule identification sequence 11316 may include less than about 5 or more than about 113 nucleotides. The unique molecule identification sequence 11316 may be a unique sequence that varies between individual nucleic acid molecules (e.g., 11302, 11318, 11320, etc.) coupled to a single bead (e.g., bead 11304). In some cases, the unique molecule identification sequence 11316 may be a random sequence (e.g., such as a random N-mer sequence). For example, the UMI can provide a unique identifier of a captured starting mRNA molecule to allow quantification of the amount of originally expressed RNA. It should be understood that although Fig.113 Three nucleic acid molecules 11302, 11318, 11320 are shown coupled to the surface of a bead 11304, but a single bead can be coupled to any number of individual nucleic acid molecules, for example, from one to tens to hundreds, thousands, or even millions of individual nucleic acid molecules. Individual barcodes of individual nucleic acid molecules can include common or relatively common sequence segments (e.g., 11308, 11310, 11312, etc.) and variable or unique sequence segments (e.g., 11316) between different individual nucleic acid molecules coupled to the same bead.
[0530] In operation, biological particles (e.g., cells, DNA, RNA, etc.) can be co-zoned with beads 11304 carrying barcodes. Barcoded nucleic acid molecules 11302, 11318, 11320 can be released from beads 11304 into the compartment. For example, in the case of analyzing sample RNA, the poly-T segment (e.g., 11312) of one of the released nucleic acid molecules (e.g., 11302) can hybridize with the poly-A tail of the mRNA molecule. Reverse transcription can produce a cDNA transcript of the mRNA, but the transcript includes each sequence segment 11308, 11310, 11316 of the nucleic acid molecule 11302. Because the nucleic acid molecule 11302 includes an anchor sequence 11314, it is more likely to hybridize at the sequence end of the poly-A tail of the mRNA and initiate reverse transcription. In any given compartment, all cDNA transcripts of a single mRNA molecule can include a common barcode sequence segment 11310. However, transcripts made from different mRNA molecules within a given compartment may vary in unique molecular identification sequence 11312 segments (e.g., UMI segments). Beneficially, the number of different UMIs can indicate the amount of mRNA derived from a given compartment, and therefore the amount of mRNA derived from a biological particle (e.g., a cell), even after any subsequent amplification of the contents of a given compartment. As described above, the transcripts can be amplified, purified, and sequenced to identify the sequence of the cDNA transcript of the mRNA, as well as to sequence the barcode segments and UMI segments. Although poly-T primer sequences are described, other targeted or random primer sequences can also be used to initiate the reverse transcription reaction. Similarly, although described as releasing barcoded oligonucleotides into compartments, in some cases, nucleic acid molecules bound to beads (e.g., gel beads) can be used to hybridize and capture mRNA on the solid phase of the beads, for example, to facilitate separation of RNA from other cellular contents.
[0531] In some cases, precursors containing reactive or activated functional groups can be polymerized with other precursors to produce gel beads containing activated or activatable functional groups. The functional groups can then be used to connect other substances (e.g., disulfide linkers, primers, other oligonucleotides, etc.) to the gel beads. For example, some precursors containing carboxylic acid (COOH) groups can be copolymerized with other precursors to form gel beads that also contain COOH functional groups. In some cases, acrylic acid (a substance containing free COOH groups), acrylamide and bis (acryloyl) cystamine can be copolymerized together to produce gel beads containing free COOH groups. The COOH groups of the gel beads can be activated (e.g., by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) or 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine hydrochloride (DMTMM)) to render them reactive (e.g., reactive to amine functional groups when EDC / NHS or DMTMM is used for activation). The activated COOH groups can then be reacted with a suitable substance comprising a moiety to be attached to the beads (e.g., a substance comprising an amine functional group wherein the carboxylic acid group is activated to react with the amine functional group).
[0532] Beads containing disulfide bonds in their polymer networks can be functionalized with additional substances by reducing some of the disulfide bonds to free thiols. Disulfide bonds can be reduced by the action of, for example, a reducing agent (e.g., DTT, TCEP, etc.) to produce free thiol groups without dissolving the beads. The free thiols of the beads can then react with the free thiols of a substance or a substance containing another disulfide bond (e.g., by thiol-disulfide exchange) so that the substance can be connected to the beads (e.g., by the generated disulfide bonds). In some cases, the free thiols of the beads can react with any other suitable groups. For example, the free thiols of the beads can react with substances containing acrylate moieties. The free thiol groups of the beads can react with acrylates by Michael addition chemistry, thereby connecting the substances containing acrylates to the beads. In some cases, uncontrolled reactions can be prevented by including a thiol capping agent (e.g., N-ethylmaleimide or iodoacetate).
[0533] The activation of disulfide bonds within the beads can be controlled so that only a small number of disulfide bonds are activated. For example, this can be controlled by controlling the concentration of the reducing agent used to generate free thiol groups and / or the concentration of the reagent used to form disulfide bonds during bead polymerization. In some cases, a low concentration (e.g., a ratio of reducing agent molecules: gel beads of less than or equal to about 1:100,000,000,000, less than or equal to about 1:10,000,000,000, less than or equal to about 1:1,000,000,000, less than or equal to about 1:100,000,000, less than or equal to about 1:10,000,000, less than or equal to about 1:1,000,000, less than or equal to about 1:100,000,000, less than or equal to about 1:1,000,000, less than or equal to about 1:100,000, less than or equal to about 1:10,000) of reducing agent can be used for reduction. Controlling the number of disulfide bonds reduced to free thiols may be useful to ensure the structural integrity of the beads during the functionalization process. In some cases, optically active agents (e.g., fluorescent dyes) can be coupled to the beads via the free thiol groups of the beads and used to quantify the number of free thiols present in the beads and / or to track the beads.
[0534] In some cases, it may be advantageous to add a part to the gel beads after forming the gel beads. For example, adding oligonucleotides (for example, barcoded oligonucleotides) after the gel beads are formed can avoid the loss of material during the chain transfer termination that may occur in the polymerization process. In addition, smaller precursors (for example, monomers or cross-linking agents that do not include side chain groups and connected parts) can be used for polymerization, and can be minimally hindered by the growth chain end due to the viscosity effect. In some cases, the functionalization after the synthesis of the gel beads can minimize the exposure of the material (for example, oligonucleotide) loaded with potential destroyers (for example, free radicals) and / or chemical environments. In some cases, the gel generated can have an upper critical solution temperature (UCST), which can allow the temperature-driven swelling and collapse of beads. Such functionality can help oligonucleotides (for example, primers) to penetrate into beads during the functionalization of beads with oligonucleotides subsequently. Functionalization after generation can also be used to control the loading rate of material in the beads, so that, for example, the change of loading rate is minimized. Substance loading can also be performed in a batch process, so that multiple beads can be functionalized with the substance in a single batch.
[0535] The beads injected or otherwise introduced into the compartment may contain a releasable, cleavable or reversibly attached barcode. The beads injected or otherwise introduced into the compartment may contain an activatable barcode. The beads injected or otherwise introduced into the compartment may be degradable, destructible or soluble beads.
[0536] The barcode can be releasably, cleavably or reversibly attached to the beads so that the barcode can be released or releasable by the breaking of the bond between the barcode molecule and the beads, or released by the degradation of the beads themselves below, thereby allowing the barcode to be approached by other reagents or can be approached by other reagents, or both. In a non-limiting example, cleavage can be achieved by reducing disulfide bonds, using restriction enzymes, photoactivated cleavage or by other types of stimulation (e.g., chemical, thermal, pH, enzymatic, etc.) and / or reaction cleavage, such as described elsewhere herein. Releasable barcodes are sometimes referred to as activatable because they can be used for reactions once released. Therefore, for example, activatable barcodes can be activated by releasing the barcode from beads (or other suitable types of compartments described herein). Other activatable configurations are also contemplated in the context of the described methods and systems.
[0537] In addition to or as an alternative to a cleavable linkage between a bead and an associated molecule (e.g., a nucleic acid molecule containing a barcode (e.g., a barcoded oligonucleotide)), the bead may be degradable, destructible, or soluble either spontaneously or upon exposure to one or more stimuli (e.g., a temperature change, a pH change, exposure to a particular chemical or phase, exposure to light, a reducing agent, etc.). In some cases, the bead may be soluble such that upon exposure to a particular chemical or environmental change (e.g., a temperature change or a pH change), the material components of the bead are dissolved. In some cases, the gel beads may be degradable or soluble at elevated temperatures and / or alkaline conditions. In some cases, the beads may be thermally degradable such that the beads degrade when the beads are exposed to an appropriate temperature change (e.g., heat). Degradation or dissolution of beads bound to a substance (e.g., a nucleic acid molecule, e.g., a barcoded oligonucleotide) may result in the release of the substance from the bead.
[0538] As will be understood from the above disclosure, the degradation of beads can refer to the dissociation of bound or entrained substances from the beads, whether or not the physical beads themselves are structurally degraded. For example, the degradation of beads can involve the cleavage of cleavable connections via one or more substances and / or methods described elsewhere herein. In another example, due to, for example, a changed chemical environment, entrained substances can be released from the beads by an osmotic pressure difference. For example, changes in the pore size of the beads due to an osmotic pressure difference can generally occur without structural degradation of the beads themselves. In some cases, an increase in pore size due to osmotic swelling of the beads can allow the release of entrained substances within the beads. In other cases, due to pore size shrinkage, the osmotic shrinkage of the beads may cause the beads to better retain entrained substances.
[0539] Degradable beads can be introduced into a compartment (e.g., a droplet or well of an emulsion) such that when an appropriate stimulus is applied, the beads degrade in the compartment and release any associated substances (e.g., oligonucleotides) into the droplet. Free substances (e.g., oligonucleotides, nucleic acid molecules) can interact with other reagents contained in the compartment. For example, polyacrylamide beads containing cystamine and connected to a barcode sequence via a disulfide bond can be combined with a reducing agent in a droplet of an oil-in-water emulsion. In the droplet, the reducing agent can destroy various disulfide bonds, causing the beads to degrade and release the barcode sequence into the aqueous internal environment of the droplet. In another example, heating a droplet containing a barcode sequence bound to a bead in an alkaline solution may also cause the beads to degrade and release the attached barcode sequence into the aqueous internal environment of the droplet.
[0540] Any suitable number of molecular tag molecules (e.g., primers, barcoded oligonucleotides) can be associated with beads so that after release from the beads, the molecular tag molecules (e.g., primers, e.g., barcoded oligonucleotides) are present in the compartment at a predetermined concentration. Such a predetermined concentration can be selected to facilitate certain reactions, such as amplification, for generating a sequencing library within the compartment. In some cases, the predetermined concentration of primers can be limited by the process of generating beads carrying nucleic acid molecules (e.g., oligonucleotides).
[0541] In some cases, beads can be non-covalently loaded with one or more reagents. Beads can be non-covalently loaded by, for example, subjecting the beads to conditions sufficient to swell the beads so that the reagent has enough time to diffuse into the inside of the beads and subjecting the beads to conditions sufficient to deswell the beads. The swelling of beads can be achieved by, for example, placing the beads in a thermodynamically favorable solvent, subjecting the beads to a higher or lower temperature, subjecting the beads to a higher or lower ion concentration, and / or subjecting the beads to an electric field. The swelling of beads can be achieved by various swelling methods. The deswelling of beads can be achieved by, for example, transferring the beads to a thermodynamically unfavorable solvent, subjecting the beads to a lower or higher temperature, subjecting the beads to a lower or higher ion concentration, and / or removing the electric field. The deswelling of beads can be achieved by various deswelling methods. Transferring beads may cause the holes in the beads to shrink. Then, shrinkage may hinder the reagent in the beads from diffusing out of the inside of the beads. The obstacle may be due to the spatial interaction between the reagent and the inside of the beads. Transfer can be achieved microfluidically. For example, the transfer can be achieved by moving the beads from one co-current solvent stream to another co-current solvent stream.The swelling properties and / or pore size of the beads can be adjusted by varying the polymer composition of the beads.
[0542] In some cases, an acrylate moiety attached to a precursor, another substance attached to a precursor, or the precursor itself may contain an unstable bond, e.g., a chemical, heat or light sensitive bond, e.g., a disulfide bond, a UV-sensitive bond, etc. Once an acrylate moiety or other moiety containing an unstable bond is incorporated into a bead, the bead may also contain an unstable bond. An unstable bond may, for example, be used to reversibly attach (e.g., covalently attach) a substance (e.g., a barcode, a primer, etc.) to a bead. In some cases, a thermally unstable bond may include attachment based on nucleic acid hybridization, e.g., when an oligonucleotide hybridizes with a complementary sequence attached to a bead, so that thermal melting of the hybrid releases the oligonucleotide from the bead or microcapsule, e.g., a sequence containing a barcode.
[0543] Adding multiple types of unstable bonds to gel beads can result in beads that can respond to various stimuli. Each type of unstable bond may be sensitive to relevant stimuli (e.g., chemical stimuli, light, temperature, enzymes, etc.), so that the release of substances attached to beads by each unstable bond can be controlled by applying appropriate stimuli. Such functionality can be used for controlled release of substances from gel beads. In some cases, another substance containing unstable bonds can be connected to the gel beads by, for example, activated functional groups of gel beads as described above after forming gel beads. It should be understood that the barcodes releasably, cleavably or reversibly attached to the beads described herein include barcodes released or releasable by cleaving the connection between the barcode molecule and the beads or barcodes released by the degradation of the beads themselves below (thereby allowing other reagents to use close or accessible barcodes), or both.
[0544] In addition to thermally cleavable bonds, disulfide bonds, and UV-sensitive bonds, other non-limiting examples of labile bonds that can be coupled to the precursor or bead include ester bonds (e.g., cleavable by acid, base, or hydroxylamine), vicinal diol bonds (e.g., cleavable by sodium periodate), Diels-Alder bonds (e.g., cleavable by heat), sulfone bonds (e.g., cleavable by base), silyl ether bonds (e.g., cleavable by acid), glycosidic bonds (e.g., cleavable by amylase), peptide bonds (e.g., cleavable by proteases), or phosphodiester bonds (e.g., cleavable by nucleases (e.g., DNases)). Bonds can be cleaved by other nucleic acid molecule targeting enzymes (e.g., restriction enzymes (e.g., restriction endonucleases)), as further described below.
[0545] Substances can be encapsulated in beads during bead generation (e.g., during precursor polymerization). Such substances may or may not participate in polymerization. Such substances can be added to a polymerization reaction mixture so that the generated beads contain the substance when the beads are formed. In some cases, such substances can be added to gel beads after formation. Such substances can include, for example, nucleic acid molecules (e.g., oligonucleotides), reagents for nucleic acid amplification reactions (e.g., primers, polymerases, dNTPs, cofactors (e.g., ionic cofactors), buffers), including those described herein, reagents for enzymatic reactions (e.g., enzymes, cofactors, substrates, buffers), reagents for nucleic acid modification reactions (e.g., polymerization, ligation or digestion) and / or reagents for one or more sequencing platforms (e.g., of ) template preparation (e.g., labeling) reagent. Such substances may include one or more enzymes described herein, including but not limited to polymerases, reverse transcriptases, restriction enzymes (e.g., endonucleases), transposases, ligases, proteinase K, DNA enzymes, etc. Such substances may include one or more reagents described elsewhere herein (e.g., cleavage agents, inhibitors, inactivators, chelators, stimulants). The capture of such substances can be controlled by the density of the polymer network generated during the polymerization of the precursor, the control of the ionic charge in the gel beads (e.g., by ionic substances connected to the polymerized substances) or by releasing other substances. The encapsulated substances can be released from the beads when the beads are degraded and / or by applying a stimulus that can release the substances from the beads. Alternatively or additionally, the substances can be partitioned in the compartments (e.g., droplets) during or after the compartments are formed. Such substances may include but are not limited to the substances described above that can also be encapsulated in the beads.
[0546] Degradable beads can include one or more substances with unstable bonds, so that when the beads / substances are exposed to an appropriate stimulus, the bonds break and the beads degrade. The unstable bonds can be chemical bonds (e.g., covalent bonds, ionic bonds), or can be another type of physical interaction (e.g., van der Waals interactions, dipole-dipole interactions, etc.). In some cases, the cross-linking agent used to produce the beads can include unstable bonds. When exposed to appropriate conditions, the unstable bonds may be broken and the beads degrade. For example, when polyacrylamide gel beads containing cystamine cross-linking agent are exposed to a reducing agent, the disulfide bonds of cystamine can be broken and the beads degrade.
[0547] Compared with non-degradable beads, degradable beads can be used to release attached substances (e.g., nucleic acid molecules, barcode sequences, primers, etc.) from beads faster when appropriate stimulation is applied to the beads. For example, for substances bound to the inner surface of porous beads, or in the case of encapsulated substances, when the beads are degraded, the substance can have greater mobility and accessibility to other substances in solution. In some cases, the substance can also be attached to the degradable beads by a degradable linker (e.g., a disulfide bond). The degradable linker can respond to the same stimulation as the degradable beads, or two degradable substances can respond to different stimulations. For example, a barcode sequence can be attached to polyacrylamide beads containing cystamine by a disulfide bond. When the barcoded beads are exposed to a reducing agent, the beads degrade and the barcode sequence is released when the disulfide bonds between the barcode sequence and the beads and the disulfide bonds of the cystamine in the beads are broken.
[0548] In the case of providing degradable beads, it may be beneficial to avoid exposing such beads to stimuli that cause such degradation before a given time, for example, to avoid premature degradation of beads and problems caused by such degradation, including, for example, poor flow characteristics and aggregation. For example, in the case where the beads contain reducible cross-linking groups (e.g., disulfide groups), it is desirable to avoid contacting such beads with reducing agents (e.g., DTT or other disulfide bond cleavage agents). In such cases, in some cases, treatment of beads described herein without reducing agents (e.g., DTT) will be provided. Because reducing agents are often provided in commercial enzyme preparations, it may be desirable to provide enzyme preparations without reducing agents (or without DTT) when treating beads described herein. Examples of such enzymes include, for example, polymerase preparations, reverse transcriptase preparations, ligase preparations, and many other enzyme preparations that can be used to treat beads described herein. The term "reducing agent-free" or "DTT-free" preparations may refer to having less than about 1 / 10, less than about 1 / 50, or even less than about 1 / 100 of the lower limit of such materials for degrading beads. For example, for DTT, a reducing agent-free formulation may have less than about 0.01 millimolar (mM), 0.005 mM, 0.001 mM DTT, 0.0005 mM DTT, or even less than about 0.0001 mM DTT. In many cases, the amount of DTT may be undetectable.
[0549] A number of chemical triggers may be used to trigger degradation of the beads. Examples of these chemical changes may include, but are not limited to, pH-mediated changes in the integrity of components within the beads, degradation of bead components by cleavage of cross-links, and depolymerization of bead components.
[0550] In some embodiments, the beads may be formed of a material comprising a degradable chemical cross-linking agent (e.g., BAC or cystamine). The degradation of such a degradable cross-linking agent may be accomplished by a variety of mechanisms. In some examples, the beads may be contacted with a chemical degradation agent that may cause oxidation, reduction, or other chemical changes. For example, the chemical degradation agent may be a reducing agent, such as dithiothreitol (DTT). Other examples of reducing agents may include β-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl)phosphine (TCEP), or a combination thereof. The reducing agent may degrade the disulfide bonds formed between the gel precursors that form the beads, thereby degrading the beads. In other cases, a change in the pH of the solution (e.g., an increase in pH) may trigger the degradation of the beads. In other cases, exposure to an aqueous solution (e.g., water) may trigger hydrolytic degradation, thereby causing degradation of the beads. In some cases, any combination of stimuli may trigger the degradation of the beads. For example, a change in pH may enable a chemical agent (e.g., DTT) to become an effective reducing agent.
[0551] The beads can also be induced to release their contents by applying a thermal stimulus. A change in temperature can cause a variety of changes in the beads. For example, heat can cause solid beads to liquefy. A change in heat can cause the beads to melt, causing a portion of the beads to degrade. In other cases, heat can increase the internal pressure of the bead components, causing the beads to break or explode. Heat can also act on thermosensitive polymers used as materials for constructing the beads.
[0552] Any suitable reagent can degrade beads. In some embodiments, changes in temperature or pH can be used to degrade thermosensitive bonds or pH-sensitive bonds in beads. In some embodiments, chemical degradation agents can be used to degrade chemical bonds in beads by oxidation, reduction or other chemical changes. For example, chemical degradation agents can be reducing agents, such as DTT, wherein DTT can degrade the disulfide bonds formed between the cross-linking agent and the gel precursor, thereby degrading the beads. In some embodiments, reducing agents can be added to degrade beads, which can cause the beads to release their contents or may not cause the beads to release their contents. Examples of reducing agents can include dithiothreitol (DTT), β-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris (2-carboxyethyl) phosphine (TCEP) or a combination thereof. Reducing agents can be present at a concentration of about 0.1mM, 0.5mM, 1mM, 5mM, 10mM. The reducing agent may be present at a concentration of at least about 0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM, or greater than 10 mM. The reducing agent may be present at a concentration of up to about 10 mM, 5 mM, 1 mM, 0.5 mM, 0.1 mM, or less.
[0553] Although the invention has been described above in terms of providing a substantially singly occupied compartment Fig.106 and Fig.107 , but in some cases, it may be desirable to provide multiply occupied compartments, for example, two, three, four or more cells and / or microcapsules (e.g., beads) containing barcoded nucleic acid molecules (e.g., oligonucleotides) within a single compartment. Thus, as described above, the flow characteristics of the bioparticles and / or beads containing fluids and partitioning fluids can be controlled to provide such multiply occupied compartments. In particular, the flow parameters can be controlled to provide a given occupancy in greater than about 50% of the compartments, greater than about 75%, and in some cases greater than about 80%, 90%, 95%, or more of the compartments.
[0554] In some cases, additional microcapsules may be used to deliver additional reagents to a compartment. In such cases, it may be advantageous to introduce different beads into a common channel or droplet generation junction from different sources of beads (e.g., containing different relevant reagents) through different channel inlets into such a common channel or droplet generation junction (e.g., junction 210). In such cases, the flow rate and frequency of different beads entering the channel or junction may be controlled to provide a certain ratio of microcapsules from each source while ensuring a given pairing or combination of such beads with a given number of bioparticles in a compartment (e.g., one bioparticle and one bead per compartment).
[0555] The compartments described herein may comprise a small volume, for example, less than about 10 microliters (μL), 5 μL, 1 μL, 500 nanoliters (nL), 100 nL, 50 nL, 900 picoliters (pL), 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, or less.
[0556] For example, in the case of droplet-based compartments, the total volume of the droplets may be less than about 1000 pL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL or less. In the case of co-partitioning with microcapsules, it should be understood that the volume of sample fluid within the compartment (e.g., including co-partitioned bioparticles and / or beads) may be less than about 90% of the volumes described above, less than about 80% of the volumes described above, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10%.
[0557] As described elsewhere herein, partitioning of material can produce a population or multiple compartments of compartments. In such a case, any suitable number of compartments can be generated or otherwise provided. For example, at least about 1,000 compartments, at least about 5,000 compartments, at least about 10,000 compartments, at least about 50,000 compartments, at least about 100,000 compartments, at least about 500,000 compartments, at least about 1,000,000 compartments, at least about 5,000,000 compartments, at least about 10,000,000 compartments, at least about 50,000,000 compartments, at least about 100,000,000 compartments, at least about 50,000,000 compartments, at least about 100,000,000 compartments, at least about 500,000,000 compartments, at least about 1,000,000,000 compartments or more compartments can be generated or otherwise provided. Furthermore, the plurality of compartments may include unoccupied compartments (eg, empty compartments) and occupied compartments.
[0558] Reagents
[0559] According to some aspects, the bioparticles can be partitioned with a lysis reagent to release the contents of the bioparticles in the compartments. In such cases, the lysis reagent can be contacted with the bioparticle suspension simultaneously with or immediately before the bioparticles are introduced into the partition junction / droplet generation region (e.g., junction 210) (e.g., through an additional channel upstream of the channel junction). According to other aspects, the bioparticles can additionally or alternatively be partitioned with other reagents, as will be further described below.
[0560] Fig.108 An example of a microfluidic channel structure 10800 for co-partitioning biological particles and reagents is shown. Channel structure 10800 may include channel segments 10801, 10802, 10804, 10806, and 10808. Channel segments 10801 and 10802 are connected at a first channel junction 10809. Channel segments 10802, 10804, 10806, and 10808 are connected at a second channel junction 10810.
[0561] In an example operation, channel segment 10801 can transport an aqueous fluid 10812 including a plurality of biological particles 10814 along channel segment 10801 into a second junction 10810. Alternatively or additionally, channel segment 10801 can transport beads (e.g., gel beads). The beads can contain barcode molecules.
[0562] For example, channel segment 10801 can be connected to a reservoir containing an aqueous suspension of biological particles 10814. Upstream of second junction 10810 and immediately before reaching second junction 10810, channel segment 10801 can meet channel segment 10802 at first junction 10809. Channel segment 10802 can transport a plurality of reagents 10815 (e.g., lysing agents) suspended in aqueous fluid 10812 along channel segment 10802 into first junction 10809. For example, channel segment 10802 can be connected to a reservoir containing reagents 10815. After first junction 10809, aqueous fluid 10812 in channel segment 10801 can carry both biological particles 10814 and reagents 10815 toward second junction 10810. In some cases, the aqueous fluid 10812 in the channel segment 10801 can include one or more reagents, which can be the same as or different from the reagent 10815. A second fluid 10816 (e.g., oil) that is immiscible with the aqueous fluid 10812 can be delivered from each of the channel segments 10804 and 10806 to the second junction 10810. Upon encountering the aqueous fluid 10812 from the channel segment 10801 and the second fluid 10816 from each of the channel segments 10804 and 10806 at the second channel junction 10810, the aqueous fluid 10812 can be partitioned into discrete droplets 10818 in the second fluid 10816 and flow out of the second junction 10810 along the channel segment 10808. The channel segment 10808 can deliver the discrete droplets 10818 to an outlet reservoir fluidly coupled to the channel segment 10808, where the discrete droplets can be collected.
[0563] The second fluid 10816 may comprise an oil, such as a fluorinated oil, comprising a fluorinated surfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 10818 .
[0564] The generated discrete droplets can include a single bioparticle 10814 and / or one or more reagents 10815. In some cases, the generated discrete droplets can include beads (not shown) carrying barcodes, such as via other microfluidic structures described elsewhere herein. In some cases, the discrete droplets can be unoccupied (e.g., no reagents, no bioparticles).
[0565] Advantageously, when the lysis reagent and the bioparticle are co-partitioned, the lysis reagent can promote the release of the contents of the bioparticle within the compartment. The released contents in the compartment can remain discrete from the contents of other compartments.
[0566] It should be understood that the channel section described herein can be coupled to any of various fluid sources or receiving components, including fluid components of a reservoir, pipeline, manifold or other system. It should be understood that microfluidic channel structure 10800 can have other geometric shapes. For example, the microfluidic channel structure can have more than two channel junctions. For example, the microfluidic channel structure can have 2,3,4,5 or more channel sections, each of which carries the same or different types of beads, reagents and / or bioparticles that meet at the channel junction. The fluid flow in each channel section can be controlled to control the partitioning of different elements into droplets. Fluid can be guided to flow along one or more channels or reservoirs via one or more fluid flow units. The fluid flow unit may include a compressor (for example, providing positive pressure), a pump (for example, providing negative pressure), an actuator, etc. to control the flow of fluid. Fluid can also be controlled by applied pressure differential, centrifugal force, an electric pump, a vacuum, a capillary or a gravity flow, etc.
[0567] The example of lysing agent includes biologically active agents, such as lysing enzymes for lysing different cell types (e.g., Gram-positive or Gram-negative bacteria, plants, yeast, mammals, etc.), such as lysozyme, chromosomal peptidase, lysostaphin, labiase, kitalase, lysin and a variety of other lysing enzymes available from, for example, Sigma-Aldrich, Inc. (St Louis, MO), and other commercially available lysing enzymes. Other lysing agents can be additionally or alternatively co-partitioned with bioparticles to cause the bioparticle contents to be released into the compartment. For example, in some cases, a lysing solution based on a surfactant can be used to lyse cells, although these may be less desirable for systems based on emulsions in which surfactants may interfere with stable emulsions. In some cases, the lysing solution may include a nonionic surfactant, such as TritonX-100, CHAPS and Tween20. In some cases, the lysing solution may include an ionic surfactant, such as sodium lauryl sarcosinate and sodium dodecyl sulfate (SDS). In some cases, lysis can be achieved by osmotic pressure, such as, using a hypotonic lysis buffer. Electroporation, thermal, acoustic, or mechanical cell disruption may also be used in some cases (e.g., non-emulsion based compartments, such as encapsulation of bioparticles which may be in addition to or in lieu of droplet partitioning, where any pore size of the encapsulant is small enough to retain nucleic acid fragments of a given size after cell disruption).
[0568] Alternatively or in addition to the lysing agent of the bioparticle co-partition as described above, other reagents can also be co-partitioned with the bioparticle, including for example DNA enzyme and RNA enzyme, inactivator or inhibitor, for example proteinase K and / or other protease inhibitors, phosphatase inhibitors, chelating agent, for example EDTA, and for removing or otherwise reducing the negative activity of different cell lysate components to nucleic acid subsequent treatment or other reagents of influence. In addition, in the case of encapsulated bioparticles, bioparticles can be exposed to appropriate stimulation to release bioparticles or their contents from the microcapsules of co-partitions. For example, in some cases, chemical stimulants can be co-partitioned with the encapsulated bioparticles to allow degradation of microcapsules and cells or their contents to be released into larger compartments. In some cases, the stimulant can be the same as the stimulant for releasing nucleic acid molecules (for example, oligonucleotides) from their respective microcapsules (for example, beads) described elsewhere herein. In alternative terms, this can be different and non-overlapping stimulants, so as to allow the encapsulated bioparticles to be released into compartments at different times from the release of nucleic acid molecules into the same compartment.
[0569] Other reagents can also be co-partitioned with the bioparticles, such as endonucleases for fragmenting the DNA of the bioparticles, DNA polymerases and dNTPs for amplifying the nucleic acid fragments of the bioparticles and attaching barcode molecular tags to the amplified fragments. Other enzymes can be co-partitioned, including but not limited to polymerases, transposases, ligases, proteinases K, DNA enzymes, etc. Other reagents can also include reverse transcriptases, including enzymes with terminal transferase activity, primers and oligonucleotides, and conversion oligonucleotides (also referred to herein as "switch oligonucleotides" or "template conversion oligonucleotides"), which can be used for template conversion. In some cases, template conversion can be used to increase the length of cDNA. In some cases, template conversion can be used to attach a predefined nucleic acid sequence to cDNA. In an example of template conversion, cDNA can be generated from reverse transcription of a template (e.g., cell mRNA), wherein a reverse transcriptase with terminal transferase activity can add additional nucleotides, such as polyC, to cDNA in a template-independent manner. The conversion oligonucleotide may include a sequence complementary to the additional nucleotide, such as polyG. The other nucleotides (e.g., polyC) on the cDNA can be hybridized with the other nucleotides (e.g., polyG) on the conversion oligonucleotide, so that the reverse transcriptase can use the conversion oligonucleotide as a template to further extend the cDNA. The template conversion oligonucleotide can include a hybridization region and a template region. The hybridization region can include any sequence that can hybridize with the target. In some cases, as previously described, the hybridization region includes a series of G bases to complement the C bases protruding at the 3' end of the cDNA molecule. A series of G bases can include 1 G base, 2 G bases, 3 G bases, 4 G bases, 5 G bases or more than 5 G bases. The template sequence can include any sequence to be incorporated into the cDNA. In some cases, the template region includes at least 1 (e.g., at least 2, 3, 4, 5 or more) tag sequences and / or functional sequences. The conversion oligonucleotide may comprise deoxyribonucleic acid; ribonucleic acid; modified nucleic acid including 2-aminopurine, 2,6-diaminopurine (2-amino-dA), inverted dT, 5-methyl dC, 2'-deoxyinosine, Super T (5-hydroxybutyne-2'-deoxyuridine), Super G (8-aza7-deazaguanosine nucleoside), locked nucleic acid (LNA), unlocked nucleic acid (UNA, e.g., UNA-A, UNA-U, UNA-C, UNA-G), Iso-dG, Iso-dC, 2' fluoro base (e.g., fluoro-C, fluoro-U, fluoro-A, and fluoro-G), or any combination.
[0570] In some cases, the length of the conversion oligonucleotide can be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 ,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137 , 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 1 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, or 250 nucleotides or longer.
[0571] 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137 , 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194 , 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides.
[0572] Once the content of cell is released in their respective compartment, the macromolecular components (for example, the macromolecular components of biological particles, such as RNA, DNA or protein) contained therein can be further processed in the compartment. According to the method and system described herein, a unique identifier can be provided for the macromolecular components content of a single biological particle, so that when characterizing those macromolecular components, they can be attributed to having derived from identical one or more biological particles. The ability that the feature is attributed to a single biological particle or biological particle group is provided by specifically distributing the unique identifier to a single biological particle or biological particle group. The unique identifier of the form of nucleic acid barcode can be distributed or associated with a single or multiple biological particle or biological particle group, so as to mark or identify the macromolecular components (therefore, its feature) of biological particles with a unique identifier. Then, these unique identifiers can be used for the component and feature of biological particles being attributed to a single biological particle or biological particle group.
[0573] In some aspects, this is performed by co-partitioning individual bioparticles or groups of bioparticles with unique identifiers, e.g., as described above (see Figure 2 ). In some aspects, a unique identifier is provided in the form of a nucleic acid molecule (e.g., an oligonucleotide) comprising a nucleic acid barcode sequence that can be attached to or otherwise associated with the nucleic acid content of a single biological particle, or to other components of a biological particle, particularly to fragments of those nucleic acids. The nucleic acid molecules are partitioned so that the nucleic acid barcode sequences contained therein are identical between nucleic acid molecules in a given compartment, but between different compartments, the nucleic acid molecules can and do have different barcode sequences, or at least represent a large number of barcode sequences that are different between all compartments in a given analysis. In some aspects, only one nucleic acid barcode sequence can be associated with a given compartment, although in some cases, two or more different barcode sequences may be present.
[0574] The nucleic acid barcode sequence can include about 6 to about 20 or more nucleotides within the sequence of a nucleic acid molecule (e.g., an oligonucleotide). The nucleic acid barcode sequence can include about 6 to about 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleotides. In some cases, the length of the barcode sequence can be about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of the barcode sequence can be at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of the barcode sequence can be at most about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or shorter. In some cases, the length of the barcode subsequence separated can be about 4 to about 16 nucleotides. In some cases, the barcode subsequence can be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence can be at least about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence can be at most about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or shorter.
[0575] The co-partitioned nucleic acid molecules may also contain other functional sequences that can be used to process nucleic acids from co-partitioned bioparticles. These sequences include, for example, targeted or random / universal amplification primer sequences for amplifying genomic DNA from individual bioparticles within a compartment while simultaneously attaching associated barcode sequences, sequencing primers or primer recognition sites, hybridization or probing sequences, such as for identifying the presence of a sequence or for pulling down and / or collecting barcoded nucleic acids, or any of many other potential functional sequences. Other mechanisms for co-partitioning oligonucleotides may also be used, including, for example, coalescence of two or more droplets, one of which contains an oligonucleotide, or microdistribution of oligonucleotides into compartments, such as droplets in a microfluidic system.
[0576] In one example, microcapsules, such as beads, are provided, each of which comprises a large number of barcoded nucleic acid molecules (e.g., barcoded oligonucleotides) described above releasably attached to the beads, wherein all nucleic acid molecules attached to a particular bead will include the same nucleic acid barcode sequence, but wherein a large number of different barcode sequences are present in the population of beads used. In some embodiments, hydrogel beads (e.g., comprising a polyacrylamide polymer matrix) are used as solid supports and delivery vehicles for nucleic acid molecules to enter compartments because they are able to carry a large number of nucleic acid molecules and can be configured to release those nucleic acid molecules upon exposure to a specific stimulus as described elsewhere herein. In some cases, the bead population provides a diverse library of barcode sequences including at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences, or more. Additionally, each bead can be provided with a plurality of nucleic acid (e.g., oligonucleotide) molecules attached. In particular, the number of molecules of nucleic acid molecules including a barcode sequence on a single bead can be at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acid molecules, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules, and in some cases at least about 1 billion nucleic acid molecules, or more. The nucleic acid molecules of a given bead can include the same (or universal) barcode sequence, different barcode sequences, or a combination of both. The nucleic acid molecules of a given bead can include multiple groups of nucleic acid molecules. A given set of nucleic acid molecules can include the same barcode sequence. The same barcode sequence can be different from the barcode sequence of another set of nucleic acid molecules.
[0577] In addition, when the bead population is partitioned, the resulting compartment population can also include a diverse barcode library comprising at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences. In addition, each compartment of the population can include at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules, and in some cases at least about 1 billion nucleic acid molecules.
[0578] In some cases, it may be desirable to incorporate multiple different barcodes into a given compartment, attached to a single or multiple beads in the compartment. For example, in some cases, a mixed but known set of barcode sequences can provide greater assurance of identity in subsequent processing, for example, by providing stronger addressing or attribution of a barcode to a given compartment, as a duplicate or independent confirmation of the output of a given compartment.
[0579] After applying a specific stimulus to the beads, the nucleic acid molecules (e.g., oligonucleotides) can be released from the beads. In some cases, the stimulus can be a light stimulus, such as a light labile bond that releases the nucleic acid molecules by cleavage. In other cases, a thermal stimulus can be used, wherein an increase in the ambient temperature of the beads will result in the breaking of the bonds of the nucleic acid molecules or other releases of the nucleic acid molecules from the beads. In other cases, a chemical stimulus can be used that cuts the connection of the nucleic acid molecules to the beads, or otherwise causes the nucleic acid molecules to be released from the beads. In one case, such a composition includes the polyacrylamide matrix described above for encapsulating bioparticles, and can be degraded by exposure to a reducing agent (e.g., DTT) to release the attached nucleic acid molecules.
[0580] In some aspects, systems and methods for controlled partitioning are provided. Droplet size can be controlled by adjusting some geometric features in a channel architecture (e.g., a microfluidic channel architecture). For example, the expansion angle, width, and / or length of the channel can be adjusted to control the size of the droplets.
[0581] Fig.109 An example of a microfluidic channel structure for controlled partitioning of beads into discrete droplets is shown. Channel structure 10900 may include a channel segment 10902 connected to a reservoir 10904 at a channel junction 10906 (or intersection). Reservoir 10904 may be a chamber. As used herein, any reference to a "reservoir" may also refer to a "chamber." In operation, an aqueous fluid 10908 including suspended beads 10912 may be transported along channel segment 10902 into junction 10906 to meet a second fluid 10910 that is immiscible with the aqueous fluid 10908 in reservoir 10904 to produce droplets 10916, 10918 of the aqueous fluid 10908 flowing into reservoir 10904. At the junction 10906 where the aqueous fluid 10908 and the second fluid 10910 meet, droplets may be formed based on factors such as the fluid dynamics at the junction 10906, the flow rates of the two fluids 10908, 10910, the fluid properties, and certain geometric parameters of the channel structure 10900 (e.g., w, h0, α, etc.). By continuously injecting the aqueous fluid 10908 from the channel segment 10902 through the junction 10906, multiple droplets may be collected in the reservoir 10904.
[0582] The generated discrete droplets may contain a bead (e.g., as in occupied droplet 10916). Alternatively, the generated discrete droplets may contain more than one bead. Alternatively, the generated discrete droplets may not contain any beads (e.g., as in unoccupied droplet 10918). In some cases, as described elsewhere herein, the generated discrete droplets may contain one or more biological particles. In some cases, the generated discrete droplets may contain one or more reagents, as described elsewhere herein.
[0583] In some cases, aqueous fluid 10908 can have a substantially uniform concentration or frequency of beads 10912. Beads 10912 can be introduced from separate channels ( Fig.109 The beads 10912 in the channel segment 10902 are introduced into the channel segment 10902 (not shown). The frequency of the beads 10912 in the channel segment 10902 can be controlled by controlling the frequency of the introduction of the beads 10912 into the channel segment 10902 and / or the relative flow rates of the fluids in the channel segment 10902 and the separate channels. In some cases, beads can be introduced into the channel segment 10902 from multiple different channels and the frequency controlled accordingly.
[0584] In some cases, aqueous fluid 10908 in channel segment 10902 may contain biological particles (e.g., see Fig.106 and 10710902). In some cases, the aqueous fluid 10908 may have a substantially uniform concentration or frequency of biological particles. As with beads, biological particles can be introduced into the channel segment 10902 from a separate channel. The frequency or concentration of biological particles in the aqueous fluid 10908 in the channel segment 10902 can be controlled by controlling the frequency at which the biological particles are introduced into the channel segment 10902 and / or the relative flow rates of the fluids in the channel segment 10902 and the separate channels. In some cases, biological particles can be introduced into the channel segment 10902 from a plurality of different channels and the frequency controlled accordingly. In some cases, a first separate channel can introduce beads and a second separate channel can introduce biological particles into the channel segment 10902. The first separate channel into which the beads are introduced can be upstream or downstream of the second separate channel into which the biological particles are introduced.
[0585] The second fluid 10910 may comprise an oil, such as a fluorinated oil, comprising a fluorinated surfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets.
[0586] In some cases, the second fluid 10910 may not be subjected to and / or directed to any flow into or out of the reservoir 10904. For example, the second fluid 10910 may be substantially stationary in the reservoir 10904. In some cases, the second fluid 10910 may be subjected to flow within the reservoir 10904, but not into or out of the reservoir 10904, such as by applying pressure to the reservoir 10904 and / or being affected by the incoming flow of the aqueous fluid 10908 at the junction 10906. Alternatively, the second fluid 10910 may be subjected to and / or directed to flow into or out of the reservoir 10904. For example, the reservoir 10904 may be a channel that directs the flow of the second fluid 10910 from upstream to downstream to transport the generated droplets.
[0587] The channel structure 10900 at or near the junction 10906 can have certain geometric features that at least partially determine the size of the droplets formed by the channel structure 10900. The channel segment 10902 can have a height h0 and a width w at or near the junction 10906. For example, the channel segment 10902 can include a rectangular cross-section that results in a reservoir 10904 with a wider cross-section (e.g., in width or diameter). Alternatively, the cross-section of the channel segment 10902 can be other shapes, such as circular, trapezoidal, polygonal, or any other shape. The top and bottom walls of the reservoir 10904 at or near the junction 10906 can be inclined at an expansion angle α. The expansion angle α allows the depth of the tongue (a portion of the aqueous fluid 10908 that leaves the channel segment 10902 at the junction 10906 and enters the reservoir 10904 before the droplet is formed) to increase and helps reduce the curvature of the droplet formed in the middle. The droplet size may decrease as the expansion angle increases. d The geometric parameters h0, w and α mentioned above can be predicted by the following equations:
[0588]
[0589] For example, for a channel structure with w=21 μm, h=21 μm, and α=3°, the predicted droplet diameter is 121 μm. In another example, for a channel structure with w=25 μm, h=25 μm, and α=5°, the predicted droplet diameter is 123 μm. In another example, for a channel structure with w=28 μm, h=28 μm, and α=7°, the predicted droplet diameter is 124 μm.
[0590] In some cases, the expansion angle α can be about 0.5° to about 4°, about 0.1° to about 10°, or about 0° to about 90°. For example, the expansion angle can be at least about 0.01°, 0.1°, 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or more. In some cases, the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0.1°, 0.01°, or less. In some cases, the width w can be about 100 micrometers (μm) to about 500 μm. In some cases, the width w can be about 10 μm to about 200 μm. Alternatively, the width can be less than about 10 μm. Alternatively, the width can be greater than about 500 μm. In some cases, the flow rate of aqueous fluid 10908 entering junction 10906 can be about 0.04 microliters (μL) / minute (min) to about 40 μL / min. In some cases, the flow rate of aqueous fluid 10908 entering junction 10906 can be about 0.01 microliters (μL) / minute (min) to about 100 μL / min. Alternatively, the flow rate of aqueous fluid 10908 entering junction 10906 can be less than about 0.01 μL / min. Alternatively, the flow rate of aqueous fluid 10908 entering junction 10906 can be greater than about 40 μL / min, for example, 45 μL / min, 50 μL / min, 55 μL / min, 60 μL / min, 65 μL / min, 70 μL / min, 75 μL / min, 80 μL / min, 85 μL / min, 90 μL / min, 95 μL / min, 100 μL / min, 110 μL / min, 120 μL / min, 130 μL / min, 140 μL / min, 150 μL / min, or more. At lower flow rates, for example, a flow rate of about less than or equal to 10 microliters / minute, the droplet radius may not depend on the flow rate of aqueous fluid 10908 entering junction 10906.
[0591] In some cases, at least about 50% of the generated droplets may have a uniform size. In some cases, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the generated droplets may have a uniform size. Alternatively, less than about 50% of the generated droplets may have a uniform size.
[0592] The throughput of droplet generation can be increased by increasing the number of generation points, such as increasing the number of junctions (e.g., junctions 10906) between an aqueous fluid 10908 channel segment (e.g., channel segment 10902) and a reservoir 10904. Alternatively or additionally, the throughput of droplet generation can be increased by increasing the flow rate of the aqueous fluid 10908 in the channel segment 10902.
[0593] Fig.110 An example of a microfluidic channel structure for increasing the throughput of droplet generation is shown. The microfluidic channel structure 11000 may include a plurality of channel segments 11002 and a reservoir 11004. Each of the plurality of channel segments 11002 may be in fluid communication with the reservoir 11004. The channel structure 11000 may include a plurality of channel junctions 11006 between the plurality of channel segments 11002 and the reservoir 11004. Each channel junction may be a point of droplet generation. Figure 4 1000 and any description of its components may correspond to a given channel segment of the plurality of channel segments 11002 in the channel structure 11000 and any description of its components. A reservoir 10904 from the channel structure 10900 and any description of its corresponding components may correspond to a reservoir 11004 from the channel structure 11000 and any description of its corresponding components.
[0594] Each channel segment in the plurality of channel segments 11002 may include an aqueous fluid 11008 including suspended beads 11012. The reservoir 11004 may include a second fluid 11010 that is immiscible with the aqueous fluid 11008. In some cases, the second fluid 11010 may not be subjected to and / or directed to flow into or out of the reservoir 11004. For example, the second fluid 11010 may be substantially stationary in the reservoir 11004. In some cases, the second fluid 11010 may be subjected to flow within the reservoir 11004, but not flow into or out of the reservoir 11004, such as by applying pressure to the reservoir 11004 and / or being affected by an incoming flow of the aqueous fluid 11008 at a junction. Alternatively, the second fluid 11010 may be subjected to and / or directed to flow into or out of the reservoir 11004. For example, the reservoir 11004 can be a channel that guides the second fluid 11010 to flow from upstream to downstream to transport the generated droplets.
[0595] In operation, an aqueous fluid 11008 including suspended beads 11012 can be transported along multiple channel segments 11002 to multiple junctions 11006 to meet a second fluid 11010 in a reservoir 11004 to produce droplets 11016, 11018. Droplets can be formed from each channel segment at each corresponding junction with the reservoir 11004. As described elsewhere herein, at the junction where the aqueous fluid 11008 and the second fluid 11010 meet, droplets can be formed based on factors such as fluid dynamics at the junction, flow rates of the two fluids 11008, 11010, fluid properties, and certain geometric parameters of the channel structure 11000 (e.g., w, h0, α, etc.). By continuously injecting the aqueous fluid 11008 from the multiple channel segments 11002 through the multiple junctions 11006, multiple droplets can be collected in the reservoir 11004. Using the parallel channel configuration of the channel structure 11000, the throughput can be significantly increased. For example, a channel structure having five inlet channel segments containing aqueous fluid 11008 produces droplets five times more frequently than a channel structure having one inlet channel segment, provided that the fluid flow rates in the channel segments are substantially the same. The fluid flow rates in different inlet channel segments may or may not be substantially the same. The channel structure may have as many parallel channel segments as practical and as the size of the reservoir allows. For example, the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 500, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments.
[0596] For each channel segment in the plurality of channel segments 11002, the geometric parameters w, h0 and α may be uniform or may not be uniform. For example, each channel segment may have the same or different widths at or near its respective channel junction with the reservoir 11004. For example, each channel segment may have the same or different heights at or near its respective channel junction with the reservoir 11004. In another example, the reservoir 11004 may have the same or different expansion angles at different channel junctions with the plurality of channel segments 11002. When the geometric parameters are uniform, advantageously, the droplet size can be controlled to be uniform even if the throughput increases. In some cases, when it is desired to have different droplet size distributions, the geometric parameters for the plurality of channel segments 11002 may be changed accordingly.
[0597] In some cases, at least about 50% of the generated droplets may have a uniform size. In some cases, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the generated droplets may have a uniform size. Alternatively, less than about 50% of the generated droplets may have a uniform size.
[0598] Fig.111 Another example of a microfluidic channel structure for increasing the throughput of droplet generation is shown. The microfluidic channel structure 11100 may include a plurality of channel segments 11102 arranged generally circularly around the perimeter of a reservoir 11104. Each of the plurality of channel segments 11102 may be in fluid communication with the reservoir 11104. The channel structure 11100 may include a plurality of channel junctions 11106 between the plurality of channel segments 11102 and the reservoir 11104. Each channel junction may be a point of droplet generation. From Fig.109 The channel segment 10902 of the channel structure 10900 in FIG. 10900 and any description of its components may correspond to a given channel segment in the plurality of channel segments 11102 in the channel structure 11100 and any description of its components. The reservoir 10904 from the channel structure 10900 and any description of its components may correspond to the reservoir 11104 from the channel structure 11100 and any description of its components.
[0599] Each channel segment of the plurality of channel segments 11102 may include an aqueous fluid 11108 including suspended beads 11112. The reservoir 11104 may include a second fluid 11110 that is immiscible with the aqueous fluid 11108. In some cases, the second fluid 11110 may not be subjected to and / or directed to flow into or out of the reservoir 11104. For example, the second fluid 11110 may be substantially stationary in the reservoir 11104. In some cases, the second fluid 11110 may be subjected to flow within the reservoir 11104, but not flow into or out of the reservoir 11104, such as by applying pressure to the reservoir 11104 and / or being affected by an incoming flow of the aqueous fluid 11108 at a junction. Alternatively, the second fluid 11110 may be subjected to and / or directed to flow into or out of the reservoir 11104. For example, the reservoir 11104 can be a channel that guides the second fluid 11110 to flow from upstream to downstream to transport the generated droplets.
[0600] In operation, an aqueous fluid 11108 including suspended beads 11112 can be transported along multiple channel segments 11102 to multiple junctions 11106 to meet the second fluid 11110 in the reservoir 11104 to produce multiple droplets 11116. Droplets can be formed from each channel segment at each corresponding junction with the reservoir 11104. As described elsewhere herein, at the junction where the aqueous fluid 11108 and the second fluid 11110 meet, droplets can be formed based on factors such as fluid dynamics at the junction, flow rates of the two fluids 11108, 11110, fluid properties, and certain geometric parameters of the channel structure 11100 (e.g., the width and height of the channel segment 11102, the expansion angle of the reservoir 11104, etc.). By continuously injecting the aqueous fluid 11108 from the multiple channel segments 11102 through the multiple junctions 11106, multiple droplets can be collected in the reservoir 11104. The parallel channel configuration using channel structure 11100 can significantly increase throughput. According to the actual and reservoir size allowed, the channel structure can have as many parallel channel segments as possible. For example, the channel structure can have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments. Multiple channel segments can be, for example, substantially evenly spaced around the edge or periphery of the reservoir. Alternatively, the spacing of multiple channel segments can be uneven.
[0601] The reservoir 11104 may have an expansion angle α ( Fig.111 1104). Each channel segment in the plurality of channel segments 11102 may have a width w and a height h0 at or near a channel junction. For each channel segment in the plurality of channel segments 11102, the geometric parameters w, h0, and α may be uniform or may not be uniform. Each channel segment may have the same or different widths at or near its respective channel junction with the reservoir 11104. For example, each channel segment may have the same or different heights at or near its respective channel junction with the reservoir 11104.
[0602] The reservoir 11104 may have the same or different expansion angles at different channel junctions with the plurality of channel segments 11102. For example, a circular reservoir (e.g. Fig.1111106) may have a conical, dome-shaped, or hemispherical ceiling (e.g., top wall) to provide the same or substantially the same expansion angle for each channel segment 11102 at or near the plurality of channel junctions 11106. When the geometric parameters are uniform, advantageously, the resulting droplet size can be controlled to be uniform even as the throughput increases. In some cases, when it is desired to have different droplet size distributions, the geometric parameters for the plurality of channel segments 11102 can be changed accordingly.
[0603] In some cases, at least about 50% of the droplets produced may have a uniform size. In some cases, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the droplets produced may have a uniform size. Alternatively, less than about 50% of the droplets produced may have a uniform size. The beads and / or bioparticles injected into the droplets may or may not have a uniform size.
[0604] Fig.112A A cross-sectional view of another example of a microfluidic channel structure having geometric features for controlled partitioning is shown. Channel structure 11200 may include channel segment 11202 that communicates with reservoir 11204 at channel junction 11206 (or intersection). In some cases, channel structure 11200 and one or more components thereof may correspond to channel structure 10600 and one or more components thereof. Fig.112B Shows Fig.112A A perspective view of the channel structure 11200.
[0605] An aqueous fluid 11212 containing a plurality of particles 11216 may be transported along the channel segment 11202 to a junction 11206 to encounter a second fluid 11214 (e.g., oil, etc.) that is immiscible with the aqueous fluid 11212 in the reservoir 11204 to produce droplets 11220 of the aqueous fluid 11212 flowing into the reservoir 11204. At the junction 11206 where the aqueous fluid 11212 and the second fluid 11214 meet, droplets may be formed based on factors such as fluid dynamics at the junction 11206, relative flow rates of the two fluids 11212, 11214, fluid properties, and certain geometric parameters (e.g., Δh, etc.) of the channel structure 11200. By continuously injecting the aqueous fluid 11212 from the channel segment 11202 at the junction 11206, a plurality of droplets may be collected ...
Claims
1. A method for treating immune cells, comprising: (a) capturing a cell, wherein the cell comprises at least one genomic deoxyribonucleic acid (gDNA) molecule and a plurality of guide ribonucleic acid (gRNA) molecules, wherein the at least one gDNA molecule comprises one or more accessible regions; (b) contacting the one or more accessible regions of the at least one gDNA molecule of the cell with a transposase to produce a plurality of labeled gDNA fragments in a labeling reaction; and (c) generating a plurality of complementary DNA (cDNA) molecules from one of the plurality of gRNA molecules or a plurality of gRNA identification barcodes of the plurality of gRNA molecules.
2. The method of claim 1, wherein a barcode in the plurality of gRNA identification barcodes identifies the identity of a gRNA molecule in the plurality of gRNA molecules and is attached to the gRNA molecule.
3. The method of claim 1, wherein the plurality of gRNA molecules comprise a plurality of target sequences, wherein, Each target sequence in the plurality of target sequences is configured to target a sequence associated with a transcription factor, a chromatin modifier, or a non-coding RNA.
4. The method of claim 3, wherein a first gRNA molecule in the plurality of gRNA molecules comprises a first target sequence in the plurality of target sequences, wherein a second gRNA molecule in the plurality of gRNA molecules comprises a second target sequence in the plurality of target sequences, and Wherein the first target sequence and the second target sequence are different.
5. The method of claim 1, further comprising: Prior to step (a), the multiple gRNA molecules are introduced into the cells.
6. The method of claim 1, wherein step (c) comprises: One of the plurality of gRNA molecules or the plurality of gRNA identification barcodes is contacted with a plurality of reverse primers and a reverse transcriptase, wherein each of the plurality of reverse primers comprises a sequence specific to or targeting the 3' end of the plurality of gRNA molecules.
7. The method of claim 6, wherein step (c) further comprises: The plurality of gRNA molecules are contacted with a plurality of forward primers, wherein each forward primer in the plurality of forward primers comprises a sequence that is specific to or targets the 5' variable end of the gRNA molecule.
8. The method of claim 1, further comprising: The plurality of labeled gDNA fragments and the plurality of cDNA molecules are contacted with a plurality of primers and a polymerase to produce at least one of a plurality of labeled gDNA fragment amplicons or a plurality of cDNA molecule amplicons.
9. The method of claim 1, further comprising: generating a plurality of amplicons from the plurality of labeled gDNA fragments and the plurality of cDNA molecules, wherein each amplicon of the plurality of amplicons comprises a barcode sequence that identifies the cell; and The plurality of amplicons are sequenced.
10. The method of claim 1, further comprising: A correlation between the accessibility of at least one gDNA molecule in the cell is determined in response to perturbation of a gRNA molecule in the plurality of gRNA molecules.
11. The method of claim 1, further comprising: At least one of the plurality of labeled gDNA fragments, the plurality of cDNA molecules, the derivatives of the plurality of labeled gDNA fragments, or the derivatives of the plurality of cDNA molecules is sequenced.
12. The method of claim 1, further comprising: After step (b) the labelling reaction is terminated.
13. The method of claim 12, wherein the terminating is performed using a chelating agent, and wherein the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), nitriloacetic acid (NTA), and diethylenetriaminepentaacetic acid (DTPA).
14. The method of claim 12, wherein the terminating comprises: a divalent metal ion required to chelate the transposase complex of the transposase; and The transposase complex is released from a labeled gDNA fragment among the plurality of labeled gDNA fragments.
15. The method of claim 12, wherein the terminating comprises using a detergent comprising a nonionic surfactant.
16. The method of claim 1, wherein step (a) comprises: The compartments are partitioned, wherein the compartments are selected from the group consisting of chambers, wells, and droplets.
17. The method of claim 1, wherein step (a) comprises: The cell is isolated from a plurality of cells, wherein the cell is an immune cell comprising one of a T cell or a B cell.
18. The method of claim 1, wherein each labeled gDNA fragment in the plurality of labeled gDNA fragments comprises one or more adaptors, and wherein an adaptor in the one or more adaptors comprises an adaptor sequence.
